Human NEDD-1

ABSTRACT

The invention provides isolated nucleic acids that encode human NEDD-1, and fragments thereof, vectors for propagating and expressing human NEDD-1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of human NEDD-1, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human NEDD-1 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human NEDD-1 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human NEDD-1 nucleic acids, proteins, and antibodies of the present invention.

FIELD OF THE INVENTION

[0001] The present invention relates to novel human NEDD-1. More specifically, the invention provides isolated nucleic acid molecules encoding human NEDD-1, fragments thereof, vectors and host cells comprising human NEDD-1 nucleic acids, human NEDD-1 polypeptides, antibodies to human NEDD-1, transgenic cells and non-human organisms, and diagnostic, therapeutic, and investigational methods of using the same.

BACKGROUND OF THE INVENTION

[0002] The murine Nedd1 gene was first identified as one of a set of mouse genes isolated from a CNS neural precursor cell cDNA library constructed from embryonic 10-day mouse. Nedd was so named for ‘neural precursor cell expressed developmentally and down-regulated’ genes (Kumar et al., Biochem. Biophys. Res. Commun. 185(3):1155-61 (1992)).

[0003] Nedd1 is expressed strongly during early development of mouse head and brain tissues in day 10-13 embryos. The expression of mouse Nedd1 in the brain rapidly decreases during the embryonic development and Nedd1 is expressed at much reduced levels in adult tissues (Kumar S. et al, J Biol Chem 1994; 269(15):11318-26).

[0004] BLAST (basic local alignment search tool) search of public databases using the sequence of Nedd1 as query reveals that the mouse Nedd1 does not belong to any known protein family. However, the common consensus motif, WD domain, found in mouse Nedd1 at residues 28-322, contains residues known to be involved in RNA-processing complexes, transcription regulators, and other protein-protein interactions of biological importance (Smith et al., Trends Biol. Sci. 24:181-5 (1999)).

[0005] The exact function of Nedd1 is still unclear. However, ectopic expression of Nedd1 gene in several cell lines results in varying degrees of growth suppression, with the strongest effect seen in differentiation-competent neuroblastoma-derived cell lines, suggesting that Nedd1 plays a potential role as a tumor suppressor gene and that Nedd1 may participate in differentiation-coupled growth arrest in neuronal cells (Kumar et al., J. Biol. Chem. 269(15):11318-26 (1994)).

[0006] Recent reports suggest that at least one-third, and likely a higher percentage, of human genes are alternatively spliced (Hanke et al., Trends Genet. 15(1): 389-390 (1999); Mironov et al., Genome Res. 9:1288-93 (1999); Brett et al., FEBS Lett. 474(1):83-6 (2000)). Alternative splicing may permit the relatively small number of human coding regions to encode millions, perhaps tens of millions, of structurally distinct proteins and protein isoforms.

[0007] The mouse Nedd1 3′ untranslated region (UTR) contains two putative polyadenylation signals AATAAA. The Northern Blot analysis of mouse Nedd1 detected a 3.5 kb as well as a 2.3 kb mRNA transcript in testis, suggesting the possibility of either an alternative splicing event or an alternative polyadenylation event, or both (Kumar et al, J. Biol. Chem. 269(15):11318-26 (1994)).

[0008] Given a likely role of mouse Nedd1 as a tumor suppressor, and the potential diagnostic and therapeutic utility of tumor suppressors, there is a need to identify and to characterize the human orthologues of the Nedd1 protein.

SUMMARY OF THE INVENTION

[0009] The present invention solves these and other needs in the art by providing isolated nucleic acids that encode human NEDD-1, and fragments thereof.

[0010] In other aspects, the invention provides vectors for propagating and expressing the nucleic acids of the present invention, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the human NEDD-1, and antibodies thereto.

[0011] The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention.

[0012] In other aspects, the invention provides transgenic cells and non-human organisms comprising human NEDD-1 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human NEDD-1.

[0013] The invention additionally provides diagnostic, investigational, and therapeutic methods based on the human NEDD-1 nucleic acids, proteins, and antibodies of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The above and other objects and advantages of the present invention will be apparent upon consideration of the following detailed description taken in conjunction with the accompanying drawings, in which like characters refer to like parts throughout, and in which:

[0015]FIG. 1 schematizes the protein domain structure of human NEDD-1, according to the present invention, and the earlier-described mouse Nedd1;

[0016]FIG. 2 is a map showing the genomic structure of human NEDD-1 encoded at chromosome 12q22;

[0017]FIG. 3 presents the nucleotide and predicted amino acid sequences of human NEDD-1;

[0018]FIG. 4 shows the intracellular localization of the NEDD-1_GFP fusion protein; and

[0019]FIG. 5 presents the hydrophobicity plot of the predicted amino acid sequences of human NEDD-1.

DETAILED DESCRIPTION OF THE INVENTION

[0020] Mining the sequence of the human genome for novel human genes, the present inventors have identified a human form of NEDD-1, a protein related to mouse Nedd1.

[0021] As schematized in FIG. 1, the newly isolated NEDD-1 shares certain protein domains and an overall structural organization with mouse Nedd1. The shared structural features strongly imply that NEDD-1 plays a role similar to that of Nedd1 as a potential tumor suppressor gene, and as a support and stabilizer of protein-protein interaction within the cell, thus making NEDD-1 a clinically useful diagnostic marker and potential therapeutic agent.

[0022] Like mouse Nedd1, the human NEDD-1 contains WD domains. WD domains are made up of highly conserved repeating units usually ending with Trp-Asp (WD). The repeat comprises a 44-60 residue sequence that contains the GH dipeptide 11-24 residues from its N-terminus. The GH and the WD dipeptides are linked by a conserved core sequence.

[0023] Motif searches on standard motif databases, such as Pfam (http://pfam.wusti.edu/) and SMART (http://smart.embl-heidelberg.de/), reveal that human NEDD-1 contains seven tandem WD domains (also called G beta motif) in the N-terminal half of the protein (28-317 a.a.). The WD repeats form a potential seven-bladed propeller structure (based on the crystal structure from the WD domain-containing protein, G rotein beta, Sondek et al., Nature 379: 369-374 (1996)); such a repetitive segment has been shown to exist in a number of proteins. The C-terminal region of the NEDD-1 protein is highly hydrophilic (see hydrophobicity plot, FIG. 5).

[0024] The localization of the NEDD-1 polypeptide was analyzed using GFP fusion experiments. The results show that the protein is in the cytoplasm (see below). Based upon this specific pattern of protein localization and the fact that the polypeptide contains multiple WD repeat motifs, which have been found in cytoplasmic and membrane-bound signal transducer molecules, it is highly likely that the human NEDD-1 protein functions in signal transduction pathways associated with cell proliferation and/or differentiation.

[0025]FIG. 2 shows the genomic organization of human NEDD-1.

[0026] At the top is shown the two bacterial artificial chromosomes (BACs), with GenBank accession numbers (AC007564.9, AC013417.4), that span the NEDD-1 locus. The genome-derived single-exon probes first used to demonstrate expression from this locus, as further described in commonly owned and copending provisional patent application No. 60/236,359, filed Sep. 27, 2000, the disclosure of which is incorporated herein by reference in its entirety, are shown below the BACs and are labeled “A” and “B”. The 500 bp probes include sequences drawn from exon eight and nine, respectively, with additional intragenic (intronic) sequences.

[0027] As shown in FIG. 2, NEDD-1, encoding a protein of 660 amino acids, comprises 15 exons. The cDNA sequence contains an alternative poly A site at nucleotide 2454, resulting the presence of two different length detectable transcripts (of sizes 3.4 kb and 2.4 kb). The presence of both the long and the short form of NEDD1 3′ UTR argues that transcript stability may be affected by the presence of the additional sequence in the long form. The alternative polyadenylation does not affect the protein structure. Predicted molecular weight of NEDD-1, prior to any post-translational modification, is 72.0 kD.

[0028] As further discussed in the examples herein, expression of NEDD-1 was assessed using hybridization to genome-derived single exon microarrays and quantitative RT_PCR assay. Microarray analysis of exons 2, 3, 8, 9, 11, 12 showed universal expression in all the tissues tested. This was confirmed by quantitative RT_PCR.

[0029] As more fully described below, the present invention provides isolated nucleic acids that encode human NEDD-1 and fragments thereof. The invention further provides vectors for propagation and expression of the nucleic acids of the present invention, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the present invention, and antibodies specific for all or any one of the isoforms. The invention provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention. The invention further provides transgenic cells and non-human organisms comprising human NEDD-1 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of human NEDD-1. The invention additionally provides diagnostic, investigational, and therapeutic methods based on the human NEDD-1 nucleic acids, proteins, and antibodies of the present invention.

[0030] Definitions

[0031] As used herein, “nucleic acid” (synonymously, “polynucleotide”) includes polynucleotides having natural nucleotides in native 5′-3′ phosphodiester linkage—e.g., DNA or RNA—as well as polynucleotides that have nonnatural nucleotide analogues, nonnative internucleoside bonds, or both, so long as the nonnatural polynucleotide is capable of sequence-discriminating basepairing under experimentally desired conditions. Unless otherwise specified, the term “nucleic acid” includes any topological conformation; the term thus explicitly comprehends single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular, and padlocked conformations.

[0032] As used herein, an “isolated nucleic acid” is a nucleic acid molecule that exists in a physical form that is nonidentical to any nucleic acid molecule of identical sequence as found in nature; “isolated” does not require, although it does not prohibit, that the nucleic acid so described has itself been physically removed from its native environment.

[0033] For example, a nucleic acid can be said to be “isolated” when it includes nucleotides and/or internucleoside bonds not found in nature. When instead composed of natural nucleosides in phosphodiester linkage, a nucleic acid can be said to be “isolated” when it exists at a purity not found in nature, where purity can be adjudged with respect to the presence of nucleic acids of other sequence, with respect to the presence of proteins, with respect to the presence of lipids, or with respect the presence of any other component of a biological cell, or when the nucleic acid lacks sequence that flanks an otherwise identical sequence in an organism's genome, or when the nucleic acid possesses sequence not identically present in nature.

[0034] As so defined, “isolated nucleic acid” includes nucleic acids integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

[0035] As used herein, an isolated nucleic acid “encodes” a reference polypeptide when at least a portion of the nucleic acid, or its complement, can be directly translated to provide the amino acid sequence of the reference polypeptide, or when the isolated nucleic acid can be used, alone or as part of an expression vector, to express the reference polypeptide in vitro, in a prokaryotic host cell, or in a eukaryotic host cell.

[0036] As used herein, the term “exon” refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute contiguous sequence to a mature mRNA transcript.

[0037] As used herein, the phrase “open reading frame” and the equivalent acronym “ORF” refer to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

[0038] As used herein, the phrase “ORF-encoded peptide” refers to the predicted or actual translation of an ORF.

[0039] As used herein, the phrase “degenerate variant” of a reference nucleic acid sequence intends all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

[0040] As used herein, the term “microarray” and the equivalent phrase “nucleic acid microarray” refer to a substrate-bound collection of plural nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed.

[0041] As so defined, the term “microarray” and phrase “nucleic acid microarray” include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999) (ISBN: 0199637768); Nature Genet. 21(1)(suppl):1-60 (1999); and Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000) (ISBN: 1881299376), the disclosures of which are incorporated herein by reference in their entireties.

[0042] As so defined, the term “microarray” and phrase “nucleic acid microarray” also include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are distributably disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, inter alia, in Brenner et al., Proc. Natl. Acad. Sci. USA 97(4):166501670 (2000), the disclosure of which is incorporated herein by reference in its entirety; in such case, the term “microarray” and phrase “nucleic acid microarray” refer to the plurality of beads in aggregate.

[0043] As used herein with respect to solution phase hybridization, the term “probe”, or equivalently, “nucleic acid probe” or “hybridization probe”, refers to an isolated nucleic acid of known sequence that is, or is intended to be, detectably labeled. As used herein with respect to a nucleic acid microarray, the term “probe” (or equivalently “nucleic acid probe” or “hybridization probe”) refers to the isolated nucleic acid that is, or is intended to be, bound to the substrate. In either such context, the term “target” refers to nucleic acid intended to be bound to probe by sequence complementarity.

[0044] As used herein, the expression “probe comprising SEQ ID NO:X”, and variants thereof, intends a nucleic acid probe, at least a portion of which probe has either (i) the sequence directly as given in the referenced SEQ ID NO:X, or (ii) a sequence complementary to the sequence as given in the referenced SEQ ID NO:X, the choice as between sequence directly as given and complement thereof dictated by the requirement that the probe be complementary to the desired target.

[0045] As used herein, the phrases “expression of a probe” and “expression of an isolated nucleic acid” and their linguistic equivalents intend that the probe (or, respectively, isolated nucleic acid), or a probe (or, respectively, isolated nucleic acid) complementary in sequence thereto, can hybridize detectably under high stringency conditions to a sample of nucleic acids that derive from mRNA transcripts from a given source. For example, and by way of illustration only, expression of a probe in “liver” means that the probe can hybridize detectably under high stringency conditions to a sample of nucleic acids that derive from mRNA obtained from liver.

[0046] As used herein, “a single exon probe” comprises at least part of an exon (“reference exon”) and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon. The single exon probe will not, however, hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon but include one or more exons that are found adjacent to the reference exon in the genome.

[0047] For purposes herein, “high stringency conditions” are defined for solution phase hybridization as aqueous hybridization (i.e., free of formamide) in 6× SSC (where 20× SSC contains 3.0 M NaCl and 0.3 M sodium citrate), 1% SDS at 65° C. for at least 8 hours, followed by one or more washes in 0.2× SSC, 0.1% SDS at 65° C. “Moderate stringency conditions” are defined for solution phase hybridization as aqueous hybridization (i.e., free of formamide) in 6× SSC, 1% SDS at 65° C. for at least 8 hours, followed by one or more washes in 2× SSC, 0.1% SDS at room temperature.

[0048] For microarray-based hybridization, standard “high stringency conditions” are defined as hybridization in 50% formamide, 5× SSC, 0.2 μg/μl poly(dA), 0.2 μg/ul human cot1 DNA, and 0.5% SDS, in a humid oven at 42° C. overnight, followed by successive washes of the microarray in 1× SSC, 0.2% SDS at 55° C. for 5 minutes, and then 0.1× SSC, 0.2% SDS, at 55° C. for 20 minutes. For microarray-based hybridization, “moderate stringency conditions”, suitable for cross-hybridization to mRNA encoding structurally—and functionally-related proteins, are defined to be the same as those for high stringency conditions but with reduction in temperature for hybridization and washing to room temperature (approximately 25° C.).

[0049] As used herein, the terms “protein”, “polypeptide”, and “peptide” are used interchangeably to refer to a naturally-occurring or synthetic polymer of amino acid monomers (residues), irrespective of length, where amino acid monomer here includes naturally-occurring amino acids, naturally-occurring amino acid structural variants, and synthetic non-naturally occurring analogs that are capable of participating in peptide bonds. The terms “protein”, “polypeptide”, and “peptide” explicitly permits of post-translational and post-synthetic modifications, such as glycosylation.

[0050] The term “oligopeptide” herein denotes a protein, polypeptide, or peptide having 25 or fewer monomeric subunits.

[0051] The phrases “isolated protein”, “isolated polypeptide”, “isolated peptide” and “isolated oligopeptide” refer to a protein (or respectively to a polypeptide, peptide, or oligopeptide) that is nonidentical to any protein molecule of identical amino acid sequence as found in nature; “isolated” does not require, although it does not prohibit, that the protein so described has itself been physically removed from its native environment.

[0052] For example, a protein can be said to be “isolated” when it includes amino acid analogues or derivatives not found in nature, or includes linkages other than standard peptide bonds.

[0053] When instead composed entirely of natural amino acids linked by peptide bonds, a protein can be said to be “isolated” when it exists at a purity not found in nature—where purity can be adjudged with respect to the presence of proteins of other sequence, with respect to the presence of non-protein compounds, such as nucleic acids, lipids, or other components of a biological cell, or when it exists in a composition not found in nature, such as in a host cell that does not naturally express that protein.

[0054] A “purified protein” (equally, a purified polypeptide, peptide, or oligopeptide) is an isolated protein, as above described, present at a concentration of at least 95%, as measured on a weight basis with respect to total protein in a composition. A “substantially purified protein” (equally, a substantially purified polypeptide, peptide, or oligopeptide) is an isolated protein, as above described, present at a concentration of at least 70%, as measured on a weight basis with respect to total protein in a composition.

[0055] As used herein, the phrase “protein isoforms” refers to a plurality of proteins having nonidentical primary amino acid sequence but that share amino acid sequence encoded by at least one common exon.

[0056] As used herein, the phrase “alternative splicing” and its linguistic equivalents includes all types of RNA processing that lead to expression of plural protein isoforms from a single gene; accordingly, the phrase “splice variant(s)” and its linguistic equivalents embraces mRNAs transcribed from a given gene that, however processed, collectively encode plural protein isoforms. For example, and by way of illustration only, splice variants can include exon insertions, exon extensions, exon truncations, exon deletions, alternatives in the 5′ untranslated region (“5′ UT”) and alternatives in the 3′ untranslated region (“3′ UT”). Such 3′ alternatives include, for example, differences in the site of RNA transcript cleavage and site of poly(A) addition. See, e.g., Gautheret et al., Genome Res. 8:524-530 (1998).

[0057] As used herein, “orthologues” are separate occurrences of the same gene in multiple species. The separate occurrences have similar, albeit nonidentical, amino acid sequences, the degree of sequence similarity depending, in part, upon the evolutionary distance of the species from a common ancestor having the same gene.

[0058] As used herein, the term “paralogues” indicates separate occurrences of a gene in one species. The separate occurrences have similar, albeit nonidentical, amino acid sequences, the degree of sequence similarity depending, in part, upon the evolutionary distance from the gene duplication event giving rise to the separate occurrences.

[0059] As used herein, the term “homologues” is generic to “orthologues” and “paralogues”.

[0060] As used herein, the term “antibody” refers to a polypeptide, at least a portion of which is encoded by at least one immunoglobulin gene, or fragment thereof, and that can bind specifically to a desired target molecule. The term includes naturally-occurring forms, as well as fragments and derivatives.

[0061] Fragments within the scope of the term “antibody” include those produced by digestion with various proteases, those produced by chemical cleavage and/or chemical dissociation, and those produced recombinantly, so long as the fragment remains capable of specific binding to a target molecule. Among such fragments are Fab, Fab′, Fv, F(ab)′₂, and single chain Fv (scFv) fragments.

[0062] Derivatives within the scope of the term “antibody” include antibodies (or fragments thereof) that have been modified in sequence, but remain capable of specific binding to a target molecule, including: interspecies chimeric and humanized antibodies; antibody fusions; heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies (see, e.g., Marasco (ed.), Intracellular Antibodies: Research and Disease Applications, Springer-Verlag New York, Inc. (1998) (ISBN: 3540641513), the disclosure of which is incorporated herein by reference in its entirety).

[0063] As used herein, “antigen” refers to a ligand that can be bound by an antibody; an antigen need not itself be immunogenic. The portions of the antigen that make contact with the antibody are denominated “repitopes”.

[0064] “Specific binding” refers to the ability of two molecular species concurrently present in a heterogeneous (inhomogeneous) sample to bind to one another in preference to binding to other molecular species in the sample. Typically, a specific binding interaction will discriminate over adventitious binding interactions in the reaction by at least two-fold, more typically by at least 10-fold, often at least 100-fold; when used to detect analyte, specific binding is sufficiently discriminatory when determinative of the presence of the analyte in a heterogeneous (inhomogeneous) sample. Typically, the affinity or avidity of a specific binding reaction is least about 10⁻⁷ M, with specific binding reactions of greater specificity typically having affinity or avidity of at least 10⁻⁸ M to at least about 10⁻⁹ M.

[0065] As used herein, “molecular binding partners”—and equivalently, “specific binding partners”—refer to pairs of molecules, typically pairs of biomolecules, that exhibit specific binding. Nonlimiting examples are receptor and ligand, antibody and antigen, and biotin to any of avidin, streptavidin, neutrAvidin and captAvidin.

[0066] The term “antisense”, as used herein, refers to a nucleic acid molecule sufficiently complementary in sequence, and sufficiently long in that complementary sequence, as to hybridize under intracellular conditions to (i) a target mRNA transcript or (ii) the genomic DNA strand complementary to that transcribed to produce the target mRNA transcript.

[0067] The term “portion”, as used with respect to nucleic acids, proteins, and antibodies, is synonymous with “fragment”.

[0068] Nucleic Acid Molecules

[0069] In a first aspect, the invention provides isolated nucleic acids that encode human NEDD-1, variants having at least 90% sequence identity thereto, degenerate variants thereof, variants that encode human NEDD-1 proteins having conservative or moderately conservative substitutions, cross-hybridizing nucleic acids, and fragments thereof.

[0070]FIG. 3 presents the nucleotide sequence of the human NEDD-1 cDNA clone, with predicted amino acid translation; the sequences are further presented in the Sequence Listing, incorporated herein by reference in its entirety, in SEQ ID Nos: 1 (full length nucleotide sequence of human NEDD-1 cDNA), 2 (alternatively polyadenylated full length nucleotide sequence of NEDD-1 cDNA) and 4 (full length amino acid sequence of NEDD-1).

[0071] Unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

[0072] Unless otherwise indicated, nucleotide sequences of the isolated nucleic acids of the present invention were determined by sequencing a DNA molecule that had resulted, directly or indirectly, from at least one enzymatic polymerization reaction (e.g., reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Molecular Dynamics, Sunnyvale, Calif., USA), or by reliance upon such sequence or upon genomic sequence prior-accessioned into a public database. Unless otherwise indicated, all amino acid sequences of the polypeptides of the present invention were predicted by translation from the nucleic acid sequences so determined.

[0073] As a consequence, any nucleic acid sequence presented herein may contain errors introduced by erroneous incorporation of nucleotides during polymerization, by erroneous base calling by the automated sequencer (although such sequencing errors have been minimized for the nucleic acids directly determined herein, unless otherwise indicated, by the sequencing of each of the complementary strands of a duplex DNA), or by similar errors accessioned into the public database.

[0074] Accordingly, the human NEDD-1 cDNA clone described herein has been deposited in a public repository (American Type Culture Collection, Manassas, Va., USA). The deposit, received at ATCC on May 23, 2001, has been accorded an accession date of ______ and accession number of ______. Any errors in sequence reported herein can be determined and corrected by sequencing nucleic acids propagated from the deposited clones using standard techniques.

[0075] Single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes—more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, Nature 409:860-921 (2001)—and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Additionally, small deletions and insertions, rather than single nucleotide polymorphisms, are not uncommon in the general population, and often do not alter the function of the protein.

[0076] Accordingly, it is an aspect of the present invention to provide nucleic acids not only identical in sequence to those described with particularity herein, but also to provide isolated nucleic acids at least about 90% identical in sequence to those described with particularity herein, typically at least about 91%, 92%, 93%, 94%, or 95% identical in sequence to those described with particularity herein, usefully at least about 96%, 97%, 98%, or 99% identical in sequence to those described with particularity herein, and, most conservatively, at least about 99.5%, 99.6%, 99.7%, 99.8% and 99.9% identical in sequence to those described with particularity herein. These sequence variants can be naturally occurring or can result from human intervention, as by random or directed mutagenesis.

[0077] For purposes herein, percent identity of two nucleic acid sequences is determined using the procedure of Tatiana et al., “Blast 2 sequences—a new tool for comparing protein and nucleotide sequences”, FEMS Microbiol Lett. 174:247-250 (1999), which procedure is effectuated by the computer program BLAST 2 SEQUENCES, available online at

[0078] http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html.

[0079] To assess percent identity of nucleic acids, the BLASTN module of BLAST 2 SEQUENCES is used with default values of (i) reward for a match: 1; (ii) penalty for a mismatch: −2; (iii) open gap 5 and extension gap 2 penalties; (iv) gap X_dropoff 50 expect 10 word size 11 filter, and both sequences are entered in their entireties.

[0080] As is well known, the genetic code is degenerate, with each amino acid except methionine translated from a plurality of codons, thus permitting a plurality of nucleic acids of disparate sequence to encode the identical protein. As is also well known, codon choice for optimal expression varies from species to species. The isolated nucleic acids of the present invention being useful for expression of human NEDD-1 proteins and protein fragments, it is, therefore, another aspect of the present invention to provide isolated nucleic acids that encode human NEDD-1 proteins and portions thereof not only identical in sequence to those described with particularity herein, but degenerate variants thereof as well.

[0081] As is also well known, amino acid substitutions occur frequently among natural allelic variants, with conservative substitutions often occasioning only de minimis change in protein function.

[0082] Accordingly, it is an aspect of the present invention to provide nucleic acids not only identical in sequence to those described with particularity herein, but also to provide isolated nucleic acids that encode human NEDD-1, and portions thereof, having conservative amino acid substitutions, and also to provide isolated nucleic acids that encode human NEDD-1, and portions thereof, having moderately conservative amino acid substitutions.

[0083] Although there are a variety of metrics for calling conservative amino acid substitutions, based primarily on either observed changes among evolutionarily related proteins or on predicted chemical similarity, for purposes herein a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix reproduced herein below (See Gonnet et al., Science 256(5062):1443-5 (1992)): A R N D C Q E G H I L K M F P S T W Y V A 2 −1 0 0 0 0 0 0 −1 −1 −1 0 −1 −2 0 1 1 −4 −2 0 R −1 5 0 0 −2 2 0 −1 1 −2 −2 3 −2 −3 −1 0 0 −2 −2 −2 N 0 0 4 2 −2 1 1 0 1 −3 −3 1 −2 −3 −1 1 0 −4 −1 −2 D 0 0 2 5 −3 1 3 0 0 −4 −4 0 −3 −4 −1 0 0 −5 −3 −3 C 0 −2 −2 −3 12 −2 −3 −2 −1 −1 −2 −3 −1 −1 −3 0 0 −1 0 0 Q 0 2 1 1 −2 3 2 −1 1 −2 −2 2 −1 −3 0 0 0 −3 −2 −2 E 0 0 1 3 −3 2 4 −1 0 −3 −3 1 −2 −4 0 0 0 −4 −3 −2 G 0 −1 0 0 −2 −1 −1 7 −1 −4 −4 −1 −4 −5 −2 0 −1 −4 −4 −3 H −1 1 1 0 −1 1 0 −1 6 −2 −2 1 −1 0 −1 0 0 −1 2 −2 I −1 −2 −3 −4 −1 −2 −3 −4 −2 4 3 −2 2 1 −3 −2 −1 −2 −1 3 L −1 −2 −3 −4 −2 −2 −3 −4 −2 3 4 −2 3 2 −2 −2 −1 −1 0 2 K 0 3 1 0 −3 2 1 −1 1 −2 −2 3 −1 −3 −1 0 0 −4 −2 −2 M −1 −2 −2 −3 −1 −1 −2 −4 −1 2 3 −1 4 2 −2 −1 −1 −1 0 2 F −2 −3 −3 −4 −1 −3 −4 −5 0 1 2 −3 2 7 −4 −3 −2 4 5 0 P 0 −1 −1 −1 −3 0 0 −2 −1 −3 −2 −1 −2 −4 8 0 0 −5 −3 −2 S 1 0 1 0 0 0 0 0 0 −2 −2 0 −1 −3 0 2 2 −3 −2 −1 T 1 0 0 0 0 0 0 −1 0 −1 −1 0 −1 −2 0 2 2 −4 −2 0 W −4 −2 −4 −5 −1 −3 −4 −4 −1 −2 −1 −4 −1 −4 −5 −3 −4 14 4 −3 Y −2 −2 −1 −3 0 −2 −3 −4 2 −1 0 −2 0 5 −3 −2 −2 4 8 −1 V 0 −2 −2 −3 0 −2 −2 −3 −2 3 2 −2 2 0 −2 −1 0 −3 −1 3

[0084] For purposes herein, a “moderately conservative” replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix reproduced herein above.

[0085] As is also well known in the art, relatedness of nucleic acids can also be characterized using a functional test, the ability of the two nucleic acids to base-pair to one another at defined hybridization stringencies.

[0086] It is, therefore, another aspect of the invention to provide isolated nucleic acids not only identical in sequence to those described with particularity herein, but also to provide isolated nucleic acids (“cross-hybridizing nucleic acids”) that hybridize under high stringency conditions (as defined herein) to all or to a portion of various of the isolated human NEDD-1 nucleic acids of the present invention (“reference nucleic acids”), as well as cross-hybridizing nucleic acids that hybridize under moderate stringency conditions to all or to a portion of various of the isolated human NEDD-1 nucleic acids of the present invention.

[0087] Such cross-hybridizing nucleic acids are useful, inter alia, as probes for, and to drive expression of, proteins related to the proteins of the present invention as alternative isoforms, homologues, paralogues, and orthologues. Particularly useful orthologues are those from other primate species, such as chimpanzee, rhesus macaque monkey, baboon, orangutan, and gorilla; from rodents, such as rats, mice, guinea pigs; from lagomorphs, such as rabbits, and from domestic livestock, such as cow, pig, sheep, horse, goat.

[0088] The hybridizing portion of the reference nucleic acid is typically at least 15 nucleotides in length, often at least 17 nucleotides in length. Often, however, the hybridizing portion of the reference nucleic acid is at least 20 nucleotides in length, 25 nucleotides in length, and even 30 nucleotides, 35 nucleotides, 40 nucleotides, and 50 nucleotides in length. Of course, cross-hybridizing nucleic acids that hybridize to a larger portion of the reference nucleic acid—for example, to a portion of at least 50 nt, at least 100 nt, at least 150 nt, 200 nt, 250 nt, 300 nt, 350 nt, 400 nt, 450 nt, or 500 nt or more—or even to the entire length of the reference nucleic acid, are also useful.

[0089] The hybridizing portion of the cross-hybridizing nucleic acid is at least 75% identical in sequence to at least a portion of the reference nucleic acid. Typically, the hybridizing portion of the cross-hybridizing nucleic acid is at least 80%, often at least 85%, 86%, 87%, 88%, 89% or even at least 90% identical in sequence to at least a portion of the reference nucleic acid. Often, the hybridizing portion of the cross-hybridizing nucleic acid will be at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical in sequence to at least a portion of the reference nucleic acid sequence. At times, the hybridizing portion of the cross-hybridizing nucleic acid will be at least 99.5% identical in sequence to at least a portion of the reference nucleic acid.

[0090] The invention also provides fragments of various of the isolated nucleic acids of the present invention.

[0091] By “fragments” of a reference nucleic acid is here intended isolated nucleic acids, however obtained, that have a nucleotide sequence identical to a portion of the reference nucleic acid sequence, which portion is at least 17 nucleotides and less than the entirety of the reference nucleic acid. As so defined, “fragments” need not be obtained by physical fragmentation of the reference nucleic acid, although such provenance is not thereby precluded.

[0092] In theory, an oligonucleotide of 17 nucleotides is of sufficient length as to occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. As is well known, further specificity can be obtained by probing nucleic acid samples of subgenomic complexity, and/or by using plural fragments as short as 17 nucleotides in length collectively to prime amplification of nucleic acids, as, e.g., by polymerase chain reaction (PCR).

[0093] As further described herein below, nucleic acid fragments that encode at least 6 contiguous amino acids (i.e., fragments of 18 nucleotides or more) are useful in directing the expression or the synthesis of peptides that have utility in mapping the epitopes of the protein encoded by the reference nucleic acid. See, e.g., Geysen et al., “Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid,” Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984); and U.S. Pat. Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties.

[0094] As further described herein below, fragments that encode at least 8 contiguous amino acids (i.e., fragments of 24 nucleotides or more) are useful in directing the expression or the synthesis of peptides that have utility as immunogens. See, e.g., Lerner, “Tapping the immunological repertoire to produce antibodies of predetermined specificity,” Nature 299:592-596 (1982); Shinnick et al., “Synthetic peptide immunogens as vaccines,” Annu. Rev. Microbiol. 37:425-46 (1983); Sutcliffe et al., “Antibodies that react with predetermined sites on proteins,” Science 219:660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties.

[0095] The nucleic acid fragment of the present invention is thus at least 17 nucleotides in length, typically at least 18 nucleotides in length, and often at least 24 nucleotides in length. Often, the nucleic acid of the present invention is at least 25 nucleotides in length, and even 30 nucleotides, 35 nucleotides, 40 nucleotides, or 45 nucleotides in length. Of course, larger fragments having at least 50 nt, at least 100 nt, at least 150 nt, 200 nt, 250 nt, 300 nt, 350 nt, 400 nt, 450 nt, or 500 nt or more are also useful, and at times preferred.

[0096] Having been based upon the mining of genomic sequence, rather than upon surveillance of expressed message, the present invention further provides isolated genome-derived nucleic acids that include portions of the human NEDD-1 gene.

[0097] The invention particularly provides genome-derived single exon probes.

[0098] As further described in commonly owned and copending U.S. patent application Ser. Nos. 09/774,203, filed Jan. 29, 2001 and 09/632,366, filed Aug. 3, 2000, and provisional U.S. patent application Nos. 60/236,359, filed May 26, 2000 and 60/236,359, filed Sep. 27, 2000, the disclosures of which are incorporated herein by reference in their entireties, “a single exon probe” comprises at least part of an exon (“reference exon”) and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon. The single exon probe will not, however, hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon but include one or more exons that are found adjacent to the reference exon in the genome.

[0099] Genome-derived single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. Often, the genome-derived single exon probe further comprises, contiguous to a second end of the exonic portion, a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome.

[0100] The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids. Accordingly, the exon portion is at least 17 nucleotides, typically at least 18 nucleotides, 20 nucleotides, 24 nucleotides, 25 nucleotides or even 30, 35, 40, 45, or 50 nucleotides in length, and can usefully include the entirety of the exon, up to 100 nt, 150 nt, 200 nt, 250 nt, 300 nt, 350 nt, 400 nt or even 500 nt or more in length.

[0101] The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon, that is, be unable to hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon but include one or more exons that are found adjacent to the reference exon in the genome.

[0102] Given variable spacing of exons through eukaryotic genomes, the maximum length of single exon probes of the present invention is typically no more than 25 kb, often no more than 20 kb, 15 kb, 10 kb or 7.5 kb, or even no more than 5 kb, 4 kb, 3 kb, or even no more than about 2.5 kb in length.

[0103] The genome-derived single exon probes of the present invention can usefully include at least a first terminal priming sequence not found in contiguity with the rest of the probe sequence in the genome, and often will contain a second terminal priming sequence not found in contiguity with the rest of the probe sequence in the genome.

[0104] The present invention also provides isolated genome-derived nucleic acids that include nucleic acid sequence elements that control transcription of the human NEDD-1 gene.

[0105] With a complete draft of the human genome now available, genomic sequences that are within the vicinity of the NEDD-1 gene (and that are additional to those described with particularity herein) can readily be obtained by PCR amplification.

[0106] The isolated nucleic acids of the present invention can be composed of natural nucleotides in native 5′-3′ phosphodiester internucleoside linkage—e.g., DNA or RNA—or can contain any or all of nonnatural nucleotide analogues, nonnative internucleoside bonds, or post-synthesis modifications, either throughout the length of the nucleic acid or localized to one or more portions thereof. As is well known in the art, when the isolated nucleic acid is used as a hybridization probe, the range of such nonnatural analogues, nonnative internucleoside bonds, or post-synthesis modifications will be limited to those that permit sequence-discriminating basepairing of the resulting nucleic acid. When used to direct expression or RNA or protein in vitro or in vivo, the range of such nonnatural analogues, nonnative internucleoside bonds, or post-synthesis modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the range of such changes will be limited to those that do not confer toxicity upon the isolated nucleic acid.

[0107] For example, when desired to be used as probes, the isolated nucleic acids of the present invention can usefully include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens.

[0108] Common radiolabeled analogues include those labeled with ³³P, ³²P, and ³⁵S, such as α-³²P-dATP, α-³²P-dCTP, α-³²P-dGTP, α-³²P-dTTP, α-³²P-3′dATP, α-³²P-ATP, α-³²P-CTP, α-³²P-GTP, α-³²P-UTP, α-³⁵S-dATP, γ-³⁵S-GTP, γ-³³P-dATP, and the like.

[0109] Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Pharmacia Biotech, Piscataway, N.J., USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas RedO-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, Oreg., USA).

[0110] Protocols are available for custom synthesis of nucleotides having other fluorophores. Henegariu et al., “Custom Fluorescent-Nucleotide Synthesis as an Alternative Method for Nucleic Acid Labeling,” Nature Biotechnol. 18:345-348 (2000), the disclosure of which is incorporated herein by reference in its entirety.

[0111] Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, Oreg., USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, Calif., USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, Ind., USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, Oreg., USA).

[0112] As another example, when desired to be used for antisense inhibition of transcription or translation, the isolated nucleic acids of the present invention can usefully include altered, often nuclease-resistant, internucleoside bonds. See Hartmann et al. (eds.), Manual of Antisense Methodology (Perspectives in Antisense Science), Kluwer Law International (1999) (ISBN:079238539X); Stein et al. (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (cover (1998) (ISBN: 0471172790); Chadwick et al. (eds.), Oligonucleotides as Therapeutic Agents—Symposium No. 209, John Wiley & Son Ltd (1997) (ISBN: 0471972797), the disclosures of which are incorporated herein by reference in their entireties. Such altered internucloside bonds are often desired also when the isolated nucleic acid of the present invention is to be used for targeted gene correction, Gamper et al., Nucl. Acids Res. 28(21):4332-4339 (2000), the disclosure of which is incorporated herein by reference in its entirety.

[0113] Modified oligonucleotide backbones often preferred when the nucleic acid is to be used for antisense purposes are, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of which are incorporated herein by reference in their entireties.

[0114] Preferred modified oligonucleotide backbones for antisense use that do not include a phosphorus atom have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, the disclosures of which are incorporated herein by reference in their entireties.

[0115] In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA).

[0116] In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages.

[0117] The uncharged nature of the PNA backbone provides PNA/DNA and PNA/RNA duplexes with a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes, resulting from the lack of charge repulsion between the PNA and DNA or RNA strand. In general, the Tm of a PNA/DNA or PNA/RNA duplex is 1° C. higher per base pair than the Tm of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl).

[0118] The neutral backbone also allows PNA to form stable DNA duplexes largely independent of salt concentration. At low ionic strength, PNA can be hybridized to a target sequence at temperatures that make DNA hybridization problematic or impossible. And unlike DNA/DNA duplex formation, PNA hybridization is possible in the absence of magnesium. Adjusting the ionic strength, therefore, is useful if competing DNA or RNA is present in the sample, or if the nucleic acid being probed contains a high level of secondary structure.

[0119] PNA also demonstrates greater specificity in binding to complementary DNA. A PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the Tm by 8-20° C. (15° C. on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the Tm by 4-16° C. (11° C. on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater.

[0120] Additionally, nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. As a result, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both in vivo and in vitro. In addition, PNA is stable over a wide pH range.

[0121] Because its backbone is formed from amide bonds, PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference; automated PNA synthesis is readily achievable on commercial synthesizers (see, e.g., “PNA User's Guide,” Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, Calif.).

[0122] PNA chemistry and applications are reviewed, inter alia, in Ray et al., FASEB J. 14(9):1041-60 (2000); Nielsen et al., Pharmacol Toxicol. 86(1):3-7 (2000); Larsen et al., Biochim Biophys Acta. 1489(1):159-66 (1999); Nielsen, Curr. Opin. Struct. Biol. 9(3):353-7 (1999), and Nielsen, Curr. Opin. Biotechnol. 10(1):71-5 (1999), the disclosures of which are incorporated herein by reference in their entireties.

[0123] Differences from nucleic acid compositions found in nature—e.g., nonnative bases, altered internucleoside linkages, post-synthesis modification—can be present throughout the length of the nucleic acid or can, instead, usefully be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and demonstrated utility for targeted gene repair, as further described in U.S. Pat. Nos. 5,760,012 and 5,731,181, the disclosures of which are incorporated herein by reference in their entireties. As another example, chimeric nucleic acids comprising both DNA and PNA have been demonstrated to have utility in modified PCR reactions. See Misra et al., Biochem. 37: 1917-1925 (1998); see also Finn et al., Nucl. Acids Res. 24: 3357-3363 (1996), incorporated herein by reference.

[0124] Unless otherwise specified, nucleic acids of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Baner et al., Curr. Opin. Biotechnol. 12:11-15 (2001); Escude et al., Proc. Natl. Acad. Sci. USA 14;96(19):10603-7 (1999); Nilsson et al., Science 265(5181):2085-8 (1994), the disclosures of which are incorporated herein by reference in their entireties. Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth et al., Biochim. Biophys. Acta. 1489(1):181-206 (1999); Fox, Curr. Med. Chem. 7(1):17-37 (2000); Kochetkova et al., Methods Mol. Biol. 130:189-201 (2000); Chan et al., J. Mol. Med. 75(4):267-82 (1997), the disclosures of which are incorporated herein by reference in their entireties.

[0125] The nucleic acids of the present invention can be detectably labeled.

[0126] Commonly-used labels include radionuclides, such as ³²P, ³³P, ³⁵S, ³H (and for NMR detection, ¹³C and ¹⁵N), haptens that can be detected by specific antibody or high affinity binding partner (such as avidin), and fluorophores.

[0127] As noted above, detectable labels can be incorporated by inclusion of labeled nucleotide analogues in the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and in vitro transcription driven, e.g., from phage promoters, such as T7, T3, and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach.

[0128] Analogues can also be incorporated during automated solid phase chemical synthesis.

[0129] As is well known, labels can also be incorporated after nucleic acid synthesis, with the 5′ phosphate and 3′ hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

[0130] Various other post-synthetic approaches permit internal labeling of nucleic acids.

[0131] For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and PNA to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, Oreg., USA and Amersham Pharmacia Biotech, Piscataway, N.J., USA); See Alers et al., Genes, Chromosomes & Cancer, Vol. 25, pp. 301-305 (1999); Jelsma et al., J. NIH Res. 5:82 (1994); Van Belkum et al., BioTechniques 16:148-153 (1994), incorporated herein by reference. As another example, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, Calif., USA) that is photo- or thermally coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

[0132] Multiple independent or interacting labels can be incorporated into the nucleic acids of the present invention.

[0133] For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching, Tyagi et al., Nature Biotechnol. 14: 303-308 (1996); Tyagi et al., Nature Biotechnol. 16, 49-53 (1998); Sokol et al., Proc. Natl. Acad. Sci. USA 95: 11538-11543 (1998); Kostrikis et al., Science 279:1228-1229 (1998); Marras et al., Genet. Anal. 14: 151-156 (1999); U.S. Pat. Nos. 5,846,726, 5,925,517, 5925517, or to report exonucleotidic excision, U.S. Pat. No. 5,538,848; Holland et al., Proc. Natl. Acad. Sci. USA 88:7276-7280 (1991); Heid et al., Genome Res. 6(10):986-94 (1996); Kuimelis et al., Nucleic Acids Symp Ser. (37):255-6 (1997); U.S. Pat. No. 5,723,591, the disclosures of which are incorporated herein by reference in their entireties.

[0134] So labeled, the isolated nucleic acids of the present invention can be used as probes, as further described below.

[0135] Nucleic acids of the present invention can also usefully be bound to a substrate. The substrate can porous or solid, planar or non-planar, unitary or distributed; the bond can be covalent or noncovalent. Bound to a substrate, nucleic acids of the present invention can be used as probes in their unlabeled state.

[0136] For example, the nucleic acids of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, nylon, or positively-charged derivatized nylon; so attached, the nucleic acids of the present invention can be used to detect human NEDD-1 nucleic acids present within a labeled nucleic acid sample, either a sample of genomic nucleic acids or a sample of transcript-derived nucleic acids, e.g. by reverse dot blot.

[0137] The nucleic acids of the present invention can also usefully be bound to a solid substrate, such as glass, although other solid materials, such as amorphous silicon, crystalline silicon, or plastics, can also be used. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof.

[0138] Typically, the solid substrate will be rectangular, although other shapes, particularly disks and even spheres, present certain advantages. Particularly advantageous alternatives to glass slides as support substrates for array of nucleic acids are optical discs, as described in Demers, “Spatially Addressable Combinatorial Chemical Arrays in CD-ROM Format,” international patent publication WO 98/12559, incorporated herein by reference in its entirety.

[0139] The nucleic acids of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some combination thereof.

[0140] The nucleic acids of the present invention can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, e.g. on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that include the nucleic acids of the present invention.

[0141] The isolated nucleic acids of the present invention can be used as hybridization probes to detect, characterize, and quantify human NEDD-1 nucleic acids in, and isolate human NEDD-1 nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

[0142] For example, the isolated nucleic acids of the present invention can be used as probes to detect and characterize gross alterations in the human NEDD-1 genomic locus, such as deletions, insertions, translocations, and duplications of the human NEDD-1 genomic locus through fluorescence in situ hybridization (FISH) to chromosome spreads. See, e.g., Andreeff et al. (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999) (ISBN: 0471013455), the disclosure of which is incorporated herein by reference in its entirety. The isolated nucleic acids of the present invention can be used as probes to assess smaller genomic alterations using, e.g., Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acids of the present invention can be used as probes to isolate genomic clones that include the nucleic acids of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

[0143] The isolated nucleic acids of the present invention can also be used as probes to detect, characterize, and quantify human NEDD-1 nucleic acids in, and isolate human NEDD-1 nucleic acids from, transcript-derived nucleic acid samples.

[0144] For example, the isolated nucleic acids of the present invention can be used as hybridization probes to detect, characterize by length, and quantify human NEDD-1 mRNA by northern blot of total or poly-A⁺ -selected RNA samples. For example, the isolated nucleic acids of the present invention can be used as hybridization probes to detect, characterize by location, and quantify human NEDD-1 message by in situ hybridization to tissue sections (see, e.g., Schwarchzacher et al., In Situ Hybridization, Springer-Verlag New York (2000) (ISBN: 0387915966), the disclosure of which is incorporated herein by reference in its entirety). For example, the isolated nucleic acids of the present invention can be used as hybridization probes to measure the representation of human NEDD-1 clones in a cDNA library. For example, the isolated nucleic acids of the present invention can be used as hybridization probes to isolate human NEDD-1 nucleic acids from cDNA libraries, permitting sequence level characterization of human NEDD-1 messages, including identification of deletions, insertions, truncations—including deletions, insertions, and truncations of exons in alternatively spliced forms—and single nucleotide polymorphisms.

[0145] All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook et al., Molecular Cloning: A Laboratory Manual (3^(rd) ed.), Cold Spring Harbor Laboratory Press (2001) (ISBN: 0879695773); Ausubel et al. (eds.), Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology (4^(th) ed.), John Wiley & Sons, 1999 (ISBN: 047132938X); and Walker et al. (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000) (ISBN: 0896034593), the disclosures of which are incorporated herein by reference in their entirety.

[0146] As described in the Examples herein below, the nucleic acids of the present invention can also be used to detect and quantify human NEDD-1 nucleic acids in transcript-derived samples—that is, to measure expression of the human NEDD-1 gene—when included in a microarray. Measurement of human NEDD-1 expression has particular utility in diagnosis and therapy of tumors, as further described in the Examples herein below.

[0147] As would be readily apparent to one of skill in the art, each human NEDD-1 nucleic acid probe—whether labeled, substrate-bound, or both—is thus currently available for use as a tool for measuring the level of human NEDD-1 expression in each of the tissues in which expression has already been confirmed, notably: testis, brain, skeletal muscle, liver, HeLa, heart, placenta, prostate, bone marrow, lung, adrenal, fetal liver and kidney. The utility is specific to the probe: under high stringency conditions, the probe reports the level of expression of message specifically containing that portion of the human NEDD-1 gene included within the probe.

[0148] Measuring tools are well known in many arts, not just in molecular biology, and are known to possess credible, specific, and substantial utility. For example, U.S. Pat. No. 6,016,191 describes and claims a tool for measuring characteristics of fluid flow in a hydrocarbon well; U.S. Pat. No. 6,042,549 describes and claims a device for measuring exercise intensity; U.S. Pat. No. 5,889,351 describes and claims a device for measuring viscosity and for measuring characteristics of a fluid; U.S. Pat. No. 5,570,694 describes and claims a device for measuring blood pressure; U.S. Pat. No. 5,930,143 describes and claims a device for measuring the dimensions of machine tools; U.S. Pat. No. 5,279,044 describes and claims a measuring device for determining an absolute position of a movable element; U.S. Pat. No. 5,186,042 describes and claims a device for measuring action force of a wheel; and U.S. Pat. No. 4,246,774 describes and claims a device for measuring the draft of smoking articles such as cigarettes.

[0149] As for tissues not yet demonstrated to express human NEDD-1, the human NEDD-1 nucleic acid probes of the present invention are currently available as tools for surveying such tissues to detect the presence of human NEDD-1 nucleic acids.

[0150] Survey tools—i.e., tools for determining the presence and/or location of a desired object by search of an area—are well known in many arts, not just in molecular biology, and are known to possess credible, specific, and substantial utility. For example, U.S. Pat. No. 6,046,800 describes and claims a device for surveying an area for objects that move; U.S. Pat. No. 6,025,201 describes and claims an apparatus for locating and discriminating platelets from non-platelet particles or cells on a cell-by-cell basis in a whole blood sample; U.S. Pat. No. 5,990,689 describes and claims a device for detecting and locating anomalies in the electromagnetic protection of a system; U.S. Pat. No. 5,984,175 describes and claims a device for detecting and identifying wearable user identification units; U.S. Patent No. 3,980,986 (“Oil well survey tool”), describes and claims a tool for finding the position of a drill bit working at the bottom of a borehole.

[0151] As noted above, the nucleic acid probes of the present invention are useful in constructing microarrays; the microarrays, in turn, are products of manufacture that are useful for measuring and for surveying gene expression.

[0152] When included on a microarray, each human NEDD-1 nucleic acid probe makes the microarray specifically useful for detecting that portion of the human NEDD-1 gene included within the probe, thus imparting upon the microarray device the ability to detect a signal where, absent such probe, it would have reported no signal. This utility makes each individual probe on such microarray akin to an antenna, circuit, firmware or software element included in an electronic apparatus, where the antenna, circuit, firmware or software element imparts upon the apparatus the ability newly and additionally to detect signal in a portion of the radio-frequency spectrum where previously it could not; such devices are known to have specific, substantial, and credible utility.

[0153] Changes in the level of expression need not be observed for the measurement of expression to have utility.

[0154] For example, where gene expression analysis is used to assess toxicity of chemical agents on cells, the failure of the agent to change a gene's expression level is evidence that the drug likely does not affect the pathway of which the gene's expressed protein is a part. Analogously, where gene expression analysis is used to assess side effects of pharmacologic agents—whether in lead compound discovery or in subsequent screening of lead compound derivatives—the inability of the agent to alter a gene's expression level is evidence that the drug does not affect the pathway of which the gene's expressed protein is a part. WO 99/58720, incorporated herein by reference in its entirety, provides methods for quantifying the relatedness of a first and second gene expression profile and for ordering the relatedness of a plurality of gene expression profiles, without regard to the identity or function of the genes whose expression is used in the calculation.

[0155] Gene expression analysis, including gene expression analysis by microarray hybridization, is, of course, principally a laboratory-based art. Devices and apparatus used principally in laboratories to facilitate laboratory research are well-established to possess specific, substantial, and credible utility. For example, U.S. Pat. No. 6,001,233 describes and claims a gel electrophoresis apparatus having a cam-activated clamp; for example, U.S. Pat. No. 6,051,831 describes and claims a high mass detector for use in time-of-flight mass spectrometers; for example, U.S. Pat. No. 5,824,269 describes and claims a flow cytometer—as is well known, few gel electrophoresis apparatuses, TOF-MS devices, or flow cytometers are sold for home use.

[0156] Indeed, and in particular, nucleic acid microarrays, as devices intended for laboratory use in measuring gene expression, are well-established to have specific, substantial and credible utility. Thus, the microarrays of the present invention have at least the specific, substantial and credible utilities of the microarrays claimed as devices and articles of manufacture in the following U.S. patents, the disclosures of each of which is incorporated herein by reference: U.S. Pat. Nos. 5,445,934 (“Array of oligonucleotides on a solid substrate”); 5,744,305 (“Arrays of materials attached to a substrate”); and 6,004,752 (“Solid support with attached molecules”).

[0157] Genome-derived single exon probes and genome-derived single exon probe microarrays have the additional utility, inter alia, of permitting high-throughput detection of splice variants of the nucleic acids of the present invention, as further described in copending and commonly owned U.S. patent application Ser. No. 09/632,366, filed Aug. 3, 2000, the disclosure of which is incorporated herein by reference in its entirety.

[0158] The isolated nucleic acids of the present invention can also be used to prime synthesis of nucleic acid, for purpose of either analysis or isolation, using mRNA, cDNA, or genomic DNA as template.

[0159] For use as primers, at least 17 contiguous nucleotides of the isolated nucleic acids of the present invention will be used. Often, at least 18, 19, or 20 contiguous nucleotides of the nucleic acids of the present invention will be used, and on occasion at least 20, 22, 24, or 25 contiguous nucleotides of the nucleic acids of the present invention will be used, and even 30 nucleotides or more of the nucleic acids of the present invention can be used to prime specific synthesis.

[0160] The nucleic acid primers of the present invention can be used, for example, to prime first strand cDNA synthesis on an mRNA template.

[0161] Such primer extension can be done directly to analyze the message. Alternatively, synthesis on an mRNA template can be done to produce first strand cDNA. The first strand cDNA can thereafter be used, inter alia, directly as a single-stranded probe, as above-describe, as a template for sequencing—permitting identification of alterations, including deletions, insertions, and substitutions, both normal allelic variants and mutations associated with abnormal phenotypes—or as a template, either for second strand cDNA synthesis (e.g., as an antecedent to insertion into a cloning or expression vector), or for amplification.

[0162] The nucleic acid primers of the present invention can also be used, for example, to prime single base extension (SBE) for SNP detection (see, e.g., U.S. Pat. No. 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

[0163] As another example, the nucleic acid primers of the present invention can be used to prime amplification of human NEDD-1 nucleic acids, using transcript-derived or genomic DNA as template.

[0164] Primer-directed amplification methods are now well-established in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, inter alia, in McPherson, PCR (Basics: From Background to Bench), Springer Verlag (2000) (ISBN: 0387916008); Innis et al. (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999) (ISBN: 0123721857); Gelfand et al. (eds.), PCR Strategies, Academic Press (1998) (ISBN: 0123721822); Newton et al., PCR, Springer-Verlag New York (1997) (ISBN: 0387915060); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996) (ISBN: 047195697X); White (ed.), PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering, Vol. 67, Humana Press (1996) (ISBN: 0896033430); McPherson et al. (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995) (ISBN: 0199634254), the disclosures of which are incorporated herein by reference in their entireties. Methods for performing RT-PCR are collected, e.g., in Siebert et al. (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998 (ISBN: 1881299147); Siebert (ed.), PCR Technique:RT-PCR, Eaton Publishing Company/BioTechniques Books (1995) (ISBN:1881299139), the disclosure of which is incorporated herein by reference in its entirety.

[0165] Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. See, e.g., Schweitzer et al., Curr. Opin. Biotechnol. 12(1):21-7 (2001); U.S. Pat. Nos. 5,854,033 and 5,714,320 and international patent publications WO 97/19193 and WO 00/15779, the disclosures of which are incorporated herein by reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. See, e.g., Lizardi et al., Nature Genet. 19(3):225-32 (1998).

[0166] As further described below, nucleic acids of the present invention, inserted into vectors that flank the nucleic acid insert with a phage promoter, such as T7, T3, or SP6 promoter, can be used to drive in vitro expression of RNA complementary to either strand of the nucleic acid of the present invention. The RNA can be used, inter alia, as a single-stranded probe, to effect in cDNA-mRNA subtraction, or for in vitro translation.

[0167] As will be further discussed herein below, nucleic acids of the present invention that encode human NEDD-1 protein or portions thereof can be used, inter alia, to express the human NEDD-1 proteins or protein fragments, either alone, or as part of fusion proteins.

[0168] Expression can be from genomic nucleic acids of the present invention, or from transcript-derived nucleic acids of the present invention.

[0169] Where protein expression is effected from genomic DNA, expression will typically be effected in eukaryotic, typically mammalian, cells capable of splicing introns from the initial RNA transcript. Expression can be driven from episomal vectors, such as EBV-based vectors, or can be effected from genomic DNA integrated into a host cell chromosome. As will be more fully described below, where expression is from transcript-derived (or otherwise intron-less) nucleic acids of the present invention, expression can be effected in wide variety of prokaryotic or eukaryotic cells.

[0170] Expressed in vitro, the protein, protein fragment, or protein fusion can thereafter be isolated, to be used, inter alia, as a standard in immunoassays specific for the proteins, or protein isoforms, of the present invention; to be used as a therapeutic agent, e.g., to be administered as passive replacement therapy in individuals deficient in the proteins of the present invention, or to be administered as a vaccine; to be used for in vitro production of specific antibody, the antibody thereafter to be used, e.g., as an analytical reagent for detection and quantitation of the proteins of the present invention or to be used as an immunotherapeutic agent.

[0171] The isolated nucleic acids of the present invention can also be used to drive in vivo expression of the proteins of the present invention. in vivo expression can be driven from a vector—typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV)—for purpose of gene therapy. In vivo expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, Calif., USA), for purpose of “naked” nucleic acid vaccination, as further described in U.S. Pat. Nos. 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; 6,204,250, the disclosures of which are incorporated herein by reference in their entireties.

[0172] The nucleic acids of the present invention can also be used for antisense inhibition of transcription or translation. See Phillips (ed.), Antisense Technology, Part B, Methods in Enzymology Vol. 314, Academic Press, Inc. (1999) (ISBN: 012182215X); Phillips (ed.), Antisense Technology, Part A, Methods in Enzymology Vol. 313, Academic Press, Inc. (1999) (ISBN: 0121822141); Hartmann et al. (eds.), Manual of Antisense Methodology (Perspectives in Antisense Science), Kluwer Law InternationaL (1999) (ISBN:079238539X); Stein et al. (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (cover (1998) (ISBN: 0471172790); Agrawal et al. (eds.), Antisense Research and Application, Springer-Verlag New York, Inc. (1998) (ISBN: 3540638334); Lichtenstein et al. (eds.), Antisense Technology: A Practical Approach, Vol. 185, Oxford University Press, INC. (1998) (ISBN: 0199635838); Gibson (ed.), Antisense and Ribozyme Methodology: Laboratory Companion, Chapman & Hall (1997) (ISBN: 3826100794); Chadwick et al. (eds.), Oligonucleotides as Therapeutic Agents—Symposium No. 209, John Wiley & Son Ltd (1997) (ISBN: 0471972797), the disclosures of which are incorporated herein by reference in their entireties.

[0173] Nucleic acids, particularly cDNAs, of the present invention that encode full-length human NEDD-1 protein isoforms, have additional, well-recognized, utility as commercial products of manufacture suitable for sale.

[0174] For example, Invitrogen Corp. (Carlsbad, Calif., USA), through its Research Genetics subsidiary, sells full length human cDNAs (other than NEDD-1) cloned into one of a selection of expression vectors as GeneStorm® expression-ready clones; utility is specific for the gene, since each gene is capable of being ordered separately and has a distinct catalogue number, and utility is substantial, each clone selling for $650.00 US. Similarly, Incyte Genomics (Palo Alto, Calif., USA) sells clones from public and proprietary sources in multi-well plates or individual tubes.

[0175] Nucleic acids of the present invention that include genomic regions encoding the human NEDD-1 protein, or portions thereof, have yet further utilities.

[0176] For example, genomic nucleic acids of the present invention can be used as amplification substrates, e.g. for preparation of genome-derived single exon probes of the present invention, described above, and further described in copending and commonly-owned U.S. patent application Ser. Nos. 09/774,203, filed Jan. 29, 2001, and 09/632,366, filed Aug. 3, 2000 and commonly-owned and copending U.S. provisional patent application Nos. 60/207,456, filed May 26, 2000, 60/234,687, filed Sep. 21, 2000, 60/236,359, filed Sep. 27, 2000, the disclosures of which are incorporated herein by reference in their entireties.

[0177] As another example, genomic nucleic acids of the present invention can be integrated non-homologously into the genome of somatic cells in order, e.g., to create stable cell lines capable of producing the proteins of the present invention.

[0178] As another example, more fully described herein below, genomic nucleic acids of the present invention can be integrated nonhomologously into embryonic stem (ES) cells to create transgenic non-human animals capable of producing the proteins of the present invention.

[0179] Genomic nucleic acids of the present invention can also be used to target homologous recombination to the human NEDD-1 locus. See, e.g., U.S. Pat. Nos. 6,187,305; 6,204,061; 5,631,153; 5,627,059; 5,487,992; 5,464,764; 5,614,396; 5,527,695 and 6,063,630; and Kmiec et al. (eds.), Gene Targeting Protocols, Vol. 133, Humana Press (2000) (ISBN: 0896033600); Joyner (ed.), Gene Targeting: A Practical Approach, Oxford University Press, Inc. (2000) (ISBN: 0199637938); Sedivy et al., Gene Targeting, Oxford University Press (1998) (ISBN: 071677013X); Tymms et al. (eds.), Gene Knockout Protocols, Humana Press (2000) (ISBN: 0896035727); Mak et al. (eds.), The Gene Knockout FactsBook, Vol. 2, Academic Press, Inc. (1998) (ISBN: 0124660444); Torres et al., Laboratory Protocols for Conditional Gene Targeting, Oxford University Press (1997) (ISBN: 019963677X); Vega (ed.), Gene Targeting, CRC Press, LLC (1994) (ISBN: 084938950X), the disclosures of which are incorporated herein by reference in their entireties.

[0180] Where the genomic region includes transcription regulatory elements, homologous recombination can be used to alter the expression of context, both for purpose of in vitro production of human NEDD-1 protein from human cells, and for purpose of gene therapy. See, e.g., U.S. Pat. Nos. 5,981,214, 6,048,524; 5,272,071.

[0181] Fragments of the nucleic acids of the present invention smaller than those typically used for homologous recombination can also be used for targeted gene correction or alteration, possibly by cellular mechanisms different from those engaged during homologous recombination.

[0182] For example, partially duplexed RNA/DNA chimeras have been shown to have utility in targeted gene correction, U.S. Pat. Nos. 5,945,339, 5,888,983, 5,871,984, 5,795,972, 5,780,296, 5,760,012, 5,756,325, 5,731,181, the disclosures of which are incorporated herein by reference in their entireties. So too have small oligonucleotides fused to triplexing domains have been shown to have utility in targeted gene correction, Culver et al., “Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides,” Nature Biotechnol. 17(10):989-93 (1999), as have oligonucleotides having modified terminal bases or modified terminal internucleoside bonds, Gamper et al., Nucl. Acids Res. 28(21):4332-9 (2000), the disclosures of which are incorporated herein by reference.

[0183] The isolated nucleic acids of the present invention can also be used to provide the initial substrate for recombinant engineering of NEDD-1 protein variants having desired phenotypic improvements. Such engineering includes, for example, site-directed mutagenesis, random mutagenesis with subsequent functional screening, and more elegant schemes for recombinant evolution of proteins, as are described, inter alia, in U.S. Pat. Nos. 6,180,406; 6,165,793; 6,117,679; and 6,096,548, the disclosures of which are incorporated herein by reference in their entireties.

[0184] Nucleic acids of the present invention can be obtained by using the labeled probes of the present invention to probe nucleic acid samples, such as genomic libraries, cDNA libraries, and mRNA samples, by standard techniques. Nucleic acids of the present invention can also be obtained by amplification, using the nucleic acid primers of the present invention, as further demonstrated in Example 1, herein below. Nucleic acids of the present invention of fewer than about 100 nt can also be synthesized chemically, typically by solid phase synthesis using commercially available automated synthesizers.

[0185] “Full Length” Human NEDD-1 Nucleic Acids

[0186] In a first series of nucleic acid embodiments, the invention provides isolated nucleic acids that encode the entirety of the human NEDD-1 protein. As discussed above, the “full-length” nucleic acids of the present invention can be used, inter alia, to express full length human NEDD-1 protein The full-length nucleic acids can also be used as nucleic acid probes; used as probes, the isolated nucleic acids of these embodiments will hybridize to human NEDD-1.

[0187] In a first such embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of the nucleic acid of the NEDD-1 ATCC deposit received at ATCC May 23, 2001 and accorded an accession date of ______, and accession no. of ______, (ii) the nucleotide sequence of SEQ ID NO: 1, or (iii) the complement of (i) or (ii). The ATCC deposit has, and SEQ ID NO: 1 presents, the entire cDNA of human NEDD-1, including the 5′ untranslated (UT) region and 3′ UT.

[0188] In a second embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 2 or (ii) the complement of (i). SEQ ID NO: 2 presents the entire cDNA of human NEDD-1 including a 208 nucleotide 3′UTR sequence.

[0189] In a third embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 3, (ii) a degenerate variant of the nucleotide sequence of SEQ ID NO: 3, or (iii) the complement of (i) or (ii). SEQ ID NO: 3 presents the open reading frame (ORF) from SEQ ID NO: 1.

[0190] In a fourth embodiment, the invention provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes a polypeptide with the amino acid sequence of SEQ ID NO: 4 or (ii) the complement of a nucleotide sequence that encodes a polypeptide with the amino acid sequence of SEQ ID NO: 4. SEQ ID NO: 4 provides the amino acid sequence of human NEDD-1.

[0191] In a fifth embodiment, the invention provides an isolated nucleic acid having a nucleotide sequence that (i) encodes a polypeptide having the sequence of SEQ ID NO: 4, (ii) encodes a polypeptide having the sequence of SEQ ID NO: 4 with conservative amino acid substitutions, or (iii) that is the complement of (i) or (ii), where SEQ ID NO: 4 provides the amino acid sequence of human NEDD-1.

[0192] Selected Partial Nucleic Acids

[0193] In a second series of nucleic acid embodiments, the invention provides isolated nucleic acids that encode select portions of human NEDD-1. As will be further discussed herein below, these “partial” nucleic acids can be used, inter alia, to express specific portions of the human NEDD-1. These “partial” nucleic acids can also be used, inter alia, as nucleic probes.

[0194] In a first such embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 5, (ii) a degenerate variant of SEQ ID NO: 5, or (iii) the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb length. SEQ ID NO: 5 encodes a novel portion of NEDD-1. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0195] In another embodiment, the invention provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes SEQ ID NO: 6 or (ii) the complement of a nucleotide sequence that encodes SEQ ID NO 6, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, frequently no more than about 50 kb in length. SEQ ID NO: 6 is the amino acid sequence encoded by SEQ ID NO:5. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0196] In another embodiment, the invention provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes SEQ ID NO: 6, (ii) a nucleotide sequence that encodes SEQ ID NO: 6 with conservative substititions, or (iii) the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0197] Cross-hybridizing Nucleic Acids

[0198] In another series of nucleic acid embodiments, the invention provides isolated nucleic acids that hybridize to various of the human NEDD-1 nucleic acids of the present invention. These cross-hybridizing nucleic acids can be used, inter alia, as probes for, and to drive expression of, proteins that are related to human NEDD-1 of the present invention as further isoforms, homologues, paralogues, or orthologues.

[0199] In a first such embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under high stringency conditions to a probe the nucleotide sequence of which consists of SEQ ID NO: 3 or the complement of SEQ ID NO: 3, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0200] In a further embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under moderate stringency conditions to a probe the nucleotide sequence of which consists of SEQ ID NO: 3 or the complement of SEQ ID NO: 3, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0201] In a further embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under high stringency conditions to a probe the nucleotide sequence of which consists of SEQ ID NO: 5 or the complement of SEQ ID NO: 5, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0202] In a further embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under moderate stringency conditions to a probe the nucleotide sequence of which consists of SEQ ID NO: 5 or the complement of SEQ ID NO: 5, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0203] In a further embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under high stringency conditions to a hybridization probe the nucleotide sequence of which (i) encodes a polypeptide having the sequence of SEQ ID NO: 6, (ii) encodes a polypeptide having the sequence of SEQ ID NO: 6 with conservative amino acid substitutions, or (iii) is the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0204] In a further embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under moderate stringency conditions to a probe the nucleotide sequence of which consists of SEQ ID NO: 6 or the complement of SEQ ID NO: 6, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0205] Particularly Useful Nucleic Acids

[0206] Particularly useful among the above-described nucleic acids are those that are expressed, or the complement of which are expressed, in testis, brain, skeletal muscle, liver, HeLa, heart, placenta, prostate, bone marrow, lung, adrenal, fetal liver and/or kidney, and whose expression is decreased in neoplastic cells.

[0207] Other particularly useful embodiments of the nucleic acids above-described are those that encode, or the complement of which encode, a polypeptide having WD motifs.

[0208] Nucleic Acid Fragments

[0209] In another series of nucleic acid embodiments, the invention provides fragments of various of the isolated nucleic acids of the present invention which prove useful, inter alia, as nucleic acid probes, as amplification primers, and to direct expression or synthesis of epitopic or immunogenic protein fragments.

[0210] In a first embodiment, the invention provides an isolated nucleic acid comprising at least 17 nucleotides, 18 nucleotides, 20 nucleotides, 24 nucleotides, or 25 nucleotides of (i) SEQ ID NO: 5, (ii) a degenerate variant of SEQ ID NO: 5, or (iii) the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0211] The invention also provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes a peptide of at least 8 contiguous amino acids of SEQ ID NO: 6, or (ii) the complement of a nucleotide sequence that encodes a peptide of at least 83 contiguous amino acids of SEQ ID NO: 6, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0212] The invention also provides an isolated nucleic acid comprising a nucleotide sequence that (i) encodes a polypeptide having the sequence of at least 8 contiguous amino acids of SEQ ID NO: 6, (ii) encodes a polypeptide having the sequence of at least 8 contiguous amino acids of SEQ ID NO: 6 with conservative amino acid substitutions, or (iii) is the complement of (i) or (ii).

[0213] Single Exon Probes

[0214] The invention further provides genome-derived single exon probes having portions of no more than one exon of the human NEDD-1 gene. As further described in commonly owned and copending U.S. patent application Ser. No. 09/632,366, filed Aug. 3, 2000, the disclosure of which is incorporated herein by reference in its entirety, such single exon probes have particular utility in identifying and characterizing splice variants. In particular, such single exon probes are useful for identifying and discriminating the expression of distinct isoforms of human NEDD-1.

[0215] In a first embodiment, the invention provides an isolated nucleic acid comprising a nucleotide sequence of no more than one portion of SEQ ID NOs: 7-21 or the complement of SEQ ID Nos: 7-21, wherein the portion comprises at least 17 contiguous nucleotides, 18 contiguous nucleotides, 20 contiguous nucleotides, 24 contiguous nucleotides, 25 contiguous nucleotides, or 50 contiguous nucleotides of any one of SEQ ID Nos: 7-21, or their complement. In a further embodiment, the exonic portion comprises the entirety of the referenced SEQ ID NO: or its complement.

[0216] In other embodiments, the invention provides isolated single exon probes having the nucleotide sequence of any one of SEQ ID NOs: 22-36.

[0217] Transcription Control Nucleic Acids

[0218] In another aspect, the present invention provides genome-derived isolated nucleic acids that include nucleic acid sequence elements that control transcription of the human NEDD-1 gene. These nucleic acids can be used, inter alia, to drive expression of heterologous coding regions in recombinant constructs, thus conferring upon such heterologous coding regions the expression pattern of the native human NEDD-1 gene. These nucleic acids can also be used, conversely, to target heterologous transcription control elements to the human NEDD-1 genomic locus, altering the expression pattern of the human NEDD-1 gene itself. In a first such embodiment, the invention provides an isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO: 37 or its complement, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length. In another embodiment, the invention provides an isolated nucleic acid comprising at least 17, 18, 20, 24, or 25 nucleotides of the sequence of SEQ ID NO: 37 or its complement, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

[0219] Vectors and Host Cells

[0220] In another aspect, the present invention provides vectors that comprise one or more of the isolated nucleic acids of the present invention, and host cells in which such vectors have been introduced.

[0221] The vectors can be used, inter alia, for propagating the nucleic acids of the present invention in host cells (cloning vectors), for shuttling the nucleic acids of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acids of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acids of the present invention in vitro or within a host cell, and for expressing polypeptides encoded by the nucleic acids of the present invention, alone or as fusions to heterologous polypeptides. Vectors of the present invention will often be suitable for several such uses.

[0222] Vectors are by now well-known in the art, and are described, inter alia, in Jones et al. (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd 1998 (ISBN: 047196266X); Jones et al. (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd, 1998 (ISBN:0471962678); Gacesa et al., Vectors: Essential Data, John Wiley & Sons, 1995 (ISBN: 0471948411); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co., 2000 (ISBN: 188129935X); Sambrook et al., Molecular Cloning: A Laboratory Manual (3^(rd) ed.), Cold Spring Harbor Laboratory Press, 2001 (ISBN: 0879695773); Ausubel et al. (eds.), Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology (4^(th) ed.), John Wiley & Sons, 1999 (ISBN: 047132938X), the disclosures of which are incorporated herein by reference in their entireties. Furthermore, an enormous variety of vectors are available commercially. Use of existing vectors and modifications thereof being well within the skill in the art, only basic features need be described here.

[0223] Typically, vectors are derived from virus, plasmid, prokaryotic or eukaryotic chromosomal elements, or some combination thereof, and include at least one origin of replication, at least one site for insertion of heterologous nucleic acid, typically in the form of a polylinker with multiple, tightly clustered, single cutting restriction sites, and at least one selectable marker, although some integrative vectors will lack an origin that is functional in the host to be chromosomally modified, and some vectors will lack selectable markers. Vectors of the present invention will further include at least one nucleic acid of the present invention inserted into the vector in at least one location.

[0224] Where present, the origin of replication and selectable markers are chosen based upon the desired host cell or host cells; the host cells, in turn, are selected based upon the desired application.

[0225] For example, prokaryotic cells, typically E. coli, are typically chosen for cloning. In such case, vector replication is predicated on the replication strategies of coliform-infecting phage—such as phage lambda, M13, T7, T3 and P1—or on the replication origin of autonomously replicating episomes, notably the ColE1 plasmid and later derivatives, including pBR322 and the pUC series plasmids. Where E. coli is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: e.g., typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin, zeocin; auxotrophic markers can also be used.

[0226] As another example, yeast cells, typically S. cerevisiae, are chosen, inter alia, for eukaryotic genetic studies, due to the ease of targeting genetic changes by homologous recombination and to the ready ability to complement genetic defects using recombinantly expressed proteins, for identification of interacting protein components, e.g. through use of a two-hybrid system, and for protein expression. Vectors of the present invention for use in yeast will typically, but not invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast.

[0227] Integrative YIp vectors do not replicate autonomously, but integrate, typically in single copy, into the yeast genome at low frequencies and thus replicate as part of the host cell chromosome; these vectors lack an origin of replication that is functional in yeast, although they typically have at least one origin of replication suitable for propagation of the vector in bacterial cells. YEp vectors, in contrast, replicate episomally and autonomously due to presence of the yeast 2 micron plasmid origin (2 μm ori). The YCp yeast centromere plasmid vectors are autonomously replicating vectors containing centromere sequences, CEN, and autonomously replicating sequences, ARS; the ARS sequences are believed to correspond to the natural replication origins of yeast chromosomes. YACs are based on yeast linear plasmids, denoted YLp, containing homologous or heterologous DNA sequences that function as telomeres (TEL) in vivo, as well as containing yeast ARS (origins of replication) and CEN (centromeres) segments.

[0228] Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in Saccharomyces cerevisiae) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as ura3-52, his3-D1, leu2-D1, trpl-D1 and lys2-201. The URA3 and LYS2 yeast genes further permit negative selection based on specific inhibitors, 5-fluoro-orotic acid (FOA) and α-aminoadipic acid (αAA), respectively, that prevent growth of the prototrophic strains but allows growth of the ura3 and lys2 mutants, respectively. Other selectable markers confer resistance to, e.g., zeocin.

[0229] As yet another example, insect cells are often chosen for high efficiency protein expression. Where the host cells are from Spodoptera frugiperda—e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, Conn., USA)—the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5′ and 3′ of the expression cassette on the transfer vectors. Following cotransfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

[0230] As yet another example, mammalian cells are often chosen for expression of proteins intended as pharmaceutical agents, and are also chosen as host cells for screening of potential agonist and antagonists of a protein or a physiological pathway.

[0231] Where mammalian cells are chosen as host cells, vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, e.g., in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy.

[0232] Selectable markers for use in mammalian cells include resistance to neomycin (G418), blasticidin, hygromycin and to zeocin, and selection based upon the purine salvage pathway using HAT medium.

[0233] Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

[0234] For propagation of nucleic acids of the present invention that are larger than can readily be accomodated in vectors derived from plasmids or virus, the invention further provides artificial chromosomes—BACs, YACs, and HACs—that comprise NEDD-1 nucleic acids, often genomic nucleic acids.

[0235] The BAC system is based on the well-characterized E. coli F-factor, a low copy plasmid that exists in a supercoiled circular form in host cells. The structural features of the F-factor allow stable maintenance of individual human DNA clones as well as easy manipulation of the cloned DNA. See Shizuya et al., Keio J. Med. 50(l):26-30 (2001); Shizuya et al., Proc. Natl. Acad. Sci. USA 89(18):8794-7 (1992).

[0236] YACs are based on yeast linear plasmids, denoted YLp, containing homologous or heterologous DNA sequences that function as telomeres (TEL) in vivo, as well as containing yeast ARS (origins of replication) and CEN (centromeres) segments.

[0237] HACs are human artifical chromosomes. Kuroiwa et al., Nature Biotechnol. 18(10):1086-90 (2000); Henning et al., Proc. Natl. Acad. Sci. USA 96(2):592-7 (1999); Harrington et al., Nature Genet. 15(4):345-55 (1997). In one version, long synthetic arrays of alpha satellite DNA are combined with telomeric DNA and genomic DNA to generate linear microchromosomes that are mitotically and cytogenetically stable in the absence of selection.

[0238] Vectors of the present invention will also often include elements that permit in vitro transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate in vitro production of both sense and antisense strands.

[0239] Expression vectors of the present invention—that is, those vectors that will drive expression of polypeptides from the inserted heterologous nucleic acid—will often include a variety of other genetic elements operatively linked to the protein-encoding heterologous nucleic acid insert, typically genetic elements that drive transcription, such as promoters and enhancer elements, those that facilitate RNA processing, such as transcription termination and/or polyadenylation signals, and those that facilitate translation, such as ribosomal consensus sequences.

[0240] For example, vectors for expressing proteins of the present invention in prokaryotic cells, typically E. coli, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the trc promoter, a hybrid derived from the trp and lac promoters, the bacteriophage T7 promoter (in E. coli cells engineered to express the T7 polymerase), or the araBAD operon. Often, such prokaryotic expression vectors will further include transcription terminators, such as the aspA terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer et al., Proc. Natl. Acad. Sci. USA 83:8506-8510 (1986).

[0241] As another example, vectors for expressing proteins of the present invention in yeast cells, typically S. cerevisiae, will include a yeast promoter, such as the CYC1 promoter, the GAL1 promoter, ADH1 promoter, or the GPD promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the CYC1 or ADHL gene.

[0242] As another example, vectors for expressing proteins of the present invention in mammalian cells will include a promoter active in mammalian cells. Such promoters are often drawn from mammalian viruses—such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), and the enhancer-promoter from SV40. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron II of rabbit β-globin gene and the SV40 splice elements.

[0243] Vector-drive protein expression can be constitutive or inducible.

[0244] Inducible vectors include either naturally inducible promoters, such as the trc promoter, which is regulated by the lac operon, and the pL promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid Plac/ara-1 promoter and the PLtetO-1 promoter. The PltetO-1 promoter takes advantage of the high expression levels from the PL promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the Tn10 tetracycline resistance operon, causing this promoter to be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline.

[0245] As another example of inducible elements, hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

[0246] Expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization.

[0247] For example, proteins of the present invention can be expressed with a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, Calif., USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, Calif., USA). As another example, the fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverley, Mass., USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, Calif., USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of in vivo biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, Wis., USA). As another useful alternative, the proteins of the present invention can be expressed as a fusion to glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, Calif., USA), with subsequent elution with free glutathione.

[0248] Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, Calif., USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, Calif., USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, Calif., USA), and the HA epitope.

[0249] For secretion of expressed proteins, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, Calif., USA) are 5.2 kb mammalian expression vectors that carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

[0250] Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides larger than purification and/or identification tags. Useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusions for use in two hybrid systems.

[0251] Vectors for phage display fuse the encoded polypeptide to, e.g., the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. See Barbas et al., Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001) (ISBN 0-87969-546-3); Kay et al. (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, San Diego: Academic Press, Inc., 1996; Abelson et al. (eds.), Combinatorial Chemistry, Methods in Enzymology vol. 267, Academic Press (May 1996).

[0252] Vectors for yeast display, e.g. the pYD1 yeast display vector (Invitrogen, Carlsbad, Calif., USA), use the α-agglutinin yeast adhesion receptor to display recombinant protein on the surface of S. cerevisiae. Vectors for mammalian display, e.g., the pDisplay™ vector (Invitrogen, Carlsbad, Calif., USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet derived growth factor receptor.

[0253] A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from Aequrea victoria (“GFP”) and its variants. These proteins are intrinsically fluorescent: the GFP-like chromophore is entirely encoded by its amino acid sequence and can fluoresce without requirement for cofactor or substrate.

[0254] Structurally, the GFP-like chromophore comprises an 11-stranded β-barrel (β-can) with a central α-helix, the central α-helix having a conjugated π-resonance system that includes two aromatic ring systems and the bridge between them. The π-resonance system is created by autocatalytic cyclization among amino acids; cyclization proceeds through an imidazolinone intermediate, with subsequent dehydrogenation by molecular oxygen at the Cα-Cβ bond of a participating tyrosine.

[0255] The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring proteins, such as A. Victoria GFP (GenBank accession number AAA27721), Renilla reniformis GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. Li et al.,“Deletions of the Aequorea Victoria Green Fluorescent Protein Define the Minimal Domain Required for Fluorescence,” J. Biol. Chem. 272:28545-28549 (1997).

[0256] Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from those found in nature. Typically, such modifications are made to improve recombinant production in heterologous expression systems (with or without change in protein sequence), to alter the excitation and/or emission spectra of the native protein, to facilitate purification, to facilitate or as a consequence of cloning, or are a fortuitous consequence of research investigation.

[0257] The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well-known in the art. Early results of these efforts are reviewed in Helm et al., Curr. Biol. 6:178-182 (1996), incorporated herein by reference in its entirety; a more recent review, with tabulation of useful mutations, is found in Palm et al., “Spectral Variants of Green Fluorescent Protein,” in Green Fluorescent Proteins, Conn (ed.), Methods Enzymol. vol. 302, pp. 378-394 (1999), incorporated herein by reference in its entirety. A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention.

[0258] For example, EGFP (“enhanced GFP”), Cormack et al., Gene 173:33-38 (1996); U.S. Pat. Nos. 6,090,919 and 5,804,387, is a red-shifted, human codon-optimized variant of GFP that has been engineered for brighter fluorescence, higher expression in mammalian cells, and for an excitation spectrum optimized for use in flow cytometers. EGFP can usefully contribute a GFP-like chromophore to the fusion proteins of the present invention. A variety of EGFP vectors, both plasmid and viral, are available commercially (Clontech Labs, Palo Alto, Calif., USA), including vectors for bacterial expression, vectors for N-terminal protein fusion expression, vectors for expression of C-terminal protein fusions, and for bicistronic expression.

[0259] Toward the other end of the emission spectrum, EBFP (“enhanced blue fluorescent protein”) and BFP2 contain four amino acid substitutions that shift the emission from green to blue, enhance the brightness of fluorescence and improve solubility of the protein, Heim et al., Curr. Biol. 6:178-182 (1996); Cormack et al., Gene 173:33-38 (1996). EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria; as is further discussed below, the host cell of production does not affect the utility of the resulting fusion protein. The GFP-like chromophores from EBFP and BFP2 can usefully be included in the fusion proteins of the present invention, and vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, Calif., USA).

[0260] Analogously, EYFP (“enhanced yellow fluorescent protein”), also available from Clontech Labs, contains four amino acid substitutions, different from EBFP, Ormö et al., Science 273:1392-139D (1996), that shift the emission from green to yellowish-green. Citrine, an improved yellow fluorescent protein mutant, is described in Heikal et al., Proc. Natl. Acad. Sci. USA 97:11996-12001 (2000). ECFP (“enhanced cyan fluorescent protein”) (Clontech Labs, Palo Alto, Calif., USA) contains six amino acid substitutions, one of which shifts the emission spectrum from green to cyan. Heim et al., Curr. Biol. 6:178-182 (1996); Miyawaki et al., Nature 388:882-887 (1997). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

[0261] The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Pat. Nos. 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. See also Conn (ed.), Green Fluorescent Protein, Methods in Enzymology, vol. 302, Academic Press, Inc. 1999 (ISBN: 0121822036), incorporated herein by reference in its entirety.

[0262] Fusions to the IgG Fc region increase serum half life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in international patent application nos. WO 97/43316, WO 97/34631, WO 96/32478, Wo 96/18412.

[0263] For long-term, high-yield recombinant production of the proteins, protein fusions, and protein fragments of the present invention, stable expression is preferred.

[0264] Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection for integrants.

[0265] For example, the pUB6/V5-His A, B, and C vectors (Invitrogen, Carlsbad, Calif., USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The bsd gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

[0266] Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, prove particularly useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines—such as RetroPack™ PT 67, EcoPack2™-293, AmphoPack-293, GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, Calif., USA)—allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus. Retroviral vectors are available with a variety of selectable markers, such as resistance to neomycin, hygromycin, and puromycin, permitting ready selection of stable integrants.

[0267] The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome.

[0268] Among other considerations, some of which are described above, a host cell strain may be chosen for its ability to process the expressed protein in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide NEDD-1 proteins with such post-translational modifications.

[0269] As noted earlier, host cells can be prokaryotic or eukaryotic.

[0270] Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as E. coli, Caulobacter crescentus, Streptomyces species, and Salmonella typhimurium; yeast cells, such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Pichia methanolica; insect cell lines, such as those from Spodoptera frugiperda—e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, Conn., USA)—Drosophila S2 cells, and Trichoplusia ni High Five® Cells (Invitrogen, Carlsbad, Calif., USA); and mammalian cells. Typical mammalian cells include COS1 and COS7 cells, chinese hamster ovary (CHO) cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, HeLa, MDCK, HEK293, WI38, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562, Jurkat cells, and BW5147. Other mammalian cell lines are well known and readily available from the American Type Culture Collection (ATCC) (Manassas, Va., USA) and the National Institute of General medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, N.J., USA).

[0271] Methods for introducing the vectors and nucleic acids of the present invention into the host cells are well known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

[0272] For example, phage lambda vectors will typically be packaged using a packaging extract (e.g., Gigapack® packaging extract, Stratagene, La Jolla, Calif., USA), and the packaged virus used to infect E. coli. Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells.

[0273]E. coli cells can be rendered chemically competent by treatment, e.g., with CaCl₂, or a solution of Mg²⁺, Mn²⁺, Ca²⁺, Rb⁺ or K⁺, dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, J. Mol. Biol. 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent strains are also available commercially (e.g., Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, Calif., USA); DH5a competent cells (Clontech Laboratories, Palo Alto, Calif., USA); TOP10 Chemically Competent E. coli Kit (Invitrogen, Carlsbad, Calif., USA)).

[0274] Bacterial cells can be rendered electrocompetent—that is, competent to take up exogenous DNA by electroporation—by various pre-pulse treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided online in Electroprotocols (BioRad, Richmond, Calif., USA) (http://www.bio-rad.com/LifeScience/pdf/New_Gene_Pulser.pdf).

[0275] Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion.

[0276] Spheroplasts are prepared by the action of hydrolytic enzymes—a snail-gut extract, usually denoted Glusulase, or Zymolyase, an enzyme from Arthrobacter luteus—to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and Ca²⁺. Subsequently, the cells are resuspended in a solution of sorbitol, mixed with molten agar and then layered on the surface of a selective plate containing sorbitol.

[0277] For lithium-mediated transformation, yeast cells are treated with lithium acetate, which apparently permeabilizes the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and subsequently spread on plates containing ordinary selective medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl et al., Curr. Genet. 16(5-6):339-46 (1989).

[0278] For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker et al., Methods Enzymol. 194:182-7 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

[0279] Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means.

[0280] For chemical transfection, DNA can be coprecipitated with CaPO₄ or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for CaPO₄ transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, Calif., USA), and lipid-mediated transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, Calif., USA), DOTAP Liposomal Transfection Reagent, FUGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, Ind. USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, Calif., USA). Protocols for electroporating mammalian cells can be found online in Electroprotocols (Bio-Rad, Richmond, Calif., USA) (http://www.bio-rad.com/LifeScience/pdf/New_Gene_Pulser.pdf).

[0281] See also, Norton et al. (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000) (ISBN 1-881299-34-1), incorporated herein by reference in its entirety.

[0282] Other transfection techniques include transfection by particle embardment. See, e.g., Cheng et al., Proc. Natl. Acad. Sci. USA 90(10):4455-9 (1993); Yang et al., Proc. Natl. Acad. Sci. USA 87(24):9568-72 (1990).

[0283] Proteins

[0284] In another aspect, the present invention provides human NEDD-1 proteins, various fragments thereof suitable for use as antigens (e.g., for epitope mapping) and for use as immunogens (e.g., for raising antibodies or as vaccines), fusions of human NEDD-1 polypeptides and fragments to heterologous polypeptides, and conjugates of the proteins, fragments, and fusions of the present invention to other moieties (e.g., to carrier proteins, to fluorophores).

[0285]FIG. 3 presents the predicted amino acid sequences encoded by the human NEDD-1 cDNA clone. The amino acid sequence is further presented, respectively, in SEQ ID NO. 4.

[0286] Unless otherwise indicated, amino acid sequences of the proteins of the present invention were determined as a predicted translation from a nucleic acid sequence. Accordingly, any amino acid sequence presented herein may contain errors due to errors in the nucleic acid sequence, as described in detail above. Furthermore, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes—more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, Nature 409:860-921 (2001)—and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Small deletions and insertions can often be found that do not alter the function of the protein.

[0287] Accordingly, it is an aspect of the present invention to provide proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins at least about 90% identical in sequence to those described with particularity herein, typically at least about 91%, 92%, 93%, 94%, or 95% identical in sequence to those described with particularity herein, usefully at least about 96%, 97%, 98%, or 99% identical in sequence to those described with particularity herein, and, most conservatively, at least about 99.5%, 99.6%, 99.7%, 99.8% and 99.9% identical in sequence to those described with particularity herein. These sequence variants can be naturally occurring or can result from human intervention by way of random or directed mutagenesis.

[0288] For purposes herein, percent identity of two amino acid sequences is determined using the procedure of Tatiana et al., “Blast 2 sequences—a new tool for comparing protein and nucleotide sequences”, FEMS Microbiol Lett. 174:247-250 (1999), which procedure is effectuated by the computer program BLAST 2 SEQUENCES, available online at

[0289] http://www.ncbi.nlm.nih.gov/blast/bl2seq/b12.html.

[0290] To assess percent identity of amino acid sequences, the BLASTP module of BLAST 2 SEQUENCES is used with default values of (i) BLOSUM62 matrix, Henikoff et al., Proc. Natl. Acad. Sci USA 89(22):10915-9 (1992); (ii) open gap 11 and extension gap 1 penalties; and (iii) gap x_dropoff 50 expect 10 word size 3 filter, and both sequences are entered in their entireties.

[0291] As is well known, amino acid substitutions occur frequently among natural allelic variants, with conservative substitutions often occasioning only de minimis change in protein function.

[0292] Accordingly, it is an aspect of the present invention to provide proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins having the sequence of human NEDD-1 proteins, or portions thereof, with conservative amino acid substitutions. It is a further aspect to provide isolated proteins having the sequence of human NEDD-1 proteins, and portions thereof, with moderately conservative amino acid substitutions. These conservatively-substituted and moderately conservatively-substituted variants can be naturally occurring or can result from human intervention.

[0293] Although there are a variety of metrics for calling conservative amino acid substitutions, based primarily on either observed changes among evolutionarily related proteins or on predicted chemical similarity, for purposes herein a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix reproduced herein below (see Gonnet et al., Science 256(5062):L443-5 (1992)): A R N D C Q E G H I L K M F P S T W Y V A 2 −1 0 0 0 0 0 0 −1 −1 −1 0 −1 −2 0 1 1 −4 −2 0 R −1 5 0 0 −2 2 0 −1 1 −2 −2 3 −2 −3 −1 0 0 −2 −2 −2 N 0 0 4 2 −2 1 1 0 1 −3 −3 1 −2 −3 −1 1 0 −4 −1 −2 D 0 0 2 5 −3 1 3 0 0 −4 −4 0 −3 −4 −1 0 0 −5 −3 −3 C 0 −2 −2 −3 12 −2 −3 −2 −1 −1 −2 −3 −1 −1 −3 0 0 −1 0 0 Q 0 2 1 1 −2 3 2 −1 1 −2 −2 2 −1 −3 0 0 0 −3 −2 −2 E 0 0 1 3 −3 2 4 −1 0 −3 −3 1 −2 −4 0 0 0 −4 −3 −2 G 0 −1 0 0 −2 −1 −1 7 −1 −4 −4 −1 −4 −5 −2 0 −1 −4 −4 −3 H −1 1 1 0 −1 1 0 −1 6 −2 −2 1 −1 0 −1 0 0 −1 2 −2 I −1 −2 −3 −4 −1 −2 −3 −4 −2 4 3 −2 2 1 −3 −2 −1 −2 −1 3 L −1 −2 −3 −4 −2 −2 −3 −4 −2 3 4 −2 3 2 −2 −2 −1 −1 0 2 K 0 3 1 0 −3 2 1 −1 1 −2 −2 3 −1 −3 −1 0 0 −4 −2 −2 M −1 −2 −2 −3 −1 −1 −2 −4 −1 2 3 −1 4 2 −2 −1 −1 −1 0 2 F −2 −3 −3 −4 −1 −3 −4 −5 0 1 2 −3 2 7 −4 −3 −2 4 5 0 P 0 −1 −1 −1 −3 0 0 −2 −1 −3 −2 −1 −2 −4 8 0 0 −5 −3 −2 S 1 0 1 0 0 0 0 0 0 −2 −2 0 −1 −3 0 2 2 −3 −2 −1 T 1 0 0 0 0 0 0 −1 0 −1 −1 0 −1 −2 0 2 2 −4 −2 0 W −4 −2 −4 −5 −1 −3 −4 −4 −1 −2 −1 −4 −1 −4 −5 −3 −4 14 4 −3 Y −2 −2 −1 −3 0 −2 −3 −4 2 −1 0 −2 0 5 −3 −2 −2 4 8 −1 V 0 −2 −2 −3 0 −2 −2 −3 −2 3 2 −2 2 0 −2 −1 0 −3 −1 3

[0294] For purposes herein, a “moderately conservative” replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix reproduced herein above.

[0295] As is also well known in the art, relatedness of proteins can also be characterized using a functional test, the ability of the encoding nucleic acids to base-pair to one another at defined hybridization stringencies.

[0296] It is, therefore, another aspect of the invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins (“hybridization related proteins”) that are encoded by nucleic acids that hybridize under high stringency conditions (as defined herein above) to all or to a portion of various of the isolated nucleic acids of the present invention (“reference nucleic acids”). It is a further aspect of the invention to provide isolated proteins (“hybridization related proteins”) that are encoded by nucleic acids that hybridize under moderate stringency conditions (as defined herein above) to all or to a portion of various of the isolated nucleic acids of the present invention (“Preference nucleic acids”).

[0297] The hybridization related proteins can be alternative isoforms, homologues, paralogues, and orthologues of the human NEDD-1 protein of the present invention. Particularly useful orthologues are those from other primate species, such as chimpanzee, rhesus macaque monkey, baboon, orangutan, and gorilla; from rodents, such as rats, mice, guinea pigs; from lagomorphs, such as rabbits, and from domestic livestock, such as cow, pig, sheep, horse, goat.

[0298] Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an antibody.

[0299] It is, therefore, another aspect of the present invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins (“cross-reactive proteins”) that competitively inhibit the binding of antibodies to all or to a portion of various of the isolated human NEDD-1 proteins of the present invention (“reference proteins”). Such competitive inhibition can readily be determined using immunoassays well known in the art.

[0300] Among the proteins of the present invention that differ in amino acid sequence from those described with particularity herein—including those that have deletions and insertions causing up to 10% non-identity, those having conservative or moderately conservative substitutions, hybridization related proteins, and cross-reactive proteins—those that substantially retain one or more human NEDD-1 activities are preferred. As described above, those activities include protein—protein interactions.

[0301] Residues that are tolerant of change while retaining function can be identified by altering the protein at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham et al., Science 244(4908):1081-5 (1989); transposon linker scanning mutagenesis, Chen et al., Gene 263(1-2):39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin et al., J. Mol. Biol. 226(3):851-65 (1992); combinatorial alanine scanning, Weiss et al., Proc. Natl. Acad. Sci USA 97(16):8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, Mass., USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, Epicentre Technologies Corporation, Madison, Wis., USA).

[0302] As further described below, the isolated proteins of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize human NEDD-1 proteins, their isoforms, homologues, paralogues, and/or orthologues. The antibodies, in turn, can be used, inter alia, specifically to assay for the human NEDD-1 proteins of the present invention—e.g. by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions—for specific antibody-mediated isolation and/or purification of human NEDD-1 proteins, as for example by immunoprecipitation, and for use as specific agonists or antagonists of human NEDD-1 action.

[0303] The isolated proteins of the present invention are also immediately available for use as specific standards in assays used to determine the concentration and/or amount specifically of the human NEDD-1 proteins of the present invention. As is well known, ELISA kits for detection and quantitation of protein analytes typically include isolated and purified protein of known concentration for use as a measurement standard (e.g., the human interferon-γ OptEIA kit, catalog no. 555142, Pharmingen, San Diego, Calif., USA includes human recombinant gamma interferon, baculovirus produced).

[0304] The isolated proteins of the present invention are also immediately available for use as specific biomolecule capture probes for surface-enhanced laser desorption ionization (SELDI) detection of protein-protein interactions, WO 98/59362; WO 98/59360; WO 98/59361; and Merchant et al., Electrophoresis 21(6):1164-77 (2000), the disclosures of which are incorporated herein by reference in their entireties. Analogously, the isolated proteins of the present invention are also immediately available for use as specific biomolecule capture probes on BIACORE surface plasmon resonance probes. See Weinberger et al., Pharmacogenomics 1(4):395-416 (2000); Malmqvist, Biochem. Soc. Trans. 27(2):335-40 (1999).

[0305] The isolated proteins of the present invention are also useful as a therapeutic supplement in patients having a specific deficiency in human NEDD-1 production.

[0306] In another aspect, the invention also provides fragments of various of the proteins of the present invention. The protein fragments are useful, inter alia, as antigenic and immunogenic fragments of human NEDD-1.

[0307] By “fragments” of a protein is here intended isolated proteins (equally, polypeptides, peptides, oligopeptides), however obtained, that have an amino acid sequence identical to a portion of the reference amino acid sequence, which portion is at least 6 amino acids and less than the entirety of the reference nucleic acid. As so defined, “fragments” need not be obtained by physical fragmentation of the reference protein, although such provenance is not thereby precluded.

[0308] Fragments of at least 6 contiguous amino acids are useful in mapping B cell and T cell epitopes of the reference protein. See, e.g., Geysen et al., “Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid,” Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984) and U.S. Pat. Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of the proteins of the present invention have utility in such a study.

[0309] Fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, have utility as immunogens for raising antibodies that recognize the proteins of the present invention. See, e.g., Lerner, “Tapping the immunological repertoire to produce antibodies of predetermined specificity,” Nature 299:592-596 (1982); Shinnick et al., “Synthetic peptide immunogens as vaccines,” Annu. Rev. Microbiol. 37:425-46 (1983); Sutcliffe et al., “Antibodies that react with predetermined sites on proteins,” Science 219:660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties. As further described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic—that is, prove capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the proteins of the present invention have utility as immunogens.

[0310] Fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire protein, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition permits identification and separation of molecules that bind specifically to the protein of interest, U.S. Pat. Nos. 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

[0311] The protein, or protein fragment, of the present invention is thus at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the protein or the present invention, or fragment thereof, is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger fragments having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

[0312] The present invention further provides fusions of each of the proteins and protein fragments of the present invention to heterologous polypeptides.

[0313] By fusion is here intended that the protein or protein fragment of the present invention is linearly contiguous to the heterologous polypeptide in a peptide-bonded polymer of amino acids or amino acid analogues; by “heterologous polypeptide” is here intended a polypeptide that does not naturally occur in contiguity with the protein or protein fragment of the present invention. As so defined, the fusion can consist entirely of a plurality of fragments of the human NEDD-1 protein in altered arrangement; in such case, any of the human NEDD-1 fragments can be considered heterologous to the other human FEDD-1 fragments in the fusion protein. More typically, however, the heterologous polypeptide is not drawn from the human NEDD-1 protein itself.

[0314] The fusion proteins of the present invention will include at least one fragment of the protein of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the protein of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of the proteins of the present invention have particular utility.

[0315] The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and usefully at least 15, 20, and 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP chromophore-containing proteins), have particular utility.

[0316] As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated herein by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of recombinantly-expressed proteins. Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included render the fusion proteins of the present invention useful as directly detectable markers of human NEDD-1 presence.

[0317] As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins—into the periplasmic space or extracellular milieu for prokaryotic hosts, into the culture medium for eukaryotic cells—through incorporation of secretion signals and/or leader sequences.

[0318] Other useful protein fusions of the present invention include those that permit use of the protein of the present invention as bait in a yeast two-hybrid system. See Bartel et al. (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997) (ISBN: 0195109384); Zhu et al., Yeast Hybrid Technologies, Eaton Publishing, (2000) (ISBN 1-881299-15-5); Fields et al., Trends Genet. 10(8):286-92 (1994); Mendelsohn et al., Curr. Opin. Biotechnol. 5(5):482-6 (1994); Luban et al., Curr. Opin. Biotechnol. 6(1): 59-64 (1995); Allen et al., Trends Biochem. Sci. 20(12): 511-6 (1995); Drees, Curr. Opin. Chem. Biol. 3(1): 64-70 (1999); Topcu et al., Pharm. Res. 17(9): 1049-55 (2000); Fashena et al., Gene 250(1-2):1-14 (2000), the disclosures of which are incorporated herein by reference in their entireties. Typically, such fusion is to either E. coli LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

[0319] Other useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above, which discussion is incorporated here by reference in its entirety.

[0320] The proteins and protein fragments of the present invention can also usefully be fused to protein toxins, such as Pseudomonas exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

[0321] The isolated proteins, protein fragments, and protein fusions of the present invention can be composed of natural amino acids linked by native peptide bonds, or can contain any or all of nonnatural amino acid analogues, nonnative bonds, and post-synthetic (post translational) modifications, either throughout the length of the protein or localized to one or more portions thereof.

[0322] As is well known in the art, when the isolated protein is used, e.g., for epitope mapping, the range of such nonnatural analogues, nonnative inter-residue bonds, or post-synthesis modifications will be limited to those that permit binding of the peptide to antibodies. When used as an immunogen for the preparation of antibodies in a non-human host, such as a mouse, the range of such nonnatural analogues, nonnative inter-residue bonds, or post-synthesis modifications will be limited to those that do not interfere with the immunogenicity of the protein. When the isolated protein is used as a therapeutic agent, such as a vaccine or for replacement therapy, the range of such changes will be limited to those that do not confer toxicity upon the isolated protein.

[0323] Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common.

[0324] Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, inter alia, in Chan et al. (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000) (ISBN: 0199637245); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (August 1992) (ISBN: 0198556683); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (December 1993) (ISBN: 0387564314), the disclosures of which are incorporated herein by reference in their entireties.

[0325] Non-natural amino acids can readily be incorporated during solid phase chemical synthesis.

[0326] For example, D-enantiomers of natural amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-enantiomers can also be used to confer specific three dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (Kole et al., Biochem. Biophys. Res. Com. 209:817-821 (1995)), and various halogenated phenylalanine derivatives.

[0327] Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide a labeled polypeptide.

[0328] Biotin, for example, can be added using biotinoyl—(9-fluorenylmethoxycarbonyl)-L-lysine (FMOC biocytin) (Molecular Probes, Eugene, Oreg., USA). (Biotin can also be added enzymatically by incorporation into a fusion protein of a E. coli BirA substrate peptide.)

[0329] The FMOC and tBOC derivatives of dabcyl-L-lysine (Molecular Probes, Inc., Eugene, Oreg., USA) can be used to incorporate the dabcyl chromophore at selected sites in the peptide sequence during synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyl quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS—FMOC-L-glutamic acid or the corresponding tBOC derivative (both from Molecular Probes, Inc., Eugene, Oreg., USA). Tetramethylrhodamine fluorophores can be incorporated during automated FMOC synthesis of peptides using (FMOC)—TMR-L-lysine (Molecular Probes, Inc. Eugene, Oreg., USA).

[0330] Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, Calif., USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

[0331] A large number of other FMOC-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, e.g., Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5—ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2′-carboxylic acid, Fmoc-N-(4-aminobenzoyl)-b-alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmcc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-?-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, Calif., USA).

[0332] Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid and. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an in vitro transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu et al., Proc. Natl Acad. Sci. USA 96(9):4780-5 (1999); Wang et al., Science 292(5516):498-500 (2001).

[0333] The isolated proteins, protein fragments and fusion proteins of the present invention can also include nonnative inter-residue bonds, including bonds that lead to circular and branched forms.

[0334] The isolated proteins and protein fragments of the present invention can also include post-translational and post-synthetic modifications, either throughout the length of the protein or localized to one or more portions thereof.

[0335] For example, when produced by recombinant expression in eukaryotic cells, the isolated proteins, fragments, and fusion proteins of the present invention will typically include N-linked and/or O-linked glycosylation, the pattern of which will reflect both the availability of glycosylation sites on the protein sequence and the identity of the host cell. Further modification of glycosylation pattern can be performed enzymatically.

[0336] As another example, recombinant polypeptides of the invention may also include an initial modified methionine residue, in some cases resulting from host-mediated processes.

[0337] When the proteins, protein fragments, and protein fusions of the present invention are produced by chemical synthesis, post-synthetic modification can be performed before deprotection and cleavage from the resin or after deprotection and cleavage. Modification before deprotection and cleavage of the synthesized protein often allows greater control, e.g. by allowing targeting of the modifying moiety to the N-terminus of a resin-bound synthetic peptide.

[0338] Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores.

[0339] A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

[0340] Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, Oreg., USA), e.g., offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

[0341] A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, Oreg., USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, Oreg., USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, Oreg., USA).

[0342] The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents.

[0343] Common homobifunctional reagents include, e.g., APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, Ill., USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available Pierce, Rockford, Ill., USA).

[0344] The proteins, protein fragments, and protein fusions of the present invention can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive.

[0345] Other labels that usefully can be conjugated to the proteins, protein fragments, and fusion proteins of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

[0346] The proteins, protein fragments, and protein fusions of the present invention can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-human NEDD-1 antibodies.

[0347] The proteins, protein fragments, and protein fusions of the present invention can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half life of proteins administered intravenously for replacement therapy. Delgado et al., Crit. Rev. Ther. Drug Carrier Syst. 9(3-4): 249-304 (1992); Scott et al., Curr. Pharm. Des. 4(6): 423-38 (1998); DeSantis et al., Curr. Opin. Biotechnol. 10(4): 324-30 (1999), incorporated herein by reference in their entireties. PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

[0348] The isolated proteins of the present invention, including fusions thereof, can be produced by recombinant expression, typically using the expression vectors of the present invention as above-described or, if fewer than about 100 amino acids, by chemical synthesis (typically, solid phase synthesis), and, on occasion, by in vitro translation.

[0349] Production of the isolated proteins of the present invention can optionally be followed by purification.

[0350] Purification of recombinantly expressed proteins is now well within the skill in the art. See, e.g., Thorner et al. (eds.), Applications of Chimeric Genes and Hybrid Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Volume 326), Academic Press (2000), (ISBN: 0121822273); Harbin (ed.), Cloning, Gene Expression and Protein Purification: Experimental Procedures and Process Rationale, Oxford Univ. Press (2001) (ISBN: 0195132947); Marshak et al., Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996) (ISBN: 0-87969-385-1); and Roe (ed.), Protein Purification Applications, Oxford University Press (2001), the disclosures of which are incorporated herein by reference in their entireties, and. thus need not be detailed here.

[0351] Briefly, however, if purification tags have been fused through use of an expression vector that appends such tag, purification can be effected, at least in part, by means appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

[0352] Purification of chemically-synthesized peptides can readily be effected, e.g., by HPLC.

[0353] Accordingly, it is an aspect of the present invention to provide the isolated proteins of the present invention in pure or substantially pure form.

[0354] A purified protein of the present invention is an isolated protein, as above described, that is present at a concentration of at least 95%, as measured on a weight basis (w/w) with respect to total protein in a composition. Such purities can often be obtained during chemical synthesis without further purification, as, e.g., by HPLC. Purified proteins of the present invention can be present at a concentration (measured on a weight basis with respect to total protein in a composition) of 96%, 97%, 98%, and even 99%. The proteins of the present invention can even be present at levels of 99.5%, 99.6%, and even 99.7%, 99.8%, or even 99.9% following purification, as by HPLC.

[0355] Although high levels of purity are preferred when the isolated proteins of the present invention are used as therapeutic agents—such as vaccines, or for replacement therapy—the isolated proteins of the present invention are also useful at lower purity. For example, partially purified proteins of the present invention can be used as immunogens to raise antibodies in laboratory animals.

[0356] Thus, in another aspect, the present invention provides the isolated proteins of the present invention in substantially purified form. A “substantially purified protein” of the present invention is an isolated protein, as above described, present at a concentration of at least 70%, measured on a weight basis with respect to total protein in a composition. Usefully, the substantially purified protein is present at a concentration, measured on a weight basis with respect to total protein in a composition, of at least 75%, 80%, or even at least 85%, 90%, 91%, 92%, 93%, 94%, 94.5% or even at least 94.9%.

[0357] In preferred embodiments, the purified and substantially purified proteins of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

[0358] The proteins, fragments, and fusions of the present invention can usefully be attached to a substrate. The substrate can porous or solid, planar or non-planar; the bond can be covalent or noncovalent.

[0359] For example, the proteins, fragments, and fusions of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the proteins, fragments, and fusions of the present invention can be used to detect and quantify antibodies, e.g. in serum, that bind specifically to the immobilized protein of the present invention.

[0360] As another example, the proteins, fragments, and fusions of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, e.g. in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in standard microtiter dish, the plastic is typically polystyrene.

[0361] The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound protein to indicate biologic interaction therebetween. The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound protein to indicate biological interaction therebetween.

[0362] Human NEDD-1 Proteins

[0363] In a first series of protein embodiments, the invention provides an isolated human NEDD-1 polypeptide having an amino acid sequence encoded by the cDNA in the ATCC Deposit of NEDD-1 received at ATCC on May 23, 2001 and accorded an accession date of ______ and accession no. ______, or the amino acid sequence in SEQ ID NO: 4, which are full length human NEDD-1 proteins. When used as immunogens, the full length proteins of the present invention can be used, inter alia, to elicit antibodies that bind to a variety of epitopes of the human NEDD-1 protein.

[0364] The invention further provides fragments of the above-described polypeptides, particularly fragments having at least 6 amino acids, typically at least 8 amino acids, often at least 15 amino acids, and even the entirety of the sequence given in SEQ ID NO: 4.

[0365] The invention further provides fragments of at least 6 amino acids, typically at least 8 amino acids, often at least 15 amino acids, and even the entirety of the sequence given in SEQ ID NO: 6.

[0366] As described above, the invention further provides proteins that differ in sequence from those described with particularity in the above-referenced SEQ ID NOs., whether by way of insertion or deletion, by way of conservative or moderately conservative substitutions, as hybridization related proteins, or as cross-hybridizing proteins, with those that substantially retain a human NEDD-1 activity preferred.

[0367] The invention further provides fusions of the proteins and protein fragments herein described to heterologous polypeptides.

[0368] Antibodies and Antibody-producing Cells

[0369] In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to human NEDD-1 proteins and protein fragments of the present invention or that bind to one or more of the proteins and protein fragments encoded by the isolated human NEDD-1 nucleic acids of the present invention. The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, e.g., by solubilization in SDS.

[0370] In other embodiments, the invention provides antibodies, including fragments and derivatives thereof, the binding of which can be competitively inhibited by one or more of the human NEDD-1 proteins and protein fragments of the present invention, or by one or more of the proteins and protein fragments encoded by the isolated human NEDD-1 nucleic acids of the present invention.

[0371] As used herein, the term “antibody” refers to a polypeptide, at least a portion of which is encoded by at least one immunoglobulin gene, which can bind specifically to a first molecular species, and to fragments or derivatives thereof that remain capable of such specific binding.

[0372] By “bind specifically” and “specific binding” is here intended the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to “recognize” a first molecular species when it can bind specifically to that first molecular species.

[0373] As is well known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-human NEDD-1 proteins by at least two-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the protein of the present invention in samples derived from human cells.

[0374] Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about 1×10⁻⁶ molar (M), typically at least about 5×10⁻⁷ M, usefully at least about 1×10⁻⁷ M, with affinities and avidities of at least 1×10⁻⁸ M, 5×10⁻⁹ M, and 1×10⁻¹⁰ M proving especially useful.

[0375] The antibodies of the present invention can be naturally-occurring forms, such as IgG, IgM, IgD, IgE, and IgA, from any mammalian species.

[0376] Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In such case, antibodies to the proteins of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization, with the protein or protein fragments of the present invention. Such antibodies will typically, but will not invariably, be polyclonal.

[0377] Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human antibodies therefrom upon specific immunization are described, inter alia, in U.S. Pat. Nos. 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically produced using techniques developed for production of murine antibodies.

[0378] Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as in vivo diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

[0379] IgG, IgM, IgD, IgE and IgA antibodies of the present invention are also usefully obtained from other mammalian species, including rodents—typically mouse, but also rat, guinea pig, and hamster—lagomorphs, typically rabbits, and also larger mammals, such as sheep, goats, cows, and horses. In such cases, as with the transgenic human-antibody-producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the protein or protein fragment of the present invention.

[0380] As discussed above, virtually all fragments of 8 or more contiguous amino acids of the proteins of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

[0381] Immunogenicity can also be conferred by fusion of the proteins and protein fragments of the present invention to other moieties.

[0382] For example, peptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam et al., Proc. Natl. Acad. Sci. USA 85:5409-5413 (1988); Posnett et al., J. Biol. Chem. 263, 1719-1725 (1988).

[0383] Protocols for immunizing non-human mammals are well-established in the art, Harlow et al. (eds.), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998) (ISBN: 0879693142); Coligan et al. (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001) (ISBN: 0-471-52276-7); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000) (ISBN: 0387915907), the disclosures of which are incorporated herein by reference, and often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant.

[0384] Antibodies from nonhuman mammals can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the proteins of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the proteins of the present invention.

[0385] Following immunization, the antibodies of the present invention can be produced using any art-accepted technique. Such techniques are well known in the art, Coligan et al. (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001) (ISBN: 0-471-52276-7); Zola, Monoclonal Antibodies Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000) (ISBN: 0387915907); Howard et al. (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000) (ISBN: 0849394457); Harlow et al. (eds.), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998) (ISBN: 0879693142); Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995) (ISBN: 0896033082); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997) (ISBN: 0471970107); Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997) (ISBN: 0412141914), incorporated herein by reference in their entireties, and thus need not be detailed here.

[0386] Briefly, however, such techniques include, inter alia, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes encoding antibodies specific for the proteins or protein fragments of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: e.g., genes encoding antibodies specific for the proteins and protein fragments of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Pat. No. 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

[0387] Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

[0388] Host cells for recombinant antibody production—either whole antibodies, antibody fragments, or antibody derivatives—can be prokaryotic or eukaryotic.

[0389] Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

[0390] The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established, Sidhu, Curr. Opin. Biotechnol. 11(6):610-6 (2000); Griffiths et al., Curr. Opin. Biotechnol. 9(1):102-8 (1998); Hoogenboom et al., Immunotechnology, 4(1):1-20 (1998); Rader et al., Current Opinion in Biotechnology 8:503-508 (1997); Aujame et al., Human Antibodies 8:155-168 (1997); Hoogenboom, Trends in Biotechnol. 15:62-70 (1997); de Kruif et al., 17:453-455 (1996); Barbas et al., Trends in Biotechnol. 14:230-234 (1996); Winter et al., Ann. Rev. Immunol. 433-455 (1994), and techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled, Barbas et al., Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001) (ISBN 0-87969-546-3); Kay et al. (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc. (1996); Abelson et al. (eds.), Combinatorial Chemistry, Methods in Enzymology vol. 267, Academic Press (May 1996), the disclosures of which are incorporated herein by reference in their entireties.

[0391] Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length antibody in a further prokaryotic or a eukaryotic host cell.

[0392] Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention.

[0393] For example, antibody fragments of the present invention can be produced in Pichia pastoris, Takahashi et al., Biosci. Biotechnol. Biochem. 64(10): 2138-44 (2000); Freyre et al., J. Biotechnol. 76(2-3): 157-63 (2000); Fischer et al., Biotechnol. Appl. Biochem. 30 (Pt 2): 117-20 (1999); Pennell et al., Res. Immunol. 149(6): 599-603 (1998); Eldin et al., J. Immunol. Methods. 201(1): 67-75 (1997); and in Saccharomyces cerevisiae, Frenken et al., Res. Immunol. 149(6): 589-99 (1998); Shusta et al., Nature Biotechnol. 16(8): 773-7 (1998), the disclosures of which are incorporated herein by reference in their entireties.

[0394] Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells, Li et al., Protein Expr. Purif. 21(1): 121-8 (2001); Ailor et al., Biotechnol. Bioeng. 58(2-3): 196-203 (1998); Hsu et al., Biotechnol. Prog. 13(1): 96-104 (1997); Edelman et al., Immunology 91(1):13-9 (1997); and Nesbit et al., J. Immunol. Methods. 151(1-2): 201-8 (1992), the disclosures of which are incorporated herein by reference in their entireties.

[0395] Antibodies and fragments and derivatives thereof of the present invention can also be produced in plant cells, Giddings et al., Nature Biotechnol. 18(11): 1151-5 (2000); Gavilondo et al., Biotechniques 29(1): 128-38 (2000); Fischer et al., J. Biol. Regul. Homeost. Agents 14(2): 83-92 (2000); Fischer et al., Biotechnol. Appl. Biochem. 30 (Pt 2): 113-6 (1999); Fischer et al., Biol. Chem. 380(7-8): 825-39 (1999); Russell, Curr. Top. Microbiol. Immunol. 240:119-38 (1999); and Ma et al., Plant Physiol. 109(2): 341-6 (1995), the disclosures of which are incorporated herein by reference in their entireties.

[0396] Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells.

[0397] Verma et al., J. Immunol. Methods 216(1-2): 165-81 (1998), review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies.

[0398] Antibodies of the present invention can also be prepared by cell free translation, as further described in Merk et al., J. Biochem. (Tokyo). 125(2): 328-33 (1999) and Ryabova et al., Nature Biotechnol. 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock et al., J. Immunol. Methods 231(1-2): 147-57 (1999), the disclosures of which are incorporated herein by reference in their entireties.

[0399] The invention further provides antibody fragments that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

[0400] Among such useful fragments are Fab, Fab′, Fv, F(ab)′₂, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, Curr. Opin. Biotechnol. 9(4): 395-402 (1998).

[0401] It is also an aspect of the present invention to provide antibody derivatives that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

[0402] Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus more suitable for in vivo administration, than are unmodified antibodies from non-human mammalian species.

[0403] Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. See, e.g., U.S. Pat. No. 5,807,715; Morrison et al., Proc. Natl. Acad. Sci USA.81(21):6851-5 (1984); Sharon et al., Nature 309(5966):364-7 (1984); Takeda et al., Nature 314(6010):452-4 (1985), the disclosures of which are incorporated herein by reference in their entireties. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann et al., Nature 332(6162): 323-7 (1988); Co et al., Nature 351(6326):501-2 (1991); U.S. Pat. Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties.

[0404] Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

[0405] The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

[0406] The choice of label depends, in part, upon the desired use.

[0407] For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label can usefully be an enzyme that catalyzes production and local deposition of a detectable product.

[0408] Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well known, and include alkaline phosphatase, β-galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG); o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-Nitrophenyl-beta-D-galactopryanoside (PNPG); 3′,3′Diaminobenzidine (DAB); 3-Amino-9-ethylcarbazole (AEC); 4-Chloro-1-naphthol (CN); 5-Bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BluoGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS); phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

[0409] Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide (H₂O₂), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. See, e.g., Thorpe et al., Methods Enzymol. 133:331-53 (1986); Kricka et al., J. Immunoassay 17(1):67-83 (1996); and Lundqvist et al., J. Biolumin. Chemilumin. 10(6):353-9 (1995), the disclosures of which are incorporated herein by reference in their entireties. Kits for such enhanced chemiluminescent detection (ECL) are available commercially.

[0410] The antibodies can also be labeled. using colloidal gold.

[0411] As another example, when the antibodies of the present invention are used, e.g., for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores.

[0412] There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.

[0413] For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

[0414] Other fluorophores include, inter alia, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, Oreg., USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, Oreg., USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention.

[0415] For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

[0416] When the antibodies of the present invention are used, e.g., for western blotting applications, they can usefully be labeled with radioisotopes, such as ³³P, ³²P, ³⁵S, ³H, and ¹²⁵I.

[0417] As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be ²²⁸Th, ²²⁷Ac, ²²⁵Ac, ²²³Ra, ²¹³Bi, ²¹²Pb, ²¹²Bi, ²¹¹At, ²⁰³Pb, ¹⁹⁴Os, ¹⁸⁸Re, ¹⁸⁶Re, ¹⁵³Sm, ¹⁴⁹Tb, 131I, ¹²⁵I, ¹¹¹In, ¹⁰⁵Rh, ^(99m)Tc, ⁹⁷Ru, ⁹⁰Y, ⁹⁰Sr, ⁸⁸Y, ⁷²Se, ⁶⁷Cu, or ⁴⁷Sc.

[0418] As another example, when the antibodies of the present invention are to be used for in vivo diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer et al., Radiology 207(2):529-38 (1998), or by radioisotopic labeling.

[0419] As would be understood, use of the labels described above is not restricted to the application as for which they were mentioned.

[0420] The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the proteins of the present invention. Commonly, the antibody in such immunotoxins is conjugated to Pseudomonas exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. See Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, Vol 166), Humana Press (2000) (ISBN:0896037754); and Frankel et al. (eds.), Clinical Applications of Immunotoxins, Springer-Verlag New York, Incorporated (1998) (ISBN:3540640975), the disclosures of which are incorporated herein by reference in their entireties, for review.

[0421] The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, attached to a substrate.

[0422] Substrates can be porous or nonporous, planar or nonplanar.

[0423] For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography.

[0424] For example, the antibodies of the present invention can usefully be attached to paramagnetic microspheres, typically by biotin-streptavidin interaction, which microsphere can then be used for isolation of cells that express or display the proteins of the present invention. As another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

[0425] As noted above, the antibodies of the present invention can be produced in prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

[0426] In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

[0427] Human NEDD-1 Antibodies

[0428] In a first series of antibody embodiments, the invention provides antibodies, both polyclonal and monoclonal, and fragments and derivatives thereof, that bind specifically to a polypeptide having an amino acid sequence encoded by the cDNA in the ATCC Deposit of NEDD-1 received at ATCC on May 23, 2001 and accorded an accession date of ______ and accession no. ______, or that have the amino acid sequence in SEQ ID NO: 4, which are full length human NEDD-1 proteins.

[0429] Such antibodies are useful in in vitro immunoassays, such as ELISA, western blot or immunohistochemical assay. Such antibodies are also useful in isolating and purifying human NEDD-1 proteins, including related cross-reactive proteins, by immunoprecipitation, immunoaffinity chromatography, or magnetic bead-mediated purification.

[0430] In a second series of antibody embodiments, the invention provides antibodies, both polyclonal and monoclonal, and fragments and derivatives thereof, the specific binding of which can be competitively inhibited by the isolated proteins and polypeptides of the present invention.

[0431] In other embodiments, the invention further provides the above-described antibodies detectably labeled, and in yet other embodiments, provides the above-described antibodies attached to a substrate.

[0432] Pharmaceutical Compositions

[0433] Human NEDD-1 protein is implicated in tumor suppression. Thus, compositions comprising nucleic acids, proteins, mimetics and agonists can be administered as inhibitors of tumorigenesis in patients in whom inadequate, or aberrant, expression leads to tumorigenesis. Conversely, compositions comprising anti-NEDD-1 antibodies, or other antagonists of NEDD-1 function, can be administered to facilitate proliferation in the clinical setting of inadequate cell division.

[0434] Accordingly, in another aspect, the invention provides pharmaceutical compositions comprising the nucleic acids, nucleic acid fragments, proteins, protein fusions, protein fragments, mimetics, agonists, antibodies, antibody derivatives, antibody fragments and antagonists of the present invention.

[0435] Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

[0436] Pharmaceutical formulation is a well-established art, and is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20^(th) ed., Lippincott, Williams & Wilkins (2000) (ISBN: 0683306472); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7^(th) ed., Lippincott Williams & Wilkins Publishers (1999) (ISBN: 0683305727); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3^(rd) ed. (2000) (ISBN: 091733096X), the disclosures of which are incorporated herein by reference in their entireties, and thus need not be described in detail herein.

[0437] Briefly, however, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

[0438] Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

[0439] Solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

[0440] Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, corn starch, sodium starch glycolate, and alginic acid.

[0441] Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

[0442] Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

[0443] Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

[0444] Solid oral dosage forms need not be uniform throughout.

[0445] For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

[0446] Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

[0447] Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

[0448] Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.

[0449] The pharmaceutical compositions of the present invention can also be formulated for parenteral administration.

[0450] For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose (“D5”), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution.

[0451] Intramuscular preparations, e.g. a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (e.g., ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

[0452] Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

[0453] Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0454] Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition.

[0455] The pharmaceutical compositions of the present invention can be administered topically.

[0456] A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, e.g., 5 to 10%, in a carrier such as a pharmaceutical cream base. Various formulations for topical use include drops, tinctures, lotions, creams, solutions, and ointments containing the active ingredient and various supports and vehicles. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone.

[0457] Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared.

[0458] The pharmaceutically active compound in the pharmaceutical compositions of the present inention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

[0459] After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

[0460] The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

[0461] A “therapeutically effective dose” refers to that amount of active ingredient—for example NEDD-1 protein, fusion protein, or fragments thereof, antibodies specific for NEDD-1, agonists, antagonists or inhibitors of NEDD-1—which ameliorates the signs or symptoms of the disease or prevents progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

[0462] The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by in vitro tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of administration.

[0463] For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

[0464] The data obtained from cell culture assays and animal studies is used in formulating an initial dosage range for human use, and preferably provides a range of circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

[0465] The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age, weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

[0466] Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (e.g., 1 mg/kg to 5 mg/kg). The pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose.

[0467] Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0468] Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

[0469] Therapeutic Methods

[0470] The present invention further provides methods of treating subjects having defects in NEDD-1—e.g., in expression, activity, distribution, localization, and/or solubility of NEDD-1—which can manifest as neoplasia or other hyperproliferative disorder. The present invention further provides methods of treating subjects having an excess of NEDD-1 acitivity, which can manifest as an insufficiency in cellular proliferation. As used herein, “treating” includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease.

[0471] In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising NEDD-1 protein, fusion, fragment or derivative thereof is administered to a subject with a clinically-significant NEDD-1 defect.

[0472] Protein compositions are administered, for example, to complement a deficiency in native NEDD-1. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to NEDD-1. The immune response can be used to modulate activity of NEDD-1 or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate NEDD-1.

[0473] In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising nucleic acid of the present invention is administered. The nucleic acid can be delivered in a vector that drives expression of NEDD-1 protein, fusion, or fragment thereof, or without such vector.

[0474] Nucleic acid compositions that can drive expression of NEDD-1 are administered, for example, to complement a deficiency in native NEDD-1, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used—see, e.g., Cid-Arregui (ed.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co., 2000 (ISBN: 188129935X)—as can plasmids Antisense nucleic acid compositions, or vectors that drive expression of NEDD-1 antisense nucleic acids, are administered to downregulate transcription and/or translation of NEDD-1 in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

[0475] Antisense compositions useful in therapy can have sequence that is complementary to coding or to noncoding regions of the NEDD-1 gene. For example, oligonucleotides derived from the transcription initiation site, e.g., between positions −10 and +10 from the start site, are preferred.

[0476] Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to NEDD-1 transcripts, are also useful in therapy. See, e.g., Phylactou, Adv. Drug Deliv. Rev. 44(2-3):97-108 (2000); Phylactou et al., Hum. Mol. Genet. 7(10):1649-53 (1998); Rossi, Ciba Found. Symp. 209:195-204 (1997); and Sigurdsson et al., Trends Biotechnol. 13(8):286-9 (1995), the disclosures of which are incorporated herein by reference in their entireties.

[0477] Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the NEDD-1 genomic locus. Such triplexing oligonucleotides are able to inhibit transcription, Intody et al., Nucleic Acids Res. 28(21):4283-90 (2000); McGuffie et al., Cancer Res. 60(14):3790-9 (2000), the disclosures of which are incorporated herein by reference, and pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

[0478] In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is well known, antibody compositions are administered, for example, to antagonize activity of NEDD-1, or to target therapeutic agents to sites of NEDD-1 presence and/or accumulation.

[0479] In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of NEDD-1 is administered. Antagonists of NEDD-1 can be produced using methods generally known in the art. In particular, purified NEDD-1 can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of NEDD-1.

[0480] In other embodiments a pharmaceutical composition comprising an agonist of NEDD-1 is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

[0481] In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express NEDD-1, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in NEDD-1 production or activity.

[0482] In other embodiments, pharmaceutical compositions comprising the NEDD-1 proteins, nucleic acids, antibodies, antagonists, and agonists of the present invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art according to conventional pharmaceutical principles. The combination of therapeutic agents or approaches can act additively or synergistically to effect the treatment or prevention of the various disorders described above, providing greater therapeutic efficacy and/or permitting use of the pharmaceutical compositions of the present invention using lower dosages, reducing the potential for adverse side effects.

[0483] Transgenic Animals and Cells

[0484] In another aspect, the invention provides transgenic cells and non-human organisms comprising human NEDD-1 isoform nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human NEDD-1 gene.

[0485] The cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes.

[0486] Diagnostic Methods

[0487] The nucleic acids of the present invention can be used as nucleic acid probes to assess the levels of human NEDD-1 mRNA in cells, and antibodies of the present invention can be used to assess the expression levels of human NEDD-1 proteins in cells to diagnose tumorigenesis.

[0488] The following examples are offered for purpose of illustration and not by way of limitation.

EXAMPLE 1 Identification and Characterization of cDNAs Encoding Human NEDD-1 Proteins

[0489] Predicating our gene discovery efforts on use of genome-derived single exon probes and hybridization to genome-derived single exon microarrays—an approach that we have previously demonstrated will readily identify novel genes that have proven refractory to mRNA-based identification efforts—we identified an exon in raw human genomic sequence that is expressed in all tested tissues: human testis, brain, skeletal muscle, liver, HeLa, heart, placenta, prostate, bone marrow, lung, adrenal, fetal liver and kidney.

[0490] Briefly, bioinformatic algorithms were applied to human genomic sequence data to identify putative exons. Each of the predicted exons was amplified from genomic DNA, typically centering the putative coding sequence within a larger amplicon that included flanking noncoding sequence. These genome-derived single exon probes were arrayed on a support and expression of the bioinformatically predicted exons assessed through a series of simultaneous two-color hybridizations to the genome-derived single exon microarrays.

[0491] The approach and procedures are further described in detail in Penn et al., “Mining the Human Genome using Microarrays of Open Reading Frames,” Nature Genetics 26:315-318 (2000); commonly owned and copending U.S. patent application Ser. Nos. 09/774,203, filed Jan. 29, 2001 and 09/632,366, filed Aug. 3, 2000, and commonly owned and copending U.S. provisional patent application No. 60/236,359, filed Sep. 27, 2000, the disclosures of which are incorporated herein by reference in their entireties.

[0492] Using a graphical display particularly designed to facilitate computerized query of the resulting exon-specific expression data, as further described in commonly owned and copending U.S. patent application Ser. No. 09/774,203, filed Jan. 29, 2001, six exons were identified that are expressed in all human tissues tested; subsequent analysis revealed that the six exons belong to the same gene.

[0493] Tables 1 and 2 summarize the microarray expression data obtained using genome-derived single exon probes (amplicons; “ampl.”) corresponding to exons 2, 3, 8, 9, 11 and 12. Each probe was completely sequenced on both strands prior to its use on a genome-derived single exon microarray; sequencing confirmed the exact chemical structure of each probe. An added benefit of sequencing is that it placed us in possession of a set of single base-incremented fragments of the sequenced nucleic acid, starting from the sequencing primer's 3′ OH. (Since the single exon probes were first obtained by PCR amplification from genomic DNA, we were of course additionally in possession of an even larger set of single base incremented fragments of each of the single exon probes, each fragment corresponding to an extension product from one of the two amplification primers.)

[0494] Signals and expression ratios are normalized values measured and calculated as further described in commonly owned and copending U.S. patent application Ser. Nos. 09/___,___ (attorney docket no. AEOMICA-X-1), filed May 23, 2001, 09/774,203, filed Jan. 29, 2001 and 09/632,366, filed Aug. 3, 2000, the disclosures of which are incorporated herein by reference in their entireties. TABLE 1 Expression Analysis Genome-Derived Single Exon Microarray (signal). Ampl Ampl Ampl Ampl Ampl Ampl Ampl 1397 1396 1441 1421 1429 1412 1403 (exon₋ (exon (exon (exon (exon (exon (exon 2) 3) 8) 9) 9) 11) 12) ADRENAL n/d 0.64 2.46 0.60 n/d 0.56 n/d ADULT 1.35 0.47 2.20 0.74 0.62 0.54 0.34 LIVER BONE 0.72 0.74 1.73 0.57 0.48 0.83 0.38 MARROW BRAIN 0.9 0.54 1.64 0.62 0.52 0.57 0.37 FETAL n/d 0.50 2.58 0.91 0.62 0.64 0.37 LIVER HEART 1.63 n/d n/d 0.44 0.50 0.63 0.32 HELA 2.18 0.56 n/d n/d 0.49 0.54 0.55 KIDNEY 2.06 n/d 2.24 0.47 n/d 0.40 n/d LUNG 1.35 n/d n/d 0.41 n/d n/d 0.44 PLACENTA 1.11 n/d 1.96 1.09 n/d 0.58 0.39 PROSTATE 0.97 n/d 2.02 0.95 0.42 0.69 0.21 SKELETAL 1.09 0.81 2.02 1.10 0.76 1.40 0.59 MUSCLE

[0495] TABLE 2 Expression Analysis Genome-Derived Single Exon Microarray (ratio) Ampl Ampl Ampl Ampl Ampl Ampl Ampl 1397 1396 1441 1421 1429 1412 1403 (exon₋ (exon (exon (exon (exon (exon (exon 2) 3) 8) 9) 9) 11) 12) ADRENAL −1.35 n/d n/d  1.02 n/d −1.29 n/d ADULT −1.33 n/d −1.44 −1.41 n/d −2.00 −1.63 LIVER BONE  1.05 −1.09 n/d  1.08 n/d n/d −1.02 MARROW BRAIN −1.07 n/d n/d  1.16 −1.7  1.27 n/d FETAL  1.20 −1.48 −1.31  1.12 −1.07 n/d −1.81 LIVER HEART −1.17 n/d −1.47  1.04 −1.49 n/d n/d HELA  1.18 n/d −1.07 n/d −1.44 n/d −1.25 KIDNEY  1.03  1.10  1.12  1.00 2.78 −1.78 −1.12 LUNG  1.26 n/d  1.03  1.18 n/d −1.07 n/d PLACENTA n/d −1.47 −1.77 −1.07 n/d −1.86  1.69 PROSTATE −1.44 n/d −1.36  1.22 n/d −1.73 n/d SKELETAL −1.43  1.09 n/d n/d n/d  1.44 n/d MUSCLE

[0496] As shown in Tables 1 and 2, significant expression of exons 2, 3, 8, 9, 11 and 12 was seen in all the tissues tested. NEDD-1 expression in these and additional tissues was further confirmed by RT-PCR analysis (see below).

[0497] Marathon-Ready™ skeletal muscle, liver and whole fetus cDNA (Clontech Laboratories, Palo Alto, Calif., USA, catalogue nos. 7413-1, 7407-1, and 7438-1, respectively) was used as a substrate for standard RACE (rapid amplification of cDNA ends) to obtain a cDNA clone that spans 3.4 kilobases and appears to contain the entire coding region of the gene to which the exon contributes; for reasons described below, we termed this cDNA human NEDD-1. Marathon-Ready cDNAs are adaptor-ligated double stranded cDNAs suitable for 3′ and 5′ RACE. Chenchik et al., BioTechniques 21:526-532 (1996); Chenchik et al., CLONTECHniques X(1):5-8 (January 1995). RACE techniques are described, inter alia, in the Marathon-Ready™ cDNA User Manual (Clontech Labs., Palo Alto, Calif., USA, Mar. 30, 2000, Part No. PT1156-1 (PR03517)), Ausubel et al. (eds.), Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, 4^(th) edition (April 1999), John Wiley & Sons (ISBN: 047132938X) and Sambrook et al. (eds.), Molecular Cloning: A Laboratory Manual (3rd ed.), Cold Spring Harbor Laboratory Press (2000) (ISBN: 0879695773), the disclosures of which are incorporated herein by reference in their entireties.

[0498] The human NEDD-1 cDNA was sequenced on both strands using a MegaBace™ sequencer (Molecular Dynamics, Inc., Sunnyvale, Calif., USA). Sequencing both strands provided us with the exact chemical structure of the cDNA, which is shown in FIG. 3 and further presented in the SEQUENCE LISTING as SEQ ID NO: 1, and placed us in actual physical possession of the entire set of single-base incremented fragments of the sequenced clone, starting at the 5′ and 3′ termini.

[0499] Human NEDD-1 cDNA was deposited at the American Type Culture Collection; the deposit was received at ATCC on May 23, 2001, and has been accorded an accession date of ______ and accession number of ______.

[0500] As shown in FIG. 3, the human NEDD-1 cDNA spans 3420 nucleotides and contains an open reading frame from nucleotide 264 through and including nt 2246 (inclusive of termination codon), predicting a protein of 660 amino acids with a (posttranslationally unmodified) molecular weight of 72.0 kD. The open reading frame appears full length with a in-frame 5′ stop codon, a methionine start codon and a stop codon before a 3′ poly-A tail.

[0501] In an effort to clone human NEDD-1 gene, primers based on the sequence of exon 2 were used in RACE reactions against marathon-ready cDNA prepared from human liver, skeletal muscle and fetal brain (Clontech Laboratories, Palo Alto, Calif.). The sizes of the PACE products reveal that more than one NEDD-1 transcripts are expressed in human liver. Sequencing of the two RACE products show two different NEDD-1 transcripts in human liver, a short and a long form resulting from two different sites of polyadenylation within the last exon. The short form transcript was not found expressed in either skeletal muscle or fetal brain.

[0502] BLAST query of genomic sequence identified two BACs, spanning 46 kb, that constitute the minimum set of clones encompassing the cDNA sequence Based upon the known origin of the BACs (GenBank accession numbers AC007564.9 and AC013417.4), the human NEDD-1 gene can be mapped to human chromosome 12q22.

[0503] Comparison of the cDNA and genomic sequences identified 15 exons. Exon organization is listed in Table 3. TABLE 3 Human NEDD-1 Exon Structure Exon no. cDNA range genomic range BAC accession  1  1-255 40737-40481 AC007564.9  2 256-399 38591-38444  3 400-493 35616-35521  4 494-611 30719-30600  5 612-752 28358-28214  6 753-983 13367-13133  7  984-1184 11729-11527  8 1185-1380 11145-10942  9 1381-1509 7934-7802 10 1510-1557 5764-5713 11 1558-1760 4781-4577 12 1761-1917 3704-3544 13 1918-2074 2646-2490 14 2075-2141 3294-3360 AC013417.4 15 2142-3395 3811-5071

[0504]FIG. 2 schematizes the exon organization of the human NEDD-1 clone.

[0505] At the top is shown the two bacterial artificial chromosomes (BACs), with GenBank accession numbers, that span the NEDD-1 locus. The genome-derived single-exon probes first used to demonstrate expression from this locus, as further described in commonly owned and copending provisional patent application No. 60/236,359, filed Sep. 27, 2000, the disclosure of which is incorporated herein by reference in its entirety, is shown below the BACs and are labeled “A” and “B”. The 500 bp probes include sequences drawn from exons eight and nine, respectively, with additional intragenic sequences.

[0506] As shown in FIG. 2, NEDD-1, encoding a protein of 660 amino acids, comprises 15 exons. The cDNA sequence contains an alternative poly A site at nucleotideode 2454. The alternative polyadenylation does not affect the protein structure. Predicted molecular weight, prior to any post-translational modification, is 72.0 kD.

[0507] Expression of NEDD-1 was assessed using hybridization to genome-derived single exon microarrays and quantitative RT PCR assay. Microarray analysis of exons 2, 3, 8, 9, 11, 12 showed universal expression in all the tissues tested. This was confirmed by quantitative RT_PCR.

[0508] The sequence of the human NEDD-1 cDNA was used as a BLAST query into the GenBank nr and dbEst databases. The nr database includes all non-redundant GenBank coding sequence translations, sequences derived from the 3-dimensional structures in the Brookhaven Protein Data Bank (PDB), sequences from SwissProt, sequences from the protein information resource (PIR), and sequences from protein research foundation (PRF). The dbEst (database of expressed sequence tacs) includes ESTs, short, single pass read cDNA (mRNA) sequences, and cDNA sequences from differential display experiments and RACE experiments.

[0509] BLAST search identified multiple human and mouse ESTs, six ESTs from rat, two from pig (BF703165, BE013584) and one from Xenopus laevis (BG515727) as having sequence closely related to NEDD-1.

[0510] Of these, EST AA470029.1 is identical to our NEDD-1 cDNA from (NEDD-1) nucleotides 1734-2304, EST AI082441.1 is identical to NEDD-1 from nucleotides 1999-2450, EST AI915033.1 is identical to NEDD-1 from nucleotides 3053-3137, EST AA412216.1 is identical to NEDD-1 cDNA from nucleotides 1872-2389 and EST AW340374.1 is idenical to NEDD-1 nucleotides 2022-2440.

[0511] Globally, human NEDD-1 resembles mouse Nedd1 protein, with BLASTP reporting 85% amino acid identity and 91% amino acid similarity.

[0512] Motif searches using Pfam (http://pfam.wustl.edu), SMART (http://smart.emblheidelberg.de), and PROSITE pattern and profile databases (http://www.expasy.ch/prosite) identified several known domains shared with mouse Nedd1.

[0513]FIG. 1 shows the domain structure of human NEDD-1 and mouse Nedd1.

[0514] As schematized in FIG. 1, the newly isolated NEDD-1 shares certain protein domains and an overall structural organization with mouse Nedd1, the shared structural features strongly implying that NEDD-1 plays a role similar to that of Nedd1 as a potential tumor suppressor gene and as a support and stabilizer of protein-protein interactions within the cell.

[0515] In common with Nedd1, NEDD-1 has an at least seven-fold tandom repetition near the N-terminus of the G beta motif (alternatively denominated “WD” domain; relaxation of certain bioinformatic parameters causes bioinformatic algorithms to suggest a potential partial eighth repetition at the N-terminal end), which forms a potential seven bladed propeller structure (based on the crystal structure from the WD domain-containing protein, G protein beta, Sondek et al., Nature 379(6563):369-374 (1996)). Such a repetitive segment has been shown to exist in a number of proteins.

[0516] The C-terminal region of the NEDD-1 protein is highly hydrophilic as shown in FIG. 5. The hydrophobicity plot of the NEDD-1 protein was generated by PROTEAN software (DNASTAR Inc., Madison, Wis., USA), using the method developed by Kyte and Doolittle (Kyte and Doolittle, J. Mol. Biol. 157:105-132 (1982)). The hydropathy method predicts regional hydropathy of proteins from their amino acid sequences. Hydropathy values are assigned for all amino acids and are then averaged over a default window of nine amino acids. The average is plotted at the midpoint of the window. Residue hydropathy assignments are derived from water-vapor transfer free energies and the interior-exterior distribution of residue side-chains.

[0517] Possession of the genomic sequence permitted search for promoter and other control sequences for the human NEDD-1 gene.

[0518] A putative transcriptional control region, inclusive of promoter and downstream elements, was defined as 1 kb around the transcription start site, itself defined as the first nucleotide of the human NEDD-1 cDNA clone. The region, drawn from sequence of BAC AC007564.9, has the sequence given in SEQ ID NO:37, which lists 1000 nucleotides before the transcription start site.

[0519] Transcription factor binding sites were identified using a web based program (http://motif.genome.ad.jp/), including a binding site for CRE-binding protein 1/c-Jun heterodimer (590-597 bp) and for activating transcription factor (587-600 bp, with numbering according to SEQ ID NO: 37), amongst others.

[0520] We have thus identified a newly described human gene, which shares certain protein domains and an overall structural organization with mouse Nedd1. The shared structural features strongly imply that the human NEDD-1 protein plays a role similar to mouse Nedd1, as a potential tumor suppressor gene, and as a support and stabilizer of protein-protein interactions within the cell, making the human NEDD-1 proteins and nucleic acids clinically useful diagnostic markers and potential therapeutic agents for inhibitors of tumorigenesis.

EXAMPLE 2 RT-PCR Analysis of Expression of Human NEDD-1

[0521] Quantitative real-time PCR was used to measure relative levels of NEDD-1 and GAPDH in a spectrum of human tissues. Roche's LightCycler instrument, FastStart SYBR green I (dsDNA-binding fluorescent dye, Roche) kit reagents and protocols (Roche Molecular Biochemicals, Mannheim, Germany) were used for these experiments in accordance with the manufacturer's protocol. The accumulated PCR product was measured at the end of each cycle by detecting the amount of intercalated SYBR green I dye. The point at which each sample begins the exponential phase of amplification is defined as its crossing point.

[0522] In looking at the expression of the NEDD-1 gene across 10 tissues, primers were designed to assay for the presence of the gene's open reading frame (ORF primers). The forward primer used, 5′ACTGCGGTAGATTTCATGCC 3′ [SEQ ID NO:468], and the reverse primer, 5′CGTTTGTTCACTGTTGTGGG 3′ [SEQ ID NO:469], produced a 217 bp PCR product which spans exons 8-9 of the gene. As a standard, the presence of GAPDH was monitored across the same tissues. The forward primer used, 5′ CGACCACTTTGTCAAGCTCA 3′ [SEQ ID NO:470], and the reverse primer, 5′ TGTGAGGAGGGGAGATTCAG 3′ [SEQ ID NO:471], produced approximately a 200 bp product. In-house cDNA templates were made from mRNA, through a reverse transcription reaction [Sambrook, J., et al., in Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY, Vol. 1, 2, 3 (1989)] of the following human tissues: skeletal muscle, liver, HeLa, testis, heart, brain, placenta, prostate, bone marrow and lung. PCR conditions were 95C denaturation for 10 min, followed by 50 amplification cycles of 95° C. 15 sec, 60° C. 0 sec, 72° C. 10 sec. The results showed great distinction between the expression of GAPDH in the tissue panel versus NEDD-1 expression. A 15-20 fold difference was found of lower mRNA levels of NEDD-1 compared to GAPDH. By contrast, differences in NEDD-1 mRNA levels between tissues were <6 fold. It was observed that all tissues assayed showed some level of expression of the NEDD-1 transcript. TABLE 4 Expression of NEDD-1 through quantitative RT_PCR fold difference of ORF product Tissue NEDD-1 b/n tissues crossing point Skeletal Muscle 4.0 23.0 Liver  1.0* 25.0 HeLa 5.0 22.5 Testis 5.8 22.1 Heart 3.0 23.5 Brain 2.0 24.0 Placenta 2.6 23.7 Prostate 4.4 22.8 Bone Marrow  1.0* 25.0 Lung 1.2 24.8

EXAMPLE 3 Subcellular Distribution of Human NEDD-1

[0523] To determine the subcellular location of NEDD-1 protein in human cells, a fusion gene containing the coding regions of NEDD-1 and wild-type green fluorescent protein (GFP) was generated and introduced into HeLa cells via transient transfection.

[0524] A recombinant plasmid (NT-GFP-NEDD-1) was first created such that the complete open reading frame (ORF) of NEDD-1 (nt 264-2246) was fused in frame to the ORF of wild-type GFP in the parent mammalian expression vector NT-GFP (Invitrogen) using standard DNA cloning techniques (Sambrook et al., 1989). The NEDD-1 ORF was amplified with the forward primer 5′ACGGTACCAATGCAGGAAAACCTCAGATT 3′ [SEQ ID NO:472] and the reverse primer 5′CGTCTAGATTACAGAACATTAAGGTATTCAC3′ [SEQ ID NO:473] in standard PCR reactions (94° C., 20 s; 60° C., 20 s; 72° C., 60 s; for 35 cycles) and with skeletal muscle as the cDNA template. The product was subsequently digested with KpnI and XbaI and cloned into the matching restriction enzyme sites of NT-GFP. Cloning junctions were verified by DNA sequencing (MegaBace1000, Molecular Dynamics).

[0525] Human HeLa cells were plated onto coverslips at a density of 1×10⁶ in 60mm dishes and were transfected using lipofectamine and Plus reagent (GibcoBRL/Life Technologies) according to the manufacturer's protocol 24 hours post-plating. As a control, HeLa cells were transfected under identical conditions with empty parent vector (NT-GFP). Cells were fixed in 4% paraformaldehyde 24 hours post-transfection, mounted on slides, and subjected to confocal microscopy (Sarastro 1000, Molecular Dynamics, Sunnyvale Calif.) with excitation at 457 nm in order to visualize the sub-cellular location of the expressed GFP-NEDD-1 fusion protein or GFP protein only. The fusion protein was detected only in the cytoplasm of HeLa cells as seen in FIG. 4B. In contrast, the control GFP protein (FIG. 4A) was located throughout the cell (cytoplasm and nucleus).

EXAMPLE 4 Preparation and Labeling of Useful Fragments of Human NEDD-1

[0526] Useful fragments of human NEDD-1 are produced by PCR, using standard techniques, or solid phase chemical synthesis using an automated nucleic acid synthesizer. Each fragment is sequenced, confirming the exact chemical structure thereof.

[0527] The exact chemical structure of preferred fragments is provided in the attached SEQUENCE LISTING, the disclosure of which is incorporated herein by reference in its entirety. The following summary identifies the fragments whose structures are more fully described in the SEQUENCE LISTING, incorporated herein by reference in its entirety:

[0528] SEQ ID NO: 1 (nt; full length human NEDD-1 cDNA)

[0529] SEQ ID NO: 2 (nt; alternatively polyadenylated full length NEDD-1 cDNA)

[0530] SEQ ID NO: 3 (nt; cDNA ORF)

[0531] SEQ ID NO: 4 (aa; full length protein)

[0532] SEQ ID NO: 5 (nt; nt 904-1138 portion of NEDD-1)

[0533] SEQ ID NO: 6 (aa; aa 215-291 CDS entirely within portion of NEDD-1)

[0534] SEQ ID NOs: 7-21 (nt; exons 1-15, from genomic sequence)

[0535] SEQ ID NOs: 22-36 (nt; 500 bp genomic amplicons centered about exons 1-15)

[0536] SEQ ID NO: 37 (nt; 1000 bp putative promoter)

[0537] SEQ ID NOs: 38-256 (nt; 17-mers scanning nt 904-1138 of human NEDD-1)

[0538] SEQ ID NOs: 257-467 (nt; 25-mers scanning nt 904-1138 of human NEDD-1)

[0539] SEQ ID NO: 468 (nt; NEDD-1 amplification forward primer)

[0540] SEQ ID NO: 469 (nt; NEDD-1 amplification reverse primer)

[0541] SEQ ID NO: 470 (nt; GAPDH amplification control forward primer)

[0542] SEQ ID NO: 471 (nt; GAPDH amplification control reverse primer)

[0543] SEQ ID NO: 472 (nt; NEDD-1 amplification forward primer)

[0544] SEQ ID NO: 473 (nt; NEDD-1 amplification reverse primer)

[0545] Upon confirmation of the exact structure, each of the above-described nucleic acids of confirmed structure is recognized to be immediately useful as a human NEDD-1-specific probe.

[0546] For use as labeled nucleic acid probes, the above-described human NEDD-1 nucleic acids are separately labeled by random priming. As is well known in the art of molecular biology, random priming places the investigator in possession of a near-complete set of labeled fragments of the template of varying length and varying starting nucleotide.

[0547] The labeled probes are used to identify the human NEDD-1 gene on a Southern blot, and are used to measure expression of human NEDD-1 mRNA on a northern blot and by RT-PCR, using standard techniques.

EXAMPLE 5 Production of Human NEDD-1 Protein

[0548] The full length human NEDD-1 cDNA clone is cloned into the mammalian expression vector pcDNA3.1/HISA (Invitrogen, Carlsbad, Calif., USA), transfected into COS7 cells, transfectants selected with G418, and protein expression in transfectants confirmed by detection of the anti-Xpress™ epitope according to manufacturer's instructions. Protein is purified using immobilized metal affinity chromatography and vector-encoded protein sequence is then removed with enterokinase, per manufacturer's instructions, followed by gel filtration and/or HPLC.

[0549] Following epitope tag removal, human NEDD-1 protein is present at a concentration of at least 70%, measured on a weight basis with respect to total protein (i.e., w/w), and is free of acrylamide monomers, bis acrylamide monomers, polyacrylanide and ampholytes. Further HPLC purification provides human NEDD-1 protein at a concentration of at least 95%, measured on a weight basis with respect to total protein (i.e., w/w).

EXAMPLE 6 Production of Anti-human NEDD-1 Antibody

[0550] Purified proteins prepared as in Example 5 are conjugated to carrier proteins and used to prepare murine monoclonal antibodies by standard techniques. Initial screening with the unconjugated purified proteins, followed by competitive inhibition screening using peptide fragments of the human NEDD-1, identifies monoclonal antibodies with specificity for human NEDD-1.

EXAMPLE 7 Human NEDD-1 Disease Associations

[0551] Diseases that map to the human NEDD-1 chromosomal region are shown in Table 5: TABLE 5 Diseases mapped to human chromosome 12q22 (NEDD-1 Locus) chromosomal mim_num disease location 105200 Amyloidosis, Chr.12 renal, 601458 Inflammatory bowel 12p13.2-q24.1 disease-2 603221 Myopia, high 12q21-q23 grade, autosomal dominant 2 273300 Male germ cell 12q22 tumor

[0552] A chromosome change associated with chromosome 12 has been identified in testicular tumors (Atkin et al., Lancet II:1349, 1982). Such Human male germ cell tumors (GCT) result from malignant transformation of premeiotic or early meiotic germ cells and exhibit embryonal-like differentiation of the 3 germinal layers. Germ cell tumors (GCTs), including malignant teratomas and seminomas, are the most common malignant neoplasm of males aged 15 to 34 and a major cause of death due to cancer in this age group.

[0553] Amplification of 1 or more genes on the short arm of chromosome 12 is thought to be important in the development of malignant testicular tumors.

[0554] Deletions in 12q22 have also been implicated in male germ cell tumors (Murty et al., Cytogenet. Cell Genet. 67: 271-272, 1994) suggesting that chromosome 12 may be the site of candidate tumor suppressor genes in male germ cell tumors (Murty et al.; Proc. Nat. Acad. Sci. USA 89:11006-11010, 1992).

[0555] Other disorders that have been linked to genes on chromosome 12 include autosomal dominant high grade myopia (MYP3), (Young et al., Am. J. Hum. Genet. 63: 1419-1424, 1998) and inflammatory bowel disease including Crohn disease and ulcerative colitis (Duerr et al., Am. J. Hum. Genet. 63: 95-100, 1998).

Example 8 Use of Human NEDD-1 Probes and Antibodies For Diagnosis of Tumor Cells

[0556] After informed consent is obtained, samples are drawn from and tested for human NEDD-1 mRNA levels by standard techniques and tested additionally for human NEDD-1 protein levels using anti-human NEDD-1 antibodies in a standard ELISA.

[0557] After tumor growth is demonstrated for all patients, tabulated results demonstrate a statistically significant decrease in NEDD-1 expression correlated with adverse outcome.

EXAMPLE 9 Use of Human NEDD-1 Nucleic Acids and Proteins in Therapy

[0558] Once absence of NEDD-1 expression has been detected in patients, NEDD-1 is reintroduced into the patient's tumor cells by introduction of expression vectors that drive NEDD-1 expression or by introducing NEDD-1 proteins into cells.

[0559] All patents, patent publications, and other published references mentioned herein are hereby incorporated by reference in their entireties; as if each had been individually and specifically incorporated by reference herein. While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for purposes of illustration only and not by way of limitation. The present invention is limited only by the claims that follow.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 473 <210> SEQ ID NO 1 <211> LENGTH: 3420 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 aggtacttgg atgcatttta caggttagcc tcacttgagc tgttgtcctg caagtaaagt 60 gtatttttgg tgattgaaag ttggagaact ttcatttcag ctgagtggtg tagttgaatt 120 ggttcctgta gccgctgtcc ctaaacccag gccgacgtta ccgccttgtg tcctgactgc 180 tagctttcga cgggaccgtc tttgagggac tcatgtaaag tctctccctt aatgctcagt 240 tcttacaaga ccgaggcgca gtcatgcagg aaaacctcag atttgcttca tcaggagatg 300 atattaaaat atgggatgct tcatctatga cattggtgga taaattcaac ccacacacat 360 caccacatgg aatcagctca atatgttgga gcagcaataa taacttttta gtaacagcat 420 cttccagtgg cgacaaaata gttgtctcaa gttgcaaatg taaacctgtt ccacttttag 480 agcttgctga agggcaaaag cagacatgtg tcaatttaaa ttctacatct atgtatttgg 540 taagcggagg cctaaataac actgttaata tttgggattt aaaatcaaaa agagttcatc 600 gatctcttaa ggatcataaa gatcaagtaa cttgtgtaac atacaattgg aatgattgct 660 acattgcttc tggatctctt agtggtgaaa ttattttaca cagtgtaacc actaatttat 720 ctagtactcc ttttggccat ggtagtaacc agtctgttcg gcacttgaag tactccttgt 780 ttaagaaatc actactgggc agtgtttcgg ataatggaat agtaactctc tgggatgtaa 840 atagtcagag tccataccat aactttgaca gtgtacacaa agctccagcg tcaggcatct 900 gtttttctcc tgtcaatgaa ttgctctttg taaccatagg cttggataaa agaatcatcc 960 tctatgacac ttcaagtaag aagctagtga aaactttagt ggctgacact cctctaactg 1020 cggtagattt catgcctgat ggagccactt tggctattgg atcttcccgg gggaaaatat 1080 atcaatatga tttaagaatg ttgaaatcac cagttaagac catcagtgct cacaagacat 1140 ctgtgcagtg tatagcattt cagtactcca ctgttcttac taagtcaagt ttaaataaag 1200 gctgttcaaa taagcccaca acagtgaaca aacgaagtgt taatgtgaat gctgctagtg 1260 gaggagttca gaattccgga attgtcagag aagcacctgc cacgtccatt gccacagttc 1320 taccacaacc tatgacatca gctatgggga aaggaacagt tgctgttcaa gaaaaagcag 1380 gtttgcctcg aagcataaac acagacactt tatctaagga aacagacagt ggaaaaaatc 1440 aggatttctc cagctttgat gatactggga aaagtagttt aggtgacatg ttctcaccta 1500 tcagagatga tgctgtagtt aacaagggaa gtgatgagtc cataggcaaa ggagatggct 1560 ttgactttct accgcagttg aactcagtgt ttcctccaag aaaaaatcca gtaacttcaa 1620 gtacttcagt attgcattct agtcctctta atgtttttat gggatctcca gggaaagagg 1680 aaaatgaaaa ccgtgatcta acagctgagt ctaagaaaat atatatggga aaacaggaat 1740 ctaaagactc cttcaaacag ttagcaaagt tggtcacatc tggtgctgaa agtggaaatc 1800 taaatacctc tccatcatct aaccaaacaa gaaattctga gaaatttgaa aagccagaga 1860 atgaaattga agcccagttg atatgtgaac ccccaatcaa tggatcctca actccaaatc 1920 caaagatagc atcttctgtc actgctggag ttgccagttc actctcagaa aaaatagccg 1980 acagcattgg aaataaccgg caaaatgcac cattgacttc cattcaaatt cgttttattc 2040 agaacatgat acaggaaacg ttggatgact ttagagaagc atgccatagg gacattgtga 2100 atttgcaagt ggagatgatt aaacagtttc atatgcaact gaatgaaatg cattctttgc 2160 tggaaagata ctcagtgaat gaaggtttag tggctgaaat tgaaagacta cgagaagaaa 2220 acaaaagatt acgggcccac ttttgaaatt tcagtgaata ccttaatgtt ctgtaatttg 2280 ggaagtttct ggcaacacag aactacatag aatcagtatt gttttcatgg cctccaggga 2340 aaaaatgttt ttcaagtaag agtaaaaggg tgatgggatt ttataccaac aactgtttca 2400 tcttaaaaat atgtatattt ttatattaaa aattgtacag tatgtcatct acccaatagg 2460 aaagtcaaca ggatctttat tttttgaaag ctttagccat ccactaagtg ccctttttca 2520 taagagaaga aaattgtgca taaaaattgg ttatgttgtt ttttagtcat cttttttaac 2580 atatattttt gattgacaaa ttgcctttca aattttgggg ctagttgaga tttaaagagt 2640 ttgatatgcc ttctattttt atggagaaag taattttaaa atggcaattg gtgttctaag 2700 ccatgactaa taaaacatag ggttggctag taattatttg ttaacttgat gaagtcaagt 2760 atgactatta tttattgtac atttgataag acaatttttg gaattttgaa ttgcacaaat 2820 tacatgatat cttttgcatt tatgttacta tattgtactt ctgacaaatc tttattcctg 2880 ggtggtattt ttaagatatc tttacctata aaaatgttta aggttcatag gactcgacaa 2940 gagctatctg gtgattttct cattagtaac atgcaacgtt gtactgcaaa atttcaatca 3000 acatgacaac ttataatgag tggagatttc atattaggta ctaaatatta tagtattatt 3060 tctattttct ttttccaaat aagaagcttg gattatttta ttttgtggtc tttatcatta 3120 actttaattc tttctgtact gtgtataata tttttatatt attggcctta ccataaaatt 3180 atttagaaag gttgtcaaaa taagttatac ctctttggca atagatagat gtatacatct 3240 acctactatg atctacaatt ttaggttaag tgaagcttgg gggggctact gacttggtta 3300 ccttcttgtc tcttgtccca agatttaaac tgtgtacctt tgtatagctc ttctgcccca 3360 ttttgacttc tgagatgaaa gtatttacta aaattaaaaa aaaaaaaaaa aaaaaaaaaa 3420 <210> SEQ ID NO 2 <211> LENGTH: 2480 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 2 aggtacttgg atgcatttta caggttagcc tcacttgagc tgttgtcctg caagtaaagt 60 gtatttttgg tgattgaaag ttggagaact ttcatttcag ctgagtggtg tagttgaatt 120 ggttcctgta gccgctgtcc ctaaacccag gccgacgtta ccgccttgtg tcctgactgc 180 tagctttcga cgggaccgtc tttgagggac tcatgtaaag tctctccctt aatgctcagt 240 tcttacaaga ccgaggcgca gtcatgcagg aaaacctcag atttgcttca tcaggagatg 300 atattaaaat atgggatgct tcatctatga cattggtgga taaattcaac ccacacacat 360 caccacatgg aatcagctca atatgttgga gcagcaataa taacttttta gtaacagcat 420 cttccagtgg cgacaaaata gttgtctcaa gttgcaaatg taaacctgtt ccacttttag 480 agcttgctga agggcaaaag cagacatgtg tcaatttaaa ttctacatct atgtatttgg 540 taagcggagg cctaaataac actgttaata tttgggattt aaaatcaaaa agagttcatc 600 gatctcttaa ggatcataaa gatcaagtaa cttgtgtaac atacaattgg aatgattgct 660 acattgcttc tggatctctt agtggtgaaa ttattttaca cagtgtaacc actaatttat 720 ctagtactcc ttttggccat ggtagtaacc agtctgttcg gcacttgaag tactccttgt 780 ttaagaaatc actactgggc agtgtttcgg ataatggaat agtaactctc tgggatgtaa 840 atagtcagag tccataccat aactttgaca gtgtacacaa agctccagcg tcaggcatct 900 gtttttctcc tgtcaatgaa ttgctctttg taaccatagg cttggataaa agaatcatcc 960 tctatgacac ttcaagtaag aagctagtga aaactttagt ggctgacact cctctaactg 1020 cggtagattt catgcctgat ggagccactt tggctattgg atcttcccgg gggaaaatat 1080 atcaatatga tttaagaatg ttgaaatcac cagttaagac catcagtgct cacaagacat 1140 ctgtgcagtg tatagcattt cagtactcca ctgttcttac taagtcaagt ttaaataaag 1200 gctgttcaaa taagcccaca acagtgaaca aacgaagtgt taatgtgaat gctgctagt 1260 gaggagttca gaattccgga attgtcagag aagcacctgc cacgtccatt gccacagtt 1320 taccacaacc tatgacatca gctatgggga aaggaacagt tgctgttcaa gaaaaagca 1380 gtttgcctcg aagcataaac acagacactt tatctaagga aacagacagt ggaaaaaat 1440 aggatttctc cagctttgat gatactggga aaagtagttt aggtgacatg ttctcacct 1500 tcagagatga tgctgtagtt aacaagggaa gtgatgagtc cataggcaaa ggagatggct 1560 ttgactttct accgcagttg aactcagtgt ttcctccaag aaaaaatcca gtaacttcaa 1620 gtacttcagt attgcattct agtcctctta atgtttttat gggatctcca gggaaagagg 1680 aaaatgaaaa ccgtgatcta acagctgagt ctaagaaaat atatatggga aaacaggaat 1740 ctaaagactc cttcaaacag ttagcaaagt tggtcacatc tggtgctgaa agtggaaatc 1800 taaatacctc tccatcatct aaccaaacaa gaaattctga gaaatttgaa aagccagaga 1860 atgaaattga agcccagttg atatgtgaac ccccaatcaa tggatcctca actccaaatc 1920 caaagatagc atcttctgtc actgctggag ttgccagttc actctcagaa aaaatagccg 1980 acagcattgg aaataaccgg caaaatgcac cattgacttc cattcaaatt cgttttattc 2040 agaacatgat acaggaaacg ttggatgact ttagagaagc atgccatagg gacattgtga 2100 atttgcaagt ggagatgatt aaacagtttc atatgcaact gaatgaaatg cattctttgc 2160 tggaaagata ctcagtgaat gaaggtttag tggctgaaat tgaaagacta cgagaagaaa 2220 acaaaagatt acgggcccac ttttgaaatt tcagtgaata ccttaatgtt ctgtaatttg 2280 ggaagtttct ggcaacacag aactacatag aatcagtatt gttttcatgg cctccaggga 2340 aaaaatgttt ttcaagtaag agtaaaaggg tgatgggatt ttataccaac aactgtttca 2400 tcttaaaaat atgtatattt ttatattaaa aattgtacag tatgtcatct acccgaaaaa 2460 aaaaaaaaaa aaaaaaaaaa 2480 <210> SEQ ID NO 3 <211> LENGTH: 1983 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 3 atgcaggaaa acctcagatt tgcttcatca ggagatgata ttaaaatatg ggatgcttca 60 tctatgacat tggtggataa attcaaccca cacacatcac cacatggaat cagctcaata 120 tgttggagca gcaataataa ctttttagta acagcatctt ccagtggcga caaaatagtt 180 gtctcaagtt gcaaatgtaa acctgttcca cttttagagc ttgctgaagg gcaaaagcag 240 acatgtgtca atttaaattc tacatctatg tatttggtaa gcggaggcct aaataacact 300 gttaatattt gggatttaaa atcaaaaaga gttcatcgat ctcttaagga tcataaagat 360 caagtaactt gtgtaacata caattggaat gattgctaca ttgcttctgg atctcttagt 420 ggtgaaatta ttttacacag tgtaaccact aatttatcta gtactccttt tggccatggt 480 agtaaccagt ctgttcggca cttgaagtac tccttgttta agaaatcact actgggcagt 540 gtttcggata atggaatagt aactctctgg gatgtaaata gtcagagtcc ataccataac 600 tttgacagtg tacacaaagc tccagcgtca ggcatctgtt tttctcctgt caatgaattg 660 ctctttgtaa ccataggctt ggataaaaga atcatcctct atgacacttc aagtaagaag 720 ctagtgaaaa ctttagtggc tgacactcct ctaactgcgg tagatttcat gcctgatgga 780 gccactttgg ctattggatc ttcccggggg aaaatatatc aatatgattt aagaatgttg 840 aaatcaccag ttaagaccat cagtgctcac aagacatctg tgcagtgtat agcatttcag 900 tactccactg ttcttactaa gtcaagttta aataaaggct gttcaaataa gcccacaaca 960 gtgaacaaac gaagtgttaa tgtgaatgct gctagtggag gagttcagaa ttccggaatt 1020 gtcagagaag cacctgccac gtccattgcc acagttctac cacaacctat gacatcagct 1080 atggggaaag gaacagttgc tgttcaagaa aaagcaggtt tgcctcgaag cataaacaca 1140 gacactttat ctaaggaaac agacagtgga aaaaatcagg atttctccag ctttgatgat 1200 actgggaaaa gtagtttagg tgacatgttc tcacctatca gagatgatgc tgtagttaac 1260 aagggaagtg atgagtccat aggcaaagga gatggctttg actttctacc gcagttgaac 1320 tcagtgtttc ctccaagaaa aaatccagta acttcaagta cttcagtatt gcattctagt 1380 cctcttaatg tttttatggg atctccaggg aaagaggaaa atgaaaaccg tgatctaaca 1440 gctgagtcta agaaaatata tatgggaaaa caggaatcta aagactcctt caaacagtta 1500 gcaaagttgg tcacatctgg tgctgaaagt ggaaatctaa atacctctcc atcatctaac 1560 caaacaagaa attctgagaa atttgaaaag ccagagaatg aaattgaagc ccagttgata 1620 tgtgaacccc caatcaatgg atcctcaact ccaaatccaa agatagcatc ttctgtcact 1680 gctggagttg ccagttcact ctcagaaaaa atagccgaca gcattggaaa taaccggcaa 1740 aatgcaccat tgacttccat tcaaattcgt tttattcaga acatgataca ggaaacgttg 1800 gatgacttta gagaagcatg ccatagggac attgtgaatt tgcaagtgga gatgattaaa 1860 cagtttcata tgcaactgaa tgaaatgcat tctttgctgg aaagatactc agtgaatgaa 1920 ggtttagtgg ctgaaattga aagactacga gaagaaaaca aaagattacg ggcccacttt 1980 tga 1983 <210> SEQ ID NO 4 <211> LENGTH: 660 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 Met Gln Glu Asn Leu Arg Phe Ala Ser Ser Gly Asp Asp Ile Lys Ile 1 5 10 15 Trp Asp Ala Ser Ser Met Thr Leu Val Asp Lys Phe Asn Pro His Thr 20 25 30 Ser Pro His Gly Ile Ser Ser Ile Cys Trp Ser Ser Asn Asn Asn Phe 35 40 45 Leu Val Thr Ala Ser Ser Ser Gly Asp Lys Ile Val Val Ser Ser Cys 50 55 60 Lys Cys Lys Pro Val Pro Leu Leu Glu Leu Ala Glu Gly Gln Lys Gln 65 70 75 80 Thr Cys Val Asn Leu Asn Ser Thr Ser Met Tyr Leu Val Ser Gly Gly 85 90 95 Leu Asn Asn Thr Val Asn Ile Trp Asp Leu Lys Ser Lys Arg Val His 100 105 110 Arg Ser Leu Lys Asp His Lys Asp Gln Val Thr Cys Val Thr Tyr Asn 115 120 125 Trp Asn Asp Cys Tyr Ile Ala Ser Gly Ser Leu Ser Gly Glu Ile Ile 130 135 140 Leu His Ser Val Thr Thr Asn Leu Ser Ser Thr Pro Phe Gly His Gly 145 150 155 160 Ser Asn Gln Ser Val Arg His Leu Lys Tyr Ser Leu Phe Lys Lys Ser 165 170 175 Leu Leu Gly Ser Val Ser Asp Asn Gly Ile Val Thr Leu Trp Asp Val 180 185 190 Asn Ser Gln Ser Pro Tyr His Asn Phe Asp Ser Val His Lys Ala Pro 195 200 205 Ala Ser Gly Ile Cys Phe Ser Pro Val Asn Glu Leu Leu Phe Val Thr 210 215 220 Ile Gly Leu Asp Lys Arg Ile Ile Leu Tyr Asp Thr Ser Ser Lys Lys 225 230 235 240 Leu Val Lys Thr Leu Val Ala Asp Thr Pro Leu Thr Ala Val Asp Phe 245 250 255 Met Pro Asp Gly Ala Thr Leu Ala Ile Gly Ser Ser Arg Gly Lys Ile 260 265 270 Tyr Gln Tyr Asp Leu Arg Met Leu Lys Ser Pro Val Lys Thr Ile Ser 275 280 285 Ala His Lys Thr Ser Val Gln Cys Ile Ala Phe Gln Tyr Ser Thr Val 290 295 300 Leu Thr Lys Ser Ser Leu Asn Lys Gly Cys Ser Asn Lys Pro Thr Thr 305 310 315 320 Val Asn Lys Arg Ser Val Asn Val Asn Ala Ala Ser Gly Gly Val Gln 325 330 335 Asn Ser Gly Ile Val Arg Glu Ala Pro Ala Thr Ser Ile Ala Thr Val 340 345 350 Leu Pro Gln Pro Met Thr Ser Ala Met Gly Lys Gly Thr Val Ala Val 355 360 365 Gln Glu Lys Ala Gly Leu Pro Arg Ser Ile Asn Thr Asp Thr Leu Ser 370 375 380 Lys Glu Thr Asp Ser Gly Lys Asn Gln Asp Phe Ser Ser Phe Asp Asp 385 390 395 400 Thr Gly Lys Ser Ser Leu Gly Asp Met Phe Ser Pro Ile Arg Asp Asp 405 410 415 Ala Val Val Asn Lys Gly Ser Asp Glu Ser Ile Gly Lys Gly Asp Gly 420 425 430 Phe Asp Phe Leu Pro Gln Leu Asn Ser Val Phe Pro Pro Arg Lys Asn 435 440 445 Pro Val Thr Ser Ser Thr Ser Val Leu His Ser Ser Pro Leu Asn Val 450 455 460 Phe Met Gly Ser Pro Gly Lys Glu Glu Asn Glu Asn Arg Asp Leu Thr 465 470 475 480 Ala Glu Ser Lys Lys Ile Tyr Met Gly Lys Gln Glu Ser Lys Asp Ser 485 490 495 Phe Lys Gln Leu Ala Lys Leu Val Thr Ser Gly Ala Glu Ser Gly Asn 500 505 510 Leu Asn Thr Ser Pro Ser Ser Asn Gln Thr Arg Asn Ser Glu Lys Phe 515 520 525 Glu Lys Pro Glu Asn Glu Ile Glu Ala Gln Leu Ile Cys Glu Pro Pro 530 535 540 Ile Asn Gly Ser Ser Thr Pro Asn Pro Lys Ile Ala Ser Ser Val Thr 545 550 555 560 Ala Gly Val Ala Ser Ser Leu Ser Glu Lys Ile Ala Asp Ser Ile Gly 565 570 575 Asn Asn Arg Gln Asn Ala Pro Leu Thr Ser Ile Gln Ile Arg Phe Ile 580 585 590 Gln Asn Met Ile Gln Glu Thr Leu Asp Asp Phe Arg Glu Ala Cys His 595 600 605 Arg Asp Ile Val Asn Leu Gln Val Glu Met Ile Lys Gln Phe His Met 610 615 620 Gln Leu Asn Glu Met His Ser Leu Leu Glu Arg Tyr Ser Val Asn Glu 625 630 635 640 Gly Leu Val Ala Glu Ile Glu Arg Leu Arg Glu Glu Asn Lys Arg Leu 645 650 655 Arg Ala His Phe 660 <210> SEQ ID NO 5 <211> LENGTH: 235 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 5 tttctcctgt caatgaattg ctctttgtaa ccataggctt ggataaaaga atcatcctct 60 atgacacttc aagtaagaag ctagtgaaaa ctttagtggc tgacactcct ctaactgcgg 120 tagatttcat gcctgatgga gccactttgg ctattggatc ttcccggggg aaaatatatc 180 aatatgattt aagaatgttg aaatcaccag ttaagaccat cagtgctcac aagac 235 <210> SEQ ID NO 6 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 6 Ser Pro Val Asn Glu Leu Leu Phe Val Thr Ile Gly Leu Asp Lys Arg 1 5 10 15 Ile Ile Leu Tyr Asp Thr Ser Ser Lys Lys Leu Val Lys Thr Leu Val 20 25 30 Ala Asp Thr Pro Leu Thr Ala Val Asp Phe Met Pro Asp Gly Ala Thr 35 40 45 Leu Ala Ile Gly Ser Ser Arg Gly Lys Ile Tyr Gln Tyr Asp Leu Arg 50 55 60 Met Leu Lys Ser Pro Val Lys Thr Ile Ser Ala His Lys 65 70 75 <210> SEQ ID NO 7 <211> LENGTH: 255 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 7 aggtacttgg atgcatttta caggttagcc tcacttgagc tgttgtcctg caagtaaagt 60 gtatttttgg tgattgaaag ttggagaact ttcatttcag ctgagtggtg tagttgaatt 120 ggttcctgta gccgctgtcc ctaaacccag gccgacgtta ccgccttgtg tcctgactgc 180 tagctttcga cgggaccgtc tttgagggac tcatgtaaag tctctccctt aatgctcagt 240 tcttacaaga ccgag 255 <210> SEQ ID NO 8 <211> LENGTH: 144 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 8 gcgcagtcat gcaggaaaac ctcagatttg cttcatcagg agatgatatt aaaatatggg 60 atgcttcatc tatgacattg gtggataaat tcaacccaca cacatcacca catggaatca 120 gctcaatatg ttggagcagc aata 144 <210> SEQ ID NO 9 <211> LENGTH: 94 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 9 ataacttttt agtaacagca tcttccagtg gcgacaaaat agttgtctca agttgcaaat 60 gtaaacctgt tccactttta gagcttgctg aagg 94 <210> SEQ ID NO 10 <211> LENGTH: 118 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10 gcaaaagcag acatgtgtca atttaaattc tacatctatg tatttggtaa gcggaggcct 60 aaataacact gttaatattt gggatttaaa atcaaaaaga gttcatcgat ctcttaag 118 <210> SEQ ID NO 11 <211> LENGTH: 141 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 11 gatcataaag atcaagtaac ttgtgtaaca tacaattgga atgattgcta cattgcttct 60 ggatctctta gtggtgaaat tattttacac agtgtaacca ctaatttatc tagtactcct 120 tttggccatg gtagtaacca g 141 <210> SEQ ID NO 12 <211> LENGTH: 231 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 12 tctgttcggc acttgaagta ctccttgttt aagaaatcac tactgggcag tgtttcggat 60 aatggaatag taactctctg ggatgtaaat agtcagagtc cataccataa ctttgacagt 120 gtacacaaag ctccagcgtc aggcatctgt ttttctcctg tcaatgaatt gctctttgta 180 accataggct tggataaaag aatcatcctc tatgacactt caagtaagaa g 231 <210> SEQ ID NO 13 <211> LENGTH: 201 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 13 ctagtgaaaa ctttagtggc tgacactcct ctaactgcgg tagatttcat gcctgatgga 60 gccactttgg ctattggatc ttcccggggg aaaatatatc aatatgattt aagaatgttg 120 aaatcaccag ttaagaccat cagtgctcac aagacatctg tgcagtgtat agcatttcag 180 tactccactg ttcttactaa g 201 <210> SEQ ID NO 14 <211> LENGTH: 196 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 14 tcaagtttaa ataaaggctg ttcaaataag cccacaacag tgaacaaacg aagtgttaat 60 gtgaatgctg ctagtggagg agttcagaat tccggaattg tcagagaagc acctgccacg 120 tccattgcca cagttctacc acaacctatg acatcagcta tggggaaagg aacagttgct 180 gttcaagaaa aagcag 196 <210> SEQ ID NO 15 <211> LENGTH: 129 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 15 gtttgcctcg aagcataaac acagacactt tatctaagga aacagacagt ggaaaaaatc 60 aggatttctc cagctttgat gatactggga aaagtagttt aggtgacatg ttctcaccta 120 tcagagatg 129 <210> SEQ ID NO 16 <211> LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 16 atgctgtagt taacaaggga agtgatgagt ccataggcaa aggagatg 48 <210> SEQ ID NO 17 <211> LENGTH: 203 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 17 gctttgactt tctaccgcag ttgaactcag tgtttcctcc aagaaaaaat ccagtaactt 60 caagtacttc agtattgcat tctagtcctc ttaatgtttt tatgggatct ccagggaaag 120 aggaaaatga aaaccgtgat ctaacagctg agtctaagaa aatatatatg ggaaaacagg 180 aatctaaaga ctccttcaaa cag 203 <210> SEQ ID NO 18 <211> LENGTH: 157 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 18 ttagcaaagt tggtcacatc tggtgctgaa agtggaaatc taaatacctc tccatcatct 60 aaccaaacaa gaaattctga gaaatttgaa aagccagaga atgaaattga agcccagttg 120 atatgtgaac ccccaatcaa tggatcctca actccaa 157 <210> SEQ ID NO 19 <211> LENGTH: 157 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 19 atccaaagat agcatcttct gtcactgctg gagttgccag ttcactctca gaaaaaatag 60 ccgacagcat tggaaataac cggcaaaatg caccattgac ttccattcaa attcgtttta 120 ttcagaacat gatacaggaa acgttggatg actttag 157 <210> SEQ ID NO 20 <211> LENGTH: 67 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 20 agaagcatgc catagggaca ttgtgaattt gcaagtggag atgattaaac agtttcatat 60 gcaactg 67 <210> SEQ ID NO 21 <211> LENGTH: 1254 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 21 aatgaaatgc attctttgct ggaaagatac tcagtgaatg aaggtttagt ggctgaaatt 60 gaaagactac gagaagaaaa caaaagatta cgggcccact tttgaaattt cagtgaatac 120 cttaatgttc tgtaatttgg gaagtttctg gcaacacaga actacataga atcagtattg 180 ttttcatggc ctccagggaa aaaatgtttt tcaagtaaga gtaaaagggt gatgggattt 240 tataccaaca actgtttcat cttaaaaata tgtatatttt tatattaaaa attgtacagt 300 atgtcatcta cccaatagga aagtcaacag gatctttatt ttttgaaagc tttagccatc 360 cactaagtgc cctttttcat aagagaagaa aattgtgcat aaaaattggt tatgttgttt 420 tttagtcatc ttttttaaca tatatttttg attgacaaat tgcctttcaa attttggggc 480 tagttgagat ttaaagagtt tgatatgcct tctattttta tggagaaagt aattttaaaa 540 tggcaattgg tgttctaagc catgactaat aaaacatagg gttggctagt aattatttgt 600 taacttgatg aagtcaagta tgactattat ttattgtaca tttgataaga caatttttgg 660 aattttgaat tgcacaaatt acatgatatc ttttgcattt atgttactat attgtacttc 720 tgacaaatct ttattcctgg gtggtatttt taagatatct ttacctataa aaatgtttaa 780 ggttcatagg actcgacaag agctatctgg tgattttctc attagtaaca tgcaacgttg 840 tactgcaaaa tttcaatcaa catgacaact tataatgagt ggagatttca tattaggtac 900 taaatattat agtattattt ctattttctt tttccaaata agaagcttgg attattttat 960 tttgtggtct ttatcattaa ctttaattct ttctgtactg tgtataatat ttttatatta 1020 ttggccttac cataaaatta tttagaaagg ttgtcaaaat aagttatacc tctttggcaa 1080 tagatagatg tatacatcta cctactatga tctacaattt taggttaagt gaagcttggg 1140 ggggctactg acttggttac cttcttgtct cttgtcccaa gatttaaact gtgtaccttt 1200 gtatagctct tctgccccat tttgacttct gagatgaaag tatttactaa aatt 1254 <210> SEQ ID NO 22 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 22 ggggaggcgc gggccggggt cgcgcacctc ccggagcctt gtggggtgtg ctgcctccga 60 aaagtttgcc tcgtctccac aagtctgtct ccttttttgt caacctcaag tacttttctt 120 ttggcaggta cttggatgca ttttacaggt tagcctcact tgagctgttg tcctgcaagt 180 aaagtgtatt tttggtgatt gaaagttgga gaactttcat ttcagctgag tggtgtagtt 240 gaattggttc ctgtagccgc tgtccctaaa cccaggccga cgttaccgcc ttgtgtcctg 300 actgctagct ttcgacggga ccgtctttga gggactcatg taaagtctct cccttaatgc 360 tcagttctta gaagaccgag gtaggtgggc agatggtcct cttccccgcc ccgctttaag 420 agccgaaaac aaacattaaa tcacccggcg agttgtgttt cctaagttgg agcaggtcgt 480 ttgaacccag tttttctgag 500 <210> SEQ ID NO 23 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 23 ttggaagggt cagctaagag aatgcgacct ggcttatgtt ttaggaaaat cacttcaact 60 gctttggtga ctgcactgtt tggaacaaaa atgaatgagt tagagccact tgttttagat 120 tagattttga cctttttttg agtatgtcta ttcttaaatg tttttaaaat acattgtttt 180 aaactatttg taggcgcagt catgcaggaa aacctcagat ttgcttcatc aggagatgat 240 attaaaatat gggatgcttc atctatgaca ttggtggata aattcaaccc acacacatca 300 ccacatggaa tcagctcaat atgttggagc agcaatagta tcctttaaaa aaaaaaaaca 360 cacacacaca cacacaaacc gcttattagg ttaaacaacc actgtcaatg aaacttttgc 420 atgtgcctca tactgagtaa tgtgttttgc attgctacca aggatagata acgtaaaata 480 gtaatttaca aaacaatata 500 <210> SEQ ID NO 24 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 24 gctagttctt ccctgcagta gtagcaaaga gaattagtct tagtaattat taatagtaat 60 gtgagccatt tttgaaagct actctgtaag ctatactcat tgcttgtctt cttagtgtgt 120 tagcttttat aatcgcaatt cttataatag tctagtgcta tagatgttca tggattgttt 180 gatgctccat aactcctcat ttagataact ttttagtaac agcatcttcc agtggcgaca 240 aaatagttgt ctcaagttgc aaatgtaaac ctgttccact tttagagctt gctgaagggg 300 taagtgattt tttttttttt taaactttta aaaatcttag ttttgcttga ctggcaattg 360 cttattgtgg tgcttgcgac taaatataaa ggtttttaaa agcattattt ttaacttaag 420 ctcaaaataa tatagtaaca cttaaaaatg agatatgtgt acttactaaa gtatttttag 480 gtaaaatagt tttgaatata 500 <210> SEQ ID NO 25 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 25 gcatttttga cccccttaaa agctgttgga tccatgtgga agaaagacga tgagagagtg 60 gctctttagt acaagattag catgtttata gtatttaatt taaccaatat ttatcatatg 120 cttactaagt gttggatgag acctgaaagt cagctctggg ctctgttaaa ttaaggtaac 180 tttttttttt ttttttaaat agcaaaagca gacatgtgtc aatttaaatt ctacatctat 240 gtatttggta agcggaggcc taaataacac tgttaatatt tgggatttaa aatcaaaaag 300 agttcatcga tctcttaagg taagcaattt aaaaaaaatc ttcatgaaaa aatggatatc 360 ttaatgcatt tagagtactt accaagcttt tatttttgag cttttatgat aaaaataaga 420 ggcttcagaa ttgaactaag atttgttagg gaaaataaag gtgctattta gccaaaaact 480 tatttttatg tcttttttct 500 <210> SEQ ID NO 26 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 26 tgaaaataat tctctgtata tttgaggaaa atgttaaagc aaatattaga ttgataaata 60 cataatgtat ggtatttaca gaaacatgaa aatgggctgt tcgaggatta tggggcagtg 120 tacttacttt catttctctc tttcaggatc ataaagatca agtaacttgt gtaacataca 180 attggaatga ttgctacatt gcttctggat ctcttagtgg tgaaattatt ttacacagtg 240 taaccactaa tttatctagt actccttttg gccatggtag taaccaggta cagtatgagt 300 ttattcagag taaaattggt aagatagatt ttgaattgta tcttacataa gactgtgaat 360 ttaagttttt gaaatgcttg attgaaaaac ttcagctatt tttaaatggt agtgttttaa 420 aatattcaga tagcaagcta attcatacta gattatggtg cttatataaa tttgattatg 480 taatcaaata gtcacatcct 500 <210> SEQ ID NO 27 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 27 tgagccacca cgtctggctg aaacctgtca ctcttacaca tcagagaaat cctaaacccc 60 atgtgaatag tgtggttggc cataatttat atggcttata tcaaatgtcc ttatgaatgc 120 ttataattac ataaaattta ttctttcatt tttatagtct gttcggcact tgaagtactc 180 cttgtttaag aaatcactac tgggcagtgt ttcggataat ggaatagtaa ctctctggga 240 tgtaaatagt cagagtccat accataactt tgacagtgta cacaaagctc cagcgtcagg 300 catctgtttt tctcctgtca atgaattgct ctttgtaacc ataggcttgg ataaaagaat 360 catcctctat gacacttcaa gtaagaagta agtgtgacat gcttatttct taatttagta 420 acaaatagct attattccat taacaggcat atttgtgatt tatatagacc tctgattagt 480 gtccaggggt cctaaagttt 500 <210> SEQ ID NO 28 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 28 aaattatgct ttaaacaaat atttgggata tgtgtgctct ttgaccagtt tgaagtgtta 60 ataactctgg ttttggtata tagttactta tataagctaa tatacctgta cacactaaca 120 tttctacaca tactttgttc tcctttccaa aggctagtga aaactttagt ggctgacact 180 cctctaactg cggtagattt catgcctgat ggagccactt tggctattgg atcttcccgg 240 gggaaaatat atcaatatga tttaagaatg ttgaaatcac cagttaagac catcagtgct 300 cacaagacat ctgtgcagtg tatagcattt cagtactcca ctgttcttac taaggtgaga 360 cattttcttt tcagcatttt ttattttatt aaataaatct aactcagaat atggaaatta 420 tatgtggtca attaaacagt atagttttgt ttcataatta cataatgatt ttacatgtaa 480 tgtataataa ttttagtaca 500 <210> SEQ ID NO 29 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens SEQUENCE: 29 agcttaagat ttgcaaggaa aaaaatatat tttttaatct aacagggaat ttataaaata 60 ttaatgtata gtatgaaaca ttagtaacct gagcttttaa atattccatt acatttcagt 120 caagtttaaa taaaggctgt tcaaataagc ccacaacagt gaacaaacga agtgttaatg 180 tgaatgctgc tagtggagga gttcagaatt ccggaattgt cagagaagca cctgccacgt 240 ccattgccac agttctacca caacctatga catcagctat ggggaaagga acagttgctg 300 ttcaagaaaa agcaggtaaa tgttgcttat atattgttgg agggttggtt tgtttttttt 360 ttgttttttt gtttttggct tgcatataat tagcacattc ttcaagaaca tagaactcaa 420 atttatttga gtacttaggt aaaattagta gaagtgaaaa tcattgaaga agtgaaaata 480 gtaactttgg ctattaattt 500 <210> SEQ ID NO 30 <211> LENGTH: 500 <212> TYPE: DNA ORGANISM: Homo sapie ns SEQUENCE: 30 atattctgtt ttattgttc catgaaaatcc tgattaactt tagctcttgt catattctgt 60 tttattctcc ttatgctca tagttgtaata ttaccaacaa tatgagtgat acattaattt 120 ttacaaccta gcttatgat aaaatttattt agatgtaata acattgattt ttatatctaa 180 ttcctataag gtttgcctc gaagcataaac acagacactt tatctaagga aacagacagt 240 ggaaaaaatc aggatttct ccagctttgat gatactggga aaagtagttt aggtgacatg 300 ttctcaccta tcagagatgg taagtctgtt cagaggatcc tgttctcttg ctggtagtta 360 atatttttat tctggctaaa agatgtgaat aatagcttca gtccaactct attcacggat 420 cagtttgcta attttctcca tccctggggt ggtatctttt tctttgccct gatatttcaa 480 atgttatcat tgtaaaatat 500 <210> SEQ ID NO 31 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 31 tatagaatta tctgttcata tttgctgcta aagtgtgaat gaagctaaaa taatgtaaaa 60 gagaaattta aatcagtatt ctcctacctt taacatcact catatttagc tttttaagat 120 tgttagtctc tgaactcttt ggggaatgaa taagaagcct aaattgatat ggtttctttt 180 tcactagttt taaaatttga ttttctaatt tgttatagat gctgtagtta acaagggaag 240 tgatgagtcc ataggcaaag gagatggtaa gaactactta gaagtatttt cgtgaaaatg 300 aaaagtgaat tgtattatct atgctgtgta acaaatctct ccaacacttt gaggcttaaa 360 aaaataaaca tttatcgtct cataatttct gtgtattaag aactgagcat gacttggctg 420 agtacctttg ccttcaagtc tatcttcctg cttcaatcag gatgtcaacc agagcttcat 480 tcaacttaag actcaactgg 500 <210> SEQ ID NO 32 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 32 gaaacaaacc agtcttcaga atgcagatcc atatcttctt ccatgttaat ctgcctatca 60 tgttaaatgc ttttcttcaa tgtccaaaat tggaggacac catatgcaca tgcagttttt 120 cccttttcca ggctttgact ttctaccgca gttgaactca gtgtttcctc caagaaaaaa 180 tccagtaact tcaagtactt cagtattgca ttctagtcct cttaatgttt ttatgggatc 240 tccagggaaa gaggaaaatg aaaaccgtga tctaacagct gagtctaaga aaatatatat 300 gggaaaacag gaatctaaag actccttcaa acaggtattt gcctgaaaat gatactgaac 360 tcactgtatg tgtttatcag tagaaagtgg gtggctgcca gtgcatgtat cctaattatt 420 agcattgcta tgcacttatt cataagtctt gatgtcagat tttaataact acagaatact 480 ttgaaatctc gctttggata 500 <210> SEQ ID NO 33 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 33 cagttctctt tttctttttc ttcttctata tctcttccta ttttccttca tttctattaa 60 cctacatact gggacaaaag agagaagtag gcaaaaatta tatgggtaat atgagtaaaa 120 aaattgtata ttaaagtcat tatttatttt aaatataaag ttagcaaagt tggtcacatc 180 tggtgctgaa agtggaaatc taaatacctc tccatcatct aaccaaacaa gaaattctga 240 gaaatttgaa aagccagaga atgaaattga agcccagttg atatgtgaac ccccaatcaa 300 tggatcctca actccaagta agtacatgaa acttcctgat gtttgaaagt gtttgattga 360 aaaatcatcc ccattattta acttgtaaag gagaaataga gtaatcatag actaaaaatg 420 ttcaaagagt ttaaagtttg tggacacttc tgttgtgtga gtgttactaa agacaatgaa 480 atggatatga atcgttaaat 500 <210> SEQ ID NO 34 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 34 ataaatgact attagaaata atgttataga aagtttctaa gatttgtatt ccagacagtg 60 aatttttcta aatgtcacag gaacactctt ctttgccagt ttttcaagtt tgcacatgcc 120 aaatcttatt tagaaatgtt tgatgtctct cagtccaagt tgactattaa tattttcttc 180 attctttatt ttagatccaa agatagcatc ttctgtcact gctggagttg ccagttcact 240 ctcagaaaaa atagccgaca gcattggaaa taaccggcaa aatgcaccat tgacttccat 300 tcaaattcgt tttattcaga acatgataca ggaaacgttg gatgacttta ggtagtaatt 360 gagaaactac tccttctatc tagaccttac ttgttttttt tttagatgta aaaccagaac 420 tatagataat gttgttggtt actattgtct aggttctggt aatcctaaag ccatagaaaa 480 cataatgagt tttgttgatc 500 <210> SEQ ID NO 35 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 35 gaaacagtgc ctagcacata gtgaataaat gctcagtgca ttggtatttt tattattata 60 gtaattatta acattcagta atttggcaaa tgaaaaagtt tagtgagttt cttgaatgac 120 ctagaattgg ttaaactatt gtaattctaa aaagtatttt acattcttcc tagagaagca 180 tgccataggg acattgtgaa tttgcaagtg gagatgatta aacagtttca tatgcaactg 240 gtatgtatgg caaattttat tttaatattt taaatgaaag tagagttgtg tgaattttta 300 aaaatccatg aaaggtaata tattttagtt gttttgttta gtttctaaga taaataggga 360 gttttataga ctaaataagt aaaatagatt ttaactggtc acctcctttt taacctctga 420 gatacttaag ccttcttttt tccatggctt tcttcctgat aagtaagcaa aaagcatttt 480 aaatgtgcaa atataaattt 500 <210> SEQ ID NO 36 <211> LENGTH: 500 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 36 cactaagtgc cctttttcat aagagaagaa aattgtgcat aaaaattggt tatgttgttt 60 tttagtcatc ttttttaaca tatatttttg attgacaaat tgcctttcaa attttggggc 120 tagttgagat ttaaagagtt tgatatgcct tctattttta tggagaaagt aattttaaaa 180 tggcaattgg tgttctaagc catgactaat aaaacatagg gttggctagt aattatttgt 240 taacttgatg aagtcaagta tgactattat ttattgtaca tttgataaga caatttttgg 300 aattttgaat tgcacaaatt acatgatatc ttttgcattt atgttactat attgtacttc 360 tgacaaatct ttattcctgg gtggtatttt taagatatct ttacctataa aaatgtttaa 420 ggttcatagg actcgacaag agctatctgg tgattttctc attagtaaca tgcaacgttg 480 tactgcaaaa tttcaatcaa 500 <210> SEQ ID NO 37 <211> LENGTH: 1000 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 37 gaattcccaa acagatgatg tttgatgttc cggacctcgc agcatgatgc gaaagaaaga 60 tcatgggttt tgaagtaggt tagtgcagac gcctactctt tgggttattt ctcagcctga 120 gcgcgtttcc tggcttgtaa atcgcatgta ggaatccttt cctaaatcca catccacaat 180 agtttccctt attatgggtc ttcgtgcatc ttataccttt cattatcata gtttcacttt 240 ccatttaagc atctaataac gtcagcttcc tatagtgcat tgtaagctcc acaaggccaa 300 ggaccacgag aattcactgt acccctgtat ccccaggcta aaccatcact gtacactcaa 360 gagtctagca cagtgcctgg cacacagtaa acagcaagtg aatgacaagc agttggcagt 420 ggccggagct ccgtcgctgg ggcgtggaga gggccgcccc ggcccgcagt tcccgccctg 480 acactgggat aacttccccc gcggctgccc agcgccgccc tgaccagacc ctctgtaccc 540 cgacttctgt ccggccagaa gccacagccg cacgcagcgc ctcgccccgt gacgtcactc 600 ggggcgggac ttccggccgc cgaagtttaa cagtccaggc gggagccgga agcccagcgc 660 ggagccggcc gcggccccct gttgtgttgc tgcggagagg tgaggttccg gaggccctga 720 ggtcagcggg cccccgcccg ccgcgtccgc gcaccctccc gatcctaaga cccgctccgt 780 ccccctcaga gggcggggcg gcggtccttg ggctttgcgc gcccggagcg gttgctgggc 840 gggggcgcgg cggcgcgctg ggctgggaag tgtccgggga ggcgcgggcc ggggtcgcgc 900 acctcccgga gccttgtggg gtgtgctgcc tccgaaaagt ttgcctcgtc tccacaagtc 960 tgtctccttt tttgtcaacc tcaagtactt ttcttttggc 1000 <210> SEQ ID NO 38 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 38 tttctcctgt caatgaa 17 <210> SEQ ID NO 39 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 39 ttctcctgtc aatgaat 17 <210> SEQ ID NO 40 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 40 tctcctgtca atgaatt 17 <210> SEQ ID NO 41 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 41 ctcctgtcaa tgaattg 17 <210> SEQ ID NO 42 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 42 tcctgtcaat gaattgc 17 <210> SEQ ID NO 43 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 43 cctgtcaatg aattgct 17 <210> SEQ ID NO 44 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 44 ctgtcaatga attgctc 17 <210> SEQ ID NO 45 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 45 tgtcaatgaa ttgctct 17 <210> SEQ ID NO 46 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 46 gtcaatgaat tgctctt 17 <210> SEQ ID NO 47 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 47 tcaatgaatt gctcttt 17 <210> SEQ ID NO 48 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 48 caatgaattg ctctttg 17 <210> SEQ ID NO 49 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 49 aatgaattgc tctttgt 17 <210> SEQ ID NO 50 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 50 atgaattgct ctttgta 17 <210> SEQ ID NO 51 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 51 tgaattgctc tttgtaa 17 <210> SEQ ID NO 52 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 52 gaattgctct ttgtaac 17 <210> SEQ ID NO 53 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 53 aattgctctt tgtaacc 17 <210> SEQ ID NO 54 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 54 attgctcttt gtaacca 17 <210> SEQ ID NO 55 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 55 ttgctctttg taaccat 17 <210> SEQ ID NO 56 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 56 tgctctttgt aaccata 17 <210> SEQ ID NO 57 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 57 gctctttgta accatag 17 <210> SEQ ID NO 58 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 58 ctctttgtaa ccatagg 17 <210> SEQ ID NO 59 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 59 tctttgtaac cataggc 17 <210> SEQ ID NO 60 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 60 aacc ataggct 17 <210> SEQ ID NO 61 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 61 tttgtaacca taggctt 17 <210> SEQ ID NO 62 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 62 ttgtaaccat aggcttg 17 <210> SEQ ID NO 63 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 63 tgtaaccata ggcttgg 17 <210> SEQ ID NO 64 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 64 gtaaccatag gcttgga 17 <210> SEQ ID NO 65 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 65 taaccatagg cttggat 17 <210> SEQ ID NO 66 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 66 aaccataggc ttggata 17 <210> SEQ ID NO 67 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 67 accataggct tggataa 17 <210> SEQ ID NO 68 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 68 ccataggctt ggataaa 17 <210> SEQ ID NO 69 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 69 cataggcttg gataaaa 17 <210> SEQ ID NO 70 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 70 ataggcttgg ataaaag 17 <210> SEQ ID NO 71 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 71 taggcttgga taaaaga 17 <210> SEQ ID NO 72 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 72 aggcttggat aaaagaa 17 <210> SEQ ID NO 73 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 73 ggcttggata aaagaat 17 <210> SEQ ID NO 74 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 74 gcttggataa aagaatc 17 <210> SEQ ID NO 75 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 75 cttggataaa agaatca 17 <210> SEQ ID NO 76 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 76 ttggataaaa gaatcat 17 <210> SEQ ID NO 77 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 77 tggataaaag aatcatc 17 <210> SEQ ID NO 78 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 78 ggataaaaga atcatcc 17 <210> SEQ ID NO 79 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 79 gataaaagaa tcatcct 17 <210> SEQ ID NO 80 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 80 ataaaagaat catcctc 17 <210> SEQ ID NO 81 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 81 taaaagaatc atcctct 17 <210> SEQ ID NO 82 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 82 aaaagaatca tcctcta 17 <210> SEQ ID NO 83 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 83 aaagaatcat cctctat 17 <210> SEQ ID NO 84 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 84 aagaatcatc ctctatg 17 <210> SEQ ID NO 85 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 85 agaatcatcc tctatga 17 <210> SEQ ID NO 86 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 86 gaatcatcct ctatgac 17 <210> SEQ ID NO 87 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 87 aatcatcctc tatgaca 17 <210> SEQ ID NO 88 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 88 atcatcctct atgacac 17 <210> SEQ ID NO 89 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 89 tcatcctcta tgacact 17 <210> SEQ ID NO 90 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 90 catcctctat gacactt 17 <210> SEQ ID NO 91 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 91 atcctctatg acacttc 17 <210> SEQ ID NO 92 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 92 tcctctatga cacttca 17 <210> SEQ ID NO 93 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 93 cctctatgac acttcaa 17 <210> SEQ ID NO 94 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 94 ctctatgaca cttcaag 17 <210> SEQ ID NO 95 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 95 tctatgacac ttcaagt 17 <210> SEQ ID NO 96 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 96 ctatgacact tcaagta 17 <210> SEQ ID NO 97 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 97 tatgacactt caagtaa 17 <210> SEQ ID NO 98 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 98 atgacacttc aagtaag 17 <210> SEQ ID NO 99 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 99 tgacacttca agtaaga 17 <210> SEQ ID NO 100 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 100 gacacttcaa gtaagaa 17 <210> SEQ ID NO 101 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 101 acacttcaag taagaag 17 <210> SEQ ID NO 102 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 102 cacttcaagt aagaagc 17 <210> SEQ ID NO 103 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 103 acttcaagta agaagct 17 <210> SEQ ID NO 104 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 104 cttcaagtaa gaagcta 17 <210> SEQ ID NO 105 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 105 ttcaagtaag aagctag 17 <210> SEQ ID NO 106 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 106 tcaagtaaga agctagt 17 <210> SEQ ID NO 107 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 107 caagtaagaa gctagtg 17 <210> SEQ ID NO 108 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 108 aagtaagaag ctagtga 17 <210> SEQ ID NO 109 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 109 agtaagaagc tagtgaa 17 <210> SEQ ID NO 110 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 110 gtaagaagct agtgaaa 17 <210> SEQ ID NO 111 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 111 taagaagcta gtgaaaa 17 <210> SEQ ID NO 112 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 112 aagaagctag tgaaaac 17 <210> SEQ ID NO 113 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 113 agaagctagt gaaaact 17 <210> SEQ ID NO 114 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 114 gaagctagtg aaaactt 17 <210> SEQ ID NO 115 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 115 aagctagtga aaacttt 17 <210> SEQ ID NO 116 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 116 agctagtgaa aacttta 17 <210> SEQ ID NO 117 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 117 gctagtgaaa actttag 17 <210> SEQ ID NO 118 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 118 ctagtgaaaa ctttagt 17 <210> SEQ ID NO 119 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 119 tagtgaaaac tttagtg 17 <210> SEQ ID NO 120 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 120 agtgaaaact ttagtgg 17 <210> SEQ ID NO 121 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 121 gtgaaaactt tagtggc 17 <210> SEQ ID NO 122 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 122 tgaaaacttt agtggct 17 <210> SEQ ID NO 123 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 123 gaaaacttta gtggctg 17 <210> SEQ ID NO 124 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 124 aaaactttag tggctga 17 <210> SEQ ID NO 125 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 125 aaactttagt ggctgac 17 <210> SEQ ID NO 126 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 126 aactttagtg gctgaca 17 <210> SEQ ID NO 127 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 127 actttagtgg ctgacac 17 <210> SEQ ID NO 128 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 128 ctttagtggc tgacact 17 <210> SEQ ID NO 129 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 129 tttagtggct gacactc 17 <210> SEQ ID NO 130 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 130 ttagtggctg acactcc 17 <210> SEQ ID NO 131 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 131 tagtggctga cactcct 17 <210> SEQ ID NO 132 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 132 agtggctgac actcctc 17 <210> SEQ ID NO 133 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 133 gtggctgaca ctcctct 17 <210> SEQ ID NO 134 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 134 tggctgacac tcctcta 17 <210> SEQ ID NO 135 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 135 ggctgacact cctctaa 17 <210> SEQ ID NO 136 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 136 gctgacactc ctctaac 17 <210> SEQ ID NO 137 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 137 ctgacactcc tctaact 17 <210> SEQ ID NO 138 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 138 tgacactcct ctaactg 17 <210> SEQ ID NO 139 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 139 gacactcctc taactgc 17 <210> SEQ ID NO 140 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 140 acactcctct aactgcg 17 <210> SEQ ID NO 141 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 141 cactcctcta actgcgg 17 <210> SEQ ID NO 142 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 142 actcctctaa ctgcggt 17 <210> SEQ ID NO 143 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 143 ctcctctaac tgcggta 17 <210> SEQ ID NO 144 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 144 tcctctaact gcggtag 17 <210> SEQ ID NO 145 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 145 cctctaactg cggtaga 17 <210> SEQ ID NO 146 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 146 ctctaactgc ggtagat 17 <210> SEQ ID NO 147 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 147 tctaactgcg gtagatt 17 <210> SEQ ID NO 148 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 148 ctaactgcgg tagattt 17 <210> SEQ ID NO 149 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 149 taactgcggt agatttc 17 <210> SEQ ID NO 150 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 150 aactgcggta gatttca 17 <210> SEQ ID NO 151 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 151 actgcggtag atttcat 17 <210> SEQ ID NO 152 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 152 ctgcggtaga tttcatg 17 <210> SEQ ID NO 153 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 153 tgcggtagat ttcatgc 17 <210> SEQ ID NO 154 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 154 gcggtagatt tcatgcc 17 <210> SEQ ID NO 155 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 155 cggtagattt catgcct 17 <210> SEQ ID NO 156 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 156 ggtagatttc atgcctg 17 <210> SEQ ID NO 157 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 157 gtagatttca tgcctga 17 <210> SEQ ID NO 158 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 158 tagatttcat gcctgat 17 <210> SEQ ID NO 159 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 159 agatttcatg cctgatg 17 <210> SEQ ID NO 160 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 160 gatttcatgc ctgatgg 17 <210> SEQ ID NO 161 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 161 atttcatgcc tgatgga 17 <210> SEQ ID NO 162 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 162 tttcatgcct gatggag 17 <210> SEQ ID NO 163 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 163 ttcatgcctg atggagc 17 <210> SEQ ID NO 164 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 164 tcatgcctga tggagcc 17 <210> SEQ ID NO 165 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 165 catgcctgat ggagcca 17 <210> SEQ ID NO 166 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 166 atgcctgatg gagccac 17 <210> SEQ ID NO 167 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 167 tgcctgatgg agccact 17 <210> SEQ ID NO 168 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 168 gcctgatgga gccactt 17 <210> SEQ ID NO 169 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 169 cctgatggag ccacttt 17 <210> SEQ ID NO 170 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 170 ctgatggagc cactttg 17 <210> SEQ ID NO 171 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 171 tgatggagcc actttgg 17 <210> SEQ ID NO 172 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 172 gatggagcca ctttggc 17 <210> SEQ ID NO 173 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 173 atggagccac tttggct 17 <210> SEQ ID NO 174 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 174 tggagccact ttggcta 17 <210> SEQ ID NO 175 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 175 ggagccactt tggctat 17 <210> SEQ ID NO 176 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 176 gagccacttt ggctatt 17 <210> SEQ ID NO 177 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 177 agccactttg gctattg 17 <210> SEQ ID NO 178 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 178 gccactttgg ctattgg 17 <210> SEQ ID NO 179 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 179 ccactttggc tattgga 17 <210> SEQ ID NO 180 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 180 cactttggct attggat 17 <210> SEQ ID NO 181 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 181 actttggcta ttggatc 17 <210> SEQ ID NO 182 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 182 ctttggctat tggatct 17 <210> SEQ ID NO 183 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 183 tttggctatt ggatctt 17 <210> SEQ ID NO 184 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 184 ttggctattg gatcttc 17 <210> SEQ ID NO 185 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 185 tggctattgg atcttcc 17 <210> SEQ ID NO 186 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 186 ggctattgga tcttccc 17 <210> SEQ ID NO 187 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 187 gctattggat cttcccg 17 <210> SEQ ID NO 188 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 188 ctattggatc ttcccgg 17 <210> SEQ ID NO 189 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 189 tattggatct tcccggg 17 <210> SEQ ID NO 190 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 190 attggatctt cccgggg 17 <210> SEQ ID NO 191 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 191 ttggatcttc ccggggg 17 <210> SEQ ID NO 192 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 192 tggatcttcc cggggga 17 <210> SEQ ID NO 193 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 193 ggatcttccc gggggaa 17 <210> SEQ ID NO 194 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 194 gatcttcccg ggggaaa 17 <210> SEQ ID NO 195 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 195 atcttcccgg gggaaaa 17 <210> SEQ ID NO 196 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 196 tcttcccggg ggaaaat 17 <210> SEQ ID NO 197 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 197 cttcccgggg gaaaata 17 <210> SEQ ID NO 198 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 198 ttcccggggg aaaatat 17 <210> SEQ ID NO 199 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 199 tcccggggga aaatata 17 <210> SEQ ID NO 200 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 200 cccgggggaa aatatat 17 <210> SEQ ID NO 201 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 201 ccgggggaaa atatatc 17 <210> SEQ ID NO 202 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 202 cgggggaaaa tatatca 17 <210> SEQ ID NO 203 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 203 gggggaaaat atatcaa 17 <210> SEQ ID NO 204 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 204 ggggaaaata tatcaat 17 <210> SEQ ID NO 205 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 205 gggaaaatat atcaata 17 <210> SEQ ID NO 206 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 206 ggaaaatata tcaatat 17 <210> SEQ ID NO 207 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 207 gaaaatatat caatatg 17 <210> SEQ ID NO 208 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 208 aaaatatatc aatatga 17 <210> SEQ ID NO 209 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 209 aaatatatca atatgat 17 <210> SEQ ID NO 210 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 210 aatatatcaa tatgatt 17 <210> SEQ ID NO 211 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 211 atatatcaat atgattt 17 <210> SEQ ID NO 212 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 212 tatatcaata tgattta 17 <210> SEQ ID NO 213 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 213 atatcaatat gatttaa 17 <210> SEQ ID NO 214 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 214 tatcaatatg atttaag 17 <210> SEQ ID NO 215 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 215 atcaatatga tttaaga 17 <210> SEQ ID NO 216 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 216 tcaatatgat ttaagaa 17 <210> SEQ ID NO 217 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 217 caatatgatt taagaat 17 <210> SEQ ID NO 218 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 218 aatatgattt aagaatg 17 <210> SEQ ID NO 219 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 219 atatgattta agaatgt 17 <210> SEQ ID NO 220 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 220 tatgatttaa gaatgtt 17 <210> SEQ ID NO 221 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 221 atgatttaag aatgttg 17 <210> SEQ ID NO 222 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 222 tgatttaaga atgttga 17 <210> SEQ ID NO 223 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 223 gatttaagaa tgttgaa 17 <210> SEQ ID NO 224 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 224 atttaagaat gttgaaa 17 <210> SEQ ID NO 225 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 225 tttaagaatg ttgaaat 17 <210> SEQ ID NO 226 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 226 ttaagaatgt tgaaatc 17 <210> SEQ ID NO 227 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 227 taagaatgtt gaaatca 17 <210> SEQ ID NO 228 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 228 aagaatgttg aaatcac 17 <210> SEQ ID NO 229 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 229 agaatgttga aatcacc 17 <210> SEQ ID NO 230 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 230 gaatgttgaa atcacca 17 <210> SEQ ID NO 231 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 231 aatgttgaaa tcaccag 17 <210> SEQ ID NO 232 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 232 atgttgaaat caccagt 17 <210> SEQ ID NO 233 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 233 tgttgaaatc accagtt 17 <210> SEQ ID NO 234 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 234 gttgaaatca ccagtta 17 <210> SEQ ID NO 235 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 235 ttgaaatcac cagttaa 17 <210> SEQ ID NO 236 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 236 tgaaatcacc agttaag 17 <210> SEQ ID NO 237 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 237 gaaatcacca gttaaga 17 <210> SEQ ID NO 238 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 238 aaatcaccag ttaagac 17 <210> SEQ ID NO 239 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 239 aatcaccagt taagacc 17 <210> SEQ ID NO 240 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 240 atcaccagtt aagacca 17 <210> SEQ ID NO 241 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 241 tcaccagtta agaccat 17 <210> SEQ ID NO 242 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 242 caccagttaa gaccatc 17 <210> SEQ ID NO 243 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 243 accagttaag accatca 17 <210> SEQ ID NO 244 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 244 ccagttaaga ccatcag 17 <210> SEQ ID NO 245 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 245 cagttaagac catcagt 17 <210> SEQ ID NO 246 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 246 agttaagacc atcagtg 17 <210> SEQ ID NO 247 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 247 gttaagacca tcagtgc 17 <210> SEQ ID NO 248 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 248 ttaagaccat cagtgct 17 <210> SEQ ID NO 249 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 249 taagaccatc agtgctc 17 <210> SEQ ID NO 250 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 250 aagaccatca gtgctca 17 <210> SEQ ID NO 251 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 251 agaccatcag tgctcac 17 <210> SEQ ID NO 252 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 252 gaccatcagt gctcaca 17 <210> SEQ ID NO 253 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 253 accatcagtg ctcacaa 17 <210> SEQ ID NO 254 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 254 ccatcagtgc tcacaag 17 <210> SEQ ID NO 255 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 255 catcagtgct cacaaga 17 <210> SEQ ID NO 256 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 256 atcagtgctc acaagac 17 <210> SEQ ID NO 257 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 257 tttctcctgt caatgaattg ctctt 25 <210> SEQ ID NO 258 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 258 ttctcctgtc aatgaattgc tcttt 25 <210> SEQ ID NO 259 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 259 tctcctgtca atgaattgct ctttg 25 <210> SEQ ID NO 260 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 260 ctcctgtcaa tgaattgctc tttgt 25 <210> SEQ ID NO 261 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 261 tcctgtcaat gaattgctct ttgta 25 <210> SEQ ID NO 262 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 262 cctgtcaatg aattgctctt tgtaa 25 <210> SEQ ID NO 263 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 263 ctgtcaatga attgctcttt gtaac 25 <210> SEQ ID NO 264 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 264 tgtcaatgaa ttgctctttg taacc 25 <210> SEQ ID NO 265 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 265 gtcaatgaat tgctctttgt aacca 25 <210> SEQ ID NO 266 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 266 tcaatgaatt gctctttgta accat 25 <210> SEQ ID NO 267 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 267 caatgaattg ctctttgtaa ccata 25 <210> SEQ ID NO 268 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 268 aatgaattgc tctttgtaac catag 25 <210> SEQ ID NO 269 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 269 atgaattgct ctttgtaacc atagg 25 <210> SEQ ID NO 270 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 270 tgaattgctc tttgtaacca taggc 25 <210> SEQ ID NO 271 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 271 gaattgctct ttgtaaccat aggct 25 <210> SEQ ID NO 272 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 272 aattgctctt tgtaaccata ggctt 25 <210> SEQ ID NO 273 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 273 attgctcttt gtaaccatag gcttg 25 <210> SEQ ID NO 274 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 274 ttgctctttg taaccatagg cttgg 25 <210> SEQ ID NO 275 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 275 tgctctttgt aaccataggc ttgga 25 <210> SEQ ID NO 276 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 276 gctctttgta accataggct tggat 25 <210> SEQ ID NO 277 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 277 ctctttgtaa ccataggctt ggata 25 <210> SEQ ID NO 278 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 278 tctttgtaac cataggcttg gataa 25 <210> SEQ ID NO 279 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 279 ctttgtaacc ataggcttgg ataaa 25 <210> SEQ ID NO 280 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 280 tttgtaacca taggcttgga taaaa 25 <210> SEQ ID NO 281 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 281 ttgtaaccat aggcttggat aaaag 25 <210> SEQ ID NO 282 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 282 tgtaaccata ggcttggata aaaga 25 <210> SEQ ID NO 283 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 283 gtaaccatag gcttggataa aagaa 25 <210> SEQ ID NO 284 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 284 taaccatagg cttggataaa agaat 25 <210> SEQ ID NO 285 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 285 aaccataggc ttggataaaa gaatc 25 <210> SEQ ID NO 286 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 286 accataggct tggataaaag aatca 25 <210> SEQ ID NO 287 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 287 ccataggctt ggataaaaga atcat 25 <210> SEQ ID NO 288 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 288 cataggcttg gataaaagaa tcatc 25 <210> SEQ ID NO 289 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 289 ataggcttgg ataaaagaat catcc 25 <210> SEQ ID NO 290 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 290 taggcttgga taaaagaatc atcct 25 <210> SEQ ID NO 291 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 291 aggcttggat aaaagaatca tcctc 25 <210> SEQ ID NO 292 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 292 ggcttggata aaagaatcat cctct 25 <210> SEQ ID NO 293 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 293 gcttggataa aagaatcatc ctcta 25 <210> SEQ ID NO 294 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 294 cttggataaa agaatcatcc tctat 25 <210> SEQ ID NO 295 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 295 ttggataaaa gaatcatcct ctatg 25 <210> SEQ ID NO 296 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 296 tggataaaag aatcatcctc tatga 25 <210> SEQ ID NO 297 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 297 ggataaaaga atcatcctct atgac 25 <210> SEQ ID NO 298 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 298 gataaaagaa tcatcctcta tgaca 25 <210> SEQ ID NO 299 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 299 ataaaagaat catcctctat gacac 25 <210> SEQ ID NO 300 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 300 taaaagaatc atcctctatg acact 25 <210> SEQ ID NO 301 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 301 aaaagaatca tcctctatga cactt 25 <210> SEQ ID NO 302 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 302 aaagaatcat cctctatgac acttc 25 <210> SEQ ID NO 303 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 303 aagaatcatc ctctatgaca cttca 25 <210> SEQ ID NO 304 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 304 agaatcatcc tctatgacac ttcaa 25 <210> SEQ ID NO 305 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 305 gaatcatcct ctatgacact tcaag 25 <210> SEQ ID NO 306 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 306 aatcatcctc tatgacactt caagt 25 <210> SEQ ID NO 307 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 307 atcatcctct atgacacttc aagta 25 <210> SEQ ID NO 308 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 308 tcatcctcta tgacacttca agtaa 25 <210> SEQ ID NO 309 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 309 catcctctat gacacttcaa gtaag 25 <210> SEQ ID NO 310 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 310 atcctctatg acacttcaag taaga 25 <210> SEQ ID NO 311 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 311 tcctctatga cacttcaagt aagaa 25 <210> SEQ ID NO 312 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 312 cctctatgac acttcaagta agaag 25 <210> SEQ ID NO 313 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 313 ctctatgaca cttcaagtaa gaagc 25 <210> SEQ ID NO 314 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 314 tctatgacac ttcaagtaag aagct 25 <210> SEQ ID NO 315 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 315 ctatgacact tcaagtaaga agcta 25 <210> SEQ ID NO 316 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 316 tatgacactt caagtaagaa gctag 25 <210> SEQ ID NO 317 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 317 atgacacttc aagtaagaag ctagt 25 <210> SEQ ID NO 318 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 318 tgacacttca agtaagaagc tagtg 25 <210> SEQ ID NO 319 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 319 gacacttcaa gtaagaagct agtga 25 <210> SEQ ID NO 320 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 320 acacttcaag taagaagcta gtgaa 25 <210> SEQ ID NO 321 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 321 cacttcaagt aagaagctag tgaaa 25 <210> SEQ ID NO 322 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 322 acttcaagta agaagctagt gaaaa 25 <210> SEQ ID NO 323 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 323 cttcaagtaa gaagctagtg aaaac 25 <210> SEQ ID NO 324 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 324 ttcaagtaag aagctagtga aaact 25 <210> SEQ ID NO 325 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 325 tcaagtaaga agctagtgaa aactt 25 <210> SEQ ID NO 326 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 326 caagtaagaa gctagtgaaa acttt 25 <210> SEQ ID NO 327 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 327 aagtaagaag ctagtgaaaa cttta 25 <210> SEQ ID NO 328 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 328 agtaagaagc tagtgaaaac tttag 25 <210> SEQ ID NO 329 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 329 gtaagaagct agtgaaaact ttagt 25 <210> SEQ ID NO 330 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 330 taagaagcta gtgaaaactt tagtg 25 <210> SEQ ID NO 331 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 331 aagaagctag tgaaaacttt agtgg 25 <210> SEQ ID NO 332 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 332 agaagctagt gaaaacttta gtggc 25 <210> SEQ ID NO 333 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 333 gaagctagtg aaaactttag tggct 25 <210> SEQ ID NO 334 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 334 aagctagtga aaactttagt ggctg 25 <210> SEQ ID NO 335 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 335 agctagtgaa aactttagtg gctga 25 <210> SEQ ID NO 336 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 336 gctagtgaaa actttagtgg ctgac 25 <210> SEQ ID NO 337 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 337 ctagtgaaaa ctttagtggc tgaca 25 <210> SEQ ID NO 338 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 338 tagtgaaaac tttagtggct gacac 25 <210> SEQ ID NO 339 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 339 agtgaaaact ttagtggctg acact 25 <210> SEQ ID NO 340 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 340 gtgaaaactt tagtggctga cactc 25 <210> SEQ ID NO 341 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 341 tgaaaacttt agtggctgac actcc 25 <210> SEQ ID NO 342 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 342 gaaaacttta gtggctgaca ctcct 25 <210> SEQ ID NO 343 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 343 aaaactttag tggctgacac tcctc 25 <210> SEQ ID NO 344 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 344 aaactttagt ggctgacact cctct 25 <210> SEQ ID NO 345 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 345 aactttagtg gctgacactc ctcta 25 <210> SEQ ID NO 346 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 346 actttagtgg ctgacactcc tctaa 25 <210> SEQ ID NO 347 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 347 ctttagtggc tgacactcct ctaac 25 <210> SEQ ID NO 348 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 348 tttagtggct gacactcctc taact 25 <210> SEQ ID NO 349 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 349 ttagtggctg acactcctct aactg 25 <210> SEQ ID NO 350 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 350 tagtggctga cactcctcta actgc 25 <210> SEQ ID NO 351 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 351 agtggctgac actcctctaa ctgcg 25 <210> SEQ ID NO 352 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 352 gtggctgaca ctcctctaac tgcgg 25 <210> SEQ ID NO 353 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 353 tggctgacac tcctctaact gcggt 25 <210> SEQ ID NO 354 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 354 ggctgacact cctctaactg cggta 25 <210> SEQ ID NO 355 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 355 gctgacactc ctctaactgc ggtag 25 <210> SEQ ID NO 356 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 356 ctgacactcc tctaactgcg gtaga 25 <210> SEQ ID NO 357 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 357 tgacactcct ctaactgcgg tagat 25 <210> SEQ ID NO 358 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 358 gacactcctc taactgcggt agatt 25 <210> SEQ ID NO 359 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 359 acactcctct aactgcggta gattt 25 <210> SEQ ID NO 360 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 360 cactcctcta actgcggtag atttc 25 <210> SEQ ID NO 361 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 361 actcctctaa ctgcggtaga tttca 25 <210> SEQ ID NO 362 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 362 ctcctctaac tgcggtagat ttcat 25 <210> SEQ ID NO 363 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 363 tcctctaact gcggtagatt tcatg 25 <210> SEQ ID NO 364 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 364 cctctaactg cggtagattt catgc 25 <210> SEQ ID NO 365 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 365 ctctaactgc ggtagatttc atgcc 25 <210> SEQ ID NO 366 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 366 tctaactgcg gtagatttca tgcct 25 <210> SEQ ID NO 367 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 367 ctaactgcgg tagatttcat gcctg 25 <210> SEQ ID NO 368 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 368 taactgcggt agatttcatg cctga 25 <210> SEQ ID NO 369 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 369 aactgcggta gatttcatgc ctgat 25 <210> SEQ ID NO 370 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 370 actgcggtag atttcatgcc tgatg 25 <210> SEQ ID NO 371 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 371 ctgcggtaga tttcatgcct gatgg 25 <210> SEQ ID NO 372 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 372 tgcggtagat ttcatgcctg atgga 25 <210> SEQ ID NO 373 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 373 gcggtagatt tcatgcctga tggag 25 <210> SEQ ID NO 374 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 374 cggtagattt catgcctgat ggagc 25 <210> SEQ ID NO 375 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 375 ggtagatttc atgcctgatg gagcc 25 <210> SEQ ID NO 376 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 376 gtagatttca tgcctgatgg agcca 25 <210> SEQ ID NO 377 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 377 tagatttcat gcctgatgga gccac 25 <210> SEQ ID NO 378 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 378 agatttcatg cctgatggag ccact 25 <210> SEQ ID NO 379 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 379 gatttcatgc ctgatggagc cactt 25 <210> SEQ ID NO 380 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 380 atttcatgcc tgatggagcc acttt 25 <210> SEQ ID NO 381 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 381 tttcatgcct gatggagcca ctttg 25 <210> SEQ ID NO 382 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 382 ttcatgcctg atggagccac tttgg 25 <210> SEQ ID NO 383 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 383 tcatgcctga tggagccact ttggc 25 <210> SEQ ID NO 384 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 384 catgcctgat ggagccactt tggct 25 <210> SEQ ID NO 385 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 385 atgcctgatg gagccacttt ggcta 25 <210> SEQ ID NO 386 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 386 tgcctgatgg agccactttg gctat 25 <210> SEQ ID NO 387 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 387 gcctgatgga gccactttgg ctatt 25 <210> SEQ ID NO 388 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 388 cctgatggag ccactttggc tattg 25 <210> SEQ ID NO 389 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 389 ctgatggagc cactttggct attgg 25 <210> SEQ ID NO 390 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 390 tgatggagcc actttggcta ttgga 25 <210> SEQ ID NO 391 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 391 gatggagcca ctttggctat tggat 25 <210> SEQ ID NO 392 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 392 atggagccac tttggctatt ggatc 25 <210> SEQ ID NO 393 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 393 tggagccact ttggctattg gatct 25 <210> SEQ ID NO 394 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 394 ggagccactt tggctattgg atctt 25 <210> SEQ ID NO 395 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 395 gagccacttt ggctattgga tcttc 25 <210> SEQ ID NO 396 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 396 agccactttg gctattggat cttcc 25 <210> SEQ ID NO 397 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 397 gccactttgg ctattggatc ttccc 25 <210> SEQ ID NO 398 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 398 ccactttggc tattggatct tcccg 25 <210> SEQ ID NO 399 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 399 cactttggct attggatctt cccgg 25 <210> SEQ ID NO 400 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 400 actttggcta ttggatcttc ccggg 25 <210> SEQ ID NO 401 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 401 ctttggctat tggatcttcc cgggg 25 <210> SEQ ID NO 402 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 402 tttggctatt ggatcttccc ggggg 25 <210> SEQ ID NO 403 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 403 ttggctattg gatcttcccg gggga 25 <210> SEQ ID NO 404 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 404 tggctattgg atcttcccgg gggaa 25 <210> SEQ ID NO 405 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 405 ggctattgga tcttcccggg ggaaa 25 <210> SEQ ID NO 406 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 406 gctattggat cttcccgggg gaaaa 25 <210> SEQ ID NO 407 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 407 ctattggatc ttcccggggg aaaat 25 <210> SEQ ID NO 408 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 408 tattggatct tcccggggga aaata 25 <210> SEQ ID NO 409 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 409 attggatctt cccgggggaa aatat 25 <210> SEQ ID NO 410 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 410 ttggatcttc ccgggggaaa atata 25 <210> SEQ ID NO 411 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 411 tggatcttcc cgggggaaaa tatat 25 <210> SEQ ID NO 412 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 412 ggatcttccc gggggaaaat atatc 25 <210> SEQ ID NO 413 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 413 gatcttcccg ggggaaaata tatca 25 <210> SEQ ID NO 414 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 414 atcttcccgg gggaaaatat atcaa 25 <210> SEQ ID NO 415 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 415 tcttcccggg ggaaaatata tcaat 25 <210> SEQ ID NO 416 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 416 cttcccgggg gaaaatatat caata 25 <210> SEQ ID NO 417 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 417 ttcccggggg aaaatatatc aatat 25 <210> SEQ ID NO 418 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 418 tcccggggga aaatatatca atatg 25 <210> SEQ ID NO 419 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 419 cccgggggaa aatatatcaa tatga 25 <210> SEQ ID NO 420 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 420 ccgggggaaa atatatcaat atgat 25 <210> SEQ ID NO 421 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 421 cgggggaaaa tatatcaata tgatt 25 <210> SEQ ID NO 422 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 422 gggggaaaat atatcaatat gattt 25 <210> SEQ ID NO 423 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 423 ggggaaaata tatcaatatg attta 25 <210> SEQ ID NO 424 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 424 gggaaaatat atcaatatga tttaa 25 <210> SEQ ID NO 425 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 425 ggaaaatata tcaatatgat ttaag 25 <210> SEQ ID NO 426 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 426 gaaaatatat caatatgatt taaga 25 <210> SEQ ID NO 427 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 427 aaaatatatc aatatgattt aagaa 25 <210> SEQ ID NO 428 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 428 aaatatatca atatgattta agaat 25 <210> SEQ ID NO 429 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 429 aatatatcaa tatgatttaa gaatg 25 <210> SEQ ID NO 430 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 430 atatatcaat atgatttaag aatgt 25 <210> SEQ ID NO 431 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 431 tatatcaata tgatttaaga atgtt 25 <210> SEQ ID NO 432 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 432 atatcaatat gatttaagaa tgttg 25 <210> SEQ ID NO 433 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 433 tatcaatatg atttaagaat gttga 25 <210> SEQ ID NO 434 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 434 atcaatatga tttaagaatg ttgaa 25 <210> SEQ ID NO 435 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 435 tcaatatgat ttaagaatgt tgaaa 25 <210> SEQ ID NO 436 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 436 caatatgatt taagaatgtt gaaat 25 <210> SEQ ID NO 437 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 437 aatatgattt aagaatgttg aaatc 25 <210> SEQ ID NO 438 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 438 atatgattta agaatgttga aatca 25 <210> SEQ ID NO 439 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 439 tatgatttaa gaatgttgaa atcac 25 <210> SEQ ID NO 440 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 440 atgatttaag aatgttgaaa tcacc 25 <210> SEQ ID NO 441 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 441 tgatttaaga atgttgaaat cacca 25 <210> SEQ ID NO 442 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 442 gatttaagaa tgttgaaatc accag 25 <210> SEQ ID NO 443 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 443 atttaagaat gttgaaatca ccagt 25 <210> SEQ ID NO 444 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 444 tttaagaatg ttgaaatcac cagtt 25 <210> SEQ ID NO 445 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 445 ttaagaatgt tgaaatcacc agtta 25 <210> SEQ ID NO 446 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 446 taagaatgtt gaaatcacca gttaa 25 <210> SEQ ID NO 447 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 447 aagaatgttg aaatcaccag ttaag 25 <210> SEQ ID NO 448 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 448 agaatgttga aatcaccagt taaga 25 <210> SEQ ID NO 449 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 449 gaatgttgaa atcaccagtt aagac 25 <210> SEQ ID NO 450 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 450 aatgttgaaa tcaccagtta agacc 25 <210> SEQ ID NO 451 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 451 atgttgaaat caccagttaa gacca 25 <210> SEQ ID NO 452 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 452 tgttgaaatc accagttaag accat 25 <210> SEQ ID NO 453 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 453 gttgaaatca ccagttaaga ccatc 25 <210> SEQ ID NO 454 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 454 ttgaaatcac cagttaagac catca 25 <210> SEQ ID NO 455 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 455 tgaaatcacc agttaagacc atcag 25 <210> SEQ ID NO 456 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 456 gaaatcacca gttaagacca tcagt 25 <210> SEQ ID NO 457 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 457 aaatcaccag ttaagaccat cagtg 25 <210> SEQ ID NO 458 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 458 aatcaccagt taagaccatc agtgc 25 <210> SEQ ID NO 459 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 459 atcaccagtt aagaccatca gtgct 25 <210> SEQ ID NO 460 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 460 tcaccagtta agaccatcag tgctc 25 <210> SEQ ID NO 461 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 461 caccagttaa gaccatcagt gctca 25 <210> SEQ ID NO 462 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 462 accagttaag accatcagtg ctcac 25 <210> SEQ ID NO 463 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 463 ccagttaaga ccatcagtgc tcaca 25 <210> SEQ ID NO 464 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 464 cagttaagac catcagtgct cacaa 25 <210> SEQ ID NO 465 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 465 agttaagacc atcagtgctc acaag 25 <210> SEQ ID NO 466 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 466 gttaagacca tcagtgctca caaga 25 <210> SEQ ID NO 467 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 467 ttaagaccat cagtgctcac aagac 25 <210> SEQ ID NO 468 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: NEDD-1 forward primer <400> SEQUENCE: 468 actgcggtag atttcatgcc 20 <210> SEQ ID NO 469 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: NEDD-1 reverse primer <400> SEQUENCE: 469 cgtttgttca ctgttgtggg 20 <210> SEQ ID NO 470 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: GAPDH amplification control forward primer <400> SEQUENCE: 470 cgaccacttt gtcaagctca 20 <210> SEQ ID NO 471 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: GAPDH amplification control reverse primer <400> SEQUENCE: 471 tgtgaggagg ggagattcag 20 <210> SEQ ID NO 472 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: NEDD-1 forward amplification primer <400> SEQUENCE: 472 acggtaccaa tgcaggaaaa cctcagatt 29 <210> SEQ ID NO 473 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <223> OTHER INFORMATION: NEDD-1 reverse amplification primer <400> SEQUENCE: 473 cgtctagatt acagaacatt aaggtattca c 31 

What is claimed is:
 1. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of: (i) the nucleotide sequence of SEQ ID NO:1, or (ii) the complement of the nucleotide sequence of SEQ ID NO: 1; (iii) the nucleotide sequence of SEQ ID NO: 3, or (iv) a degenerate variant of the nucleotide sequence of SEQ ID NO: 3, or (v) the complement (iii) or (iv); (vi) a nucleotide sequence that encodes a polypeptide having the sequence of SEQ ID NO: 4, (vii) a nucleotide sequence that encodes a polypeptide having the sequence of SEQ ID NO: 4 with conservative amino acid substitutions, or (viii) a nucleotide sequence that is the complement of (vi) or (vii).
 2. The isolated nucleic acid of claim 1, wherein said nucleic acid, or the complement of said nucleic acid, encodes a polypeptide having WD domains.
 3. The isolated nucleic acid of claim 1, wherein said nucleic acid, or the complement of said nucleic acid, is expressed in human testis, brain, skeletal muscle, liver, HeLa, heart, placenta, prostate, bone marrow, lung, adrenal, fetal liver and kidney.
 4. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is operably linked to one or more expression control elements.
 5. A replicable vector comprising an isolated nucleic acid molecule of claim
 1. 6. The isolated nucleic acid molecule of claim 1, attached to a substrate.
 7. A host cell transformed to contain the nucleic acid molecule of any one of claims 1-5, or the progeny thereof.
 8. A method for producing a polypeptide, the method comprising: culturing the host cell of claim 7 under conditions in which the protein encoded by said nucleic acid molecule is expressed.
 9. An isolated polypeptide produced by the method of claim
 8. 10. An isolated polypeptide selected from the group consisting of: (a) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 4; (b) an isolated polypeptide comprising a fragment of at least 10 amino acids of SEQ ID NO: 4; (c) an isolated polypeptide according to (a) or (b) in which at least 95% of deviations from the sequence of (a) or (b) are conservative substitutions; and (d) an isolated polypeptide having at least 90% amino acid sequence identity to the isolated polypeptides of (a) or (b).
 11. An isolated antibody or antigen-binding fragment or derivative thereof the binding of which can be competitively inhibited by a polypeptide according to claim
 10. 12. A method of identifying binding partners for a polypeptide according to claim 10, the method comprising: contacting said polypeptide to a potential binding partner; and determining if the potential binding partner binds to said polypeptide.
 13. The method of claim 12, wherein said contacting is performed in vivo.
 14. A method of altering the expression of a nucleic acid according to claim 1, the method comprising: administering to a human cell or to a human subject an effective amount of an agent which alters the expression of a nucleic acid according to claim
 1. 15. A method of modulating at least one activity of a polypeptide according to claim 10, the method comprising: administering an effective amount of an agent which modulates at least one activity of a polypeptide according to claim
 10. 16. A transgenic non-human animal modified to contain a nucleic acid molecule of any one of claims 1-5.
 17. A transgenic non-human animal unable to express the endogenous orthologue of human NEDD-1.
 18. A method of diagnosing a disease caused by mutation in human NEDD-1, comprising: detecting said mutation in a sample of nucleic acids that derives from a subject suspected to have said disease.
 19. A method of diagnosing or monitoring a disease caused by altered expression of human NEDD-1, comprising: determining the level of expression of human NEDD-1 in a sample of nucleic acids or proteins that derives from a subject suspected to have said disease, alterations from a normal level of expression providing diagnostic and/or monitoring information.
 20. A pharmaceutical composition comprising the nucleic acid of any one of claims 1-5 and a pharmaceutically acceptable excipient.
 21. A pharmaceutical composition comprising the polypeptide of claim 10 and a pharmaceutically acceptable excipient.
 22. A pharmaceutical composition comprising the antibody or antigen-binding fragment or Derivative thereof of claim 11 and a pharmaceutically acceptable excipient.
 23. A purified agonist of the polypeptide of claim
 10. 24. A purified antagonist of the polypeptide of claim
 10. 25. A pharmaceutical composition comprising the agonist of claim
 23. 26. A pharmaceutical composition comprising the antagonist of claim
 24. 27. A method for treating or preventing a disorder associated with decreased expression or activity of human NEDD-1, the method comprising: administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim
 20. 28. A method for treating or preventing a disorder associated with decreased expression or activity of human NEDD-1, the method comprising: administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of either of claim 21 or
 25. 29. A method for treating or preventing a disorder associated with increased expression or activity of human NEDD-1, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 22 or claim
 26. 30. A diagnostic composition comprising the nucleic acid of any one of claims 1-5, said nucleic acid being detectably labeled.
 31. A diagnostic composition comprising the polypeptide of claim 10, said polypeptide being detectably labeled.
 32. A diagnostic composition comprising the antibody or antigen-binding fragment or derivative thereof of claim
 11. 33. The diagnostic composition of claim 32, wherein said antibody or antigen-binding fragment or derivative thereof is detectably labeled.
 34. The diagnostic composition of claim 30, wherein said composition is further suitable for in vivo administration.
 35. The diagnostic composition of any one of claims 31-33, wherein said composition is further suitable for in vivo administration.
 36. A microarray wherein at least one probe of said array is a nucleic acid according to any one of claims 1-5.
 37. A method for detecting a target nucleic acid in a sample, said target being a nucleic acid of any one of claims 1-5, the method comprising: a) hybridizing the sample with a probe comprising at least 30 contiguous nucleotides of a sequence complementary to said target nucleic acid in said sample under hybridization conditions sufficient to permit detectable binding of said probe tc said target, and b) detecting the presence or absence, and optionally the amount, of said binding.
 38. A fusion protein, said fusion protein comprising a polypeptide of claim 10 fused to a heterologous amino acid sequence.
 39. The fusion protein of claim 38, wherein said heterologous amino acid sequence is a detectable moiety.
 40. The fusion protein of claim 39, wherein said detectable moiety is fluorescent.
 41. The fusion protein of claim 38, wherein said heterologous amino acid sequence is an Ig Fc region.
 42. A method of screening for agents that modulate the expression of human NEDD-1, the method comprising: contacting a cell or tissue sample believed to express human NEDD-1 with a chemical or biological agent, and then comparing the amount of human NEDD-1 expression with that of a control. 